View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
View conference programme - The British Society for Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
BSR 2004<br />
Annual Meeting<br />
A joint meeting with<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong><br />
20 - 23 April 2004<br />
Edinburgh International Conference<br />
Centre, Edinburgh, Scotland<br />
with the<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong><br />
Spring Meeting, 21 - 23 April 2004<br />
Printed with the assistance of
BSR Annual Meeting & BHPR<br />
Spring Meeting 2004<br />
FINAL PROGRAMME<br />
CONTENTS<br />
Meeting at a Glance 2 – 3<br />
Scientific Programme; Tuesday 20 April 4 – 9<br />
Scientific Programme; Wednesday 21 April 9 – 16<br />
Scientific Programme; Thursday 22 April 16 – 22<br />
Scientific Programme; Friday 23 April 22 – 23<br />
Additional Meetings 24<br />
Abstracts <strong>for</strong> oral presentations<br />
BSR Concurrent Oral Sessions; Tuesday 20 April, 16:30 – 18:00 25 – 27<br />
BSR Plenary Oral Session; Wednesday 21 April, 14:00 – 16:00 28<br />
BHPR Plenary Oral Session; Wednesday 21 April, 14:00 – 16:00 29<br />
BSR Concurrent Oral Sessions; Thursday 22 April, 14:30 – 16:30 30 – 33<br />
BHPR Oral Presentations; Friday 23 April, 10:00 – 11:00 34<br />
Abstracts <strong>for</strong> poster presentations<br />
Poster <strong>View</strong>ing Session 1; Wednesday 21 April, 08:30 – 10:00 34 – 50<br />
Poster <strong>View</strong>ing Session 2; Thursday 22 April, 08:30 – 10:00 51 – 65<br />
Poster <strong>View</strong>ing Session 3 (inc. BHPR); Friday 23 April, 08:30 – 10:00 66 – 80<br />
Abstract Reviewers 81<br />
Exhibition Floor Plan 82<br />
Exhibitor’s Details 83 - 88<br />
Acknowledgements 89<br />
1
BSR Annual Meeting & BHPR Spring<br />
Meeting, 20 -23 April 2004<br />
Edinburgh International Conference Centre<br />
BSR & BHPR SCIENTIFIC PROGRAMME<br />
Tuesday 20 April 2004<br />
08:00 Registration opens Strathblane Hall<br />
09:00 – 10:30 Satellite Symposium<br />
Genzyme Biosurgery Tinto<br />
10:30 – 11:00 Coffee Cromdale Hall<br />
11:00 – 13:00 BSR: Update on management of systemic sclerosis – organ based<br />
complications Pentland/Sidlaw<br />
Chair: Chris Denton<br />
• Recent advances in treatment of pulmonary arterial hypertension in<br />
systemic sclerosis Gerry Coghlan<br />
Advances in CTD associated PAH. <strong>The</strong> availability of bosentan has simplified the<br />
management of CTD-PAH at least <strong>for</strong> patients with grade 3 disease, however,<br />
remarkably little long term follow up data has been available to date. By combining<br />
our registry data with the extension trials, we have data on the survival impact on<br />
100 patients treated <strong>for</strong> up to three years. <strong>The</strong> data shows that survival at two<br />
years is 67%, thus much improved when compared to historical controls but still<br />
much higher than that observed in idiopathic PAH.<br />
• Assessment and treatment of pulmonary fibrosis in systemic sclerosis<br />
Ron du Bois<br />
Our concept of pulmonary fibrosis in systemic sclerosis has changed significantly<br />
over recent years. This has had important implications with regard to the<br />
assessment and treatment of lung complications in patients with this disease.<br />
This talk will focus on these novel aspects of management.<br />
• Pitfalls in management of scleroderma renal disease Ed Kingdon<br />
Renal involvement in scleroderma is not uncommon and scleroderma renal crisis<br />
(SRC) is well described. However, SRC is not the only renal manifestation of this<br />
disease and SRC presentation may be atypical. <strong>The</strong> pattern of renal involvement in<br />
SSc patients has therapeutic and prognostic significance and correctly identifying<br />
different types of renal disease is likely to be important when designing therapeutic<br />
trials or studies of the natural history of SSc.<br />
• Management of the peripheral vascular complications –<br />
critical digital ischaemia Ariane Herrick<br />
This session will cover assessment of severity, causation, and treatment (including<br />
prevention) of digital ulceration and ischaemia in patients with systemic sclerosis’<br />
4
11:00 – 13:00 BSR Special Interest Groups<br />
• arc/BSR Education SIG Carrick 2<br />
Convenors: Lesley Kay and Andrew Hassell<br />
<strong>The</strong> aim of the education SIG is to start a network of <strong>Rheumatology</strong> health<br />
professionals who are interested in the delivery of <strong>Rheumatology</strong> education<br />
to students and practitioners, and in educational research. This is a joint<br />
initiative between the BSR and arc. In the first session we plan to outline<br />
current work of the arc education sub-committee and the BSR Education<br />
and Training Committee, and give some examples of current educational<br />
research.<br />
• Osteoarthritis Carrick 1<br />
Convenor: Fraser Birrell<br />
11:00 Introduction & welcome Dr Fraser Birrell<br />
Deciding the role of the Osteoarthritis Special Interest Group<br />
11:00 Coordinate collaborative studies Prof Paul Dieppe<br />
11:25 Determine future research directions Prof Cyrus Cooper<br />
11:40 Develop related clinical guidelines Prof Michael Doherty<br />
11:55 Promote dissemination or implement changes of best clinical<br />
practice Dr Nigel Arden<br />
12:10 Promote public in<strong>for</strong>mation about osteoarthritis<br />
Dr Philip Conaghan<br />
12:25 General discussion<br />
12:50 Consensus & action plan Dr Fraser Birrell<br />
13:00 Close<br />
• Polymyalgia rheumatica and giant cell arteritis Harris 2<br />
Convenor: Bhaskar Dasgupta<br />
• Update on PMR Cohort Study Bhaskar Dasgupta, Southend Hospital<br />
• Consensus on PMR Andrew Hutchings, London School of Hygiene &<br />
Tropical Medicine<br />
• Infliximab in GCA Bhaskar Dasgupta, Southend Hospital<br />
• Antiphospholipid antibodies in GCA Kuntal Chakravarty,<br />
Haroldwood Hospital<br />
• Takayasu’s Arteritis Justin Mason, Hammersmith Hospital<br />
• RA Outcomes Moorfoot<br />
Chair: Dr Adam Young<br />
• Clinical guidelines <strong>for</strong> management of RA and RA outcomes<br />
Perspectives from the Arthritis & Musculo-skeletal Alliance (ARMA)<br />
Dr. Mike Webley FRCP, Stoke Mandeville<br />
BSR guidelines and relevance to outcomes<br />
Dr. Tom Kennedy FRCP, Wirral<br />
• Recent developments in use of hand bone density in<br />
assessment of outcome<br />
Prof David Reid FRCP, Aberdeen<br />
• Evaluating progression in x-ray changes. A mathematical view.<br />
Prof. Peter Jones PhD, Keele University<br />
• RA and podiatry outcomes. Brief update following BSR RA SIG 2003.<br />
Simon Otter, Lecturer in Podiatry, Brighton.<br />
• ERAN. Brief update following BSR SIG 2003. Wendy Garwood,<br />
ERAN Coordinator.<br />
5
• Spondyloarthritis Harris 1<br />
Convenor: Paul Bowness<br />
What’s new in Psoriatic Arthritis<br />
11:00 Introduction Paul Bowness<br />
11:10 What’s so special about PsA? PsA versus RA - what’s the<br />
difference and does it matter? Neil McHugh<br />
11:40 Looking into the PsA joint Douglas Veale<br />
12:10 Psoriatic arthritis, a T Cell-mediated disease. Oliver FitzGerald<br />
12:40 Comments from the floor and round table discussion<br />
• Ultrasound Carrick 3<br />
Chairpersons: David Kane and Richard Wakefield<br />
How to establish Musculoskeletal Ultrasound in a rheumatology department?<br />
13:00 – 14:00 Lunch Cromdale Hall<br />
1. How to Train in Musculoskeletal Ultrasound<br />
11:00 Musculoskeletal Ultrasound Training in <strong>Rheumatology</strong> – what is the<br />
consensus of rheumatologists already per<strong>for</strong>ming musculoskeletal<br />
ultrasound? Andrew Brown, Leeds General Infirmary<br />
11:15 How to establish Musculoskeletal Ultrasound in a busy <strong>Rheumatology</strong><br />
Department – <strong>The</strong> Belfast experience. Gary Wright, Royal Victoria<br />
Hospital, Belfast<br />
11:30 Discussion: David Kane<br />
2. How to get Equipment and Funding.<br />
11:45 Choosing the right equipment. David Kane, University of Newcastle<br />
12:00 How to get funding <strong>for</strong> ultrasound equipment in your rheumatology<br />
department? Roger Sturrock, Glasgow Royal Infirmary<br />
12:15 Discussion: Richard Wakefield<br />
BSR Standards, Audit and Guidelines Working Group Open Meeting –<br />
presentation of current clinical guidelines in development Harris 1<br />
RATs Meeting Kilsyth<br />
14:00 – 16:00 BSR: Rheumatoid arthritis from the patient’s perspective Pentland/Sidlaw<br />
Chairs: Rod Hughes and Enid Quest<br />
• <strong>The</strong> patient as educator Jane Dacre<br />
A discussion of trained patients as educators of doctors and other<br />
healthcare professionals.<br />
• <strong>The</strong> patient as expert Kate Lorig<br />
When one is diagnosed with a chronic disease life changes. Corbin and Strauss<br />
have identified three major management tasks <strong>for</strong> people with chronic disease;<br />
medical management, role management, and emotional management. At the<br />
same time patients have told us that they need two types of knowledge, medical<br />
knowledge and knowledge gained from the experience of living with an illness.<br />
Health care professionals, are experts at helping people with medical management<br />
but are less adept at helping with role and emotional management. Patients who<br />
have lived with and managed a disease over time have much to offer each other.<br />
This is especially true if this is done in a structured setting which allows sharing in a<br />
non judgmental atmosphere.<br />
This talk will discuss the sharing of expert patient knowledge and will include some<br />
of the data we have collected over the years on the similarities and difference in<br />
professional and patient led groups.<br />
6
• <strong>The</strong> patient as recipient of treatment Jenny Donovan<br />
Jenny will talk about research which shows how patients make rational and<br />
sensible decisions about the medications they take <strong>for</strong> their joint symptoms,<br />
based on the in<strong>for</strong>mation they have available to them. She will also present<br />
evidence about how doctors and patients can have very different<br />
perceptions of issues discussed in consultations which can lead to confusion<br />
and dis-satisfaction, and also some work we have done very recently<br />
synthesising qualitative research studies which summarises the contribution<br />
that qualitative research can make to rheumatology.<br />
• How do patients prioritise outcomes in RA Alison Carr<br />
Clinical management is aimed at achieving a good outcome and most<br />
clinicians have an intuitive feeling <strong>for</strong> what constitutes a good outcome in<br />
their patients but this might vary between individual patients and even<br />
within individual patients over time. Definitions of good outcome from<br />
clinical trials are based on disease based measures of outcome (acute phase<br />
response, pain) and increasingly on patient-based measures (function, quality<br />
of life) but do not take account of the ways in which patients prioritise<br />
outcomes in relation to: the stage and severity of their condition, their<br />
expectations or adaptation. This talk will present evidence of patient<br />
priorities <strong>for</strong> outcome and discuss the implications <strong>for</strong> the ways in which<br />
outcomes are measured, analysed and interpreted.<br />
14:00 – 16:00 BSR: Angiogenesis; basic science and therapeutic possibilities<br />
Tinto/Moorfoot<br />
Chair: Ewa Paleolog<br />
• Approaches to angiogenesis in oncology Andreas Bikfalvi<br />
Vascular development is governed by a number of regulatory molecules<br />
called “angiogenesis “ factors. In recent years a number of molecules have<br />
been identified and pathways of normal and pathological vascular<br />
development have been elucidated. Angiogenesis research also significantly<br />
impact on the development of new therapeutic strategies <strong>for</strong> the treatment<br />
of cancer, ocular neovascular disease, chronic inflammatory disorders or<br />
cardiovascular disease.<br />
• Angiogenesis in synovitis Michel De Bandt<br />
Angiogenesis is potentially important in RA. Angiogenesis is the sprouting<br />
of new vessels, that contributes to the proliferation of tissues and<br />
participates in the inflammatory process in the rheumatoid joint.<br />
<strong>The</strong> angiogenic pathways within the joint will be reviewed. <strong>The</strong> clinical<br />
importance of angiogenesis in RA will be discussed. Various aspects of<br />
angiogenesis inhibition in animal models will be presented.<br />
• Angiogenesis in osteoarthritis and spondylosis David Walsh<br />
Angiogenesis is an integral part of bone <strong>for</strong>mation, cartilage and disc<br />
changes in OA and spondylosis, and accompanying nerves may<br />
mediate pain.<br />
• Imaging angiogenesis in joints Peter C Taylor<br />
Power Doppler ultrasonography is a sensitive method <strong>for</strong> demonstrating the<br />
presence of blood flow in small vessels in rheumatoid synovitis and there is a<br />
very close relationship between extent of vascular flow signal and the rate of<br />
early synovial enhancement on dynamic gadolinium-enhanced MRI.<br />
Emerging evidence indicates that vascular imaging in RA is a sensitive tool<br />
<strong>for</strong> the assessment of disease activity and response to therapy and also<br />
prognostic <strong>for</strong> the rate of structural damage to joints.<br />
7
16:00 – 16:30 Tea Cromdale Hall<br />
16:30 – 18:00 BSR: Concurrent oral presentations of abstracts<br />
Osteoarthritis and crystal diseases Sidlaw<br />
Chair: Mike Doherty<br />
• Gain of function ANKH variants cause of familial and sporadic calcium<br />
pyrophosphate dehydrate chondrocalcinosis Yun Zhang<br />
• Monocyte-macrophage differentiation in vivo and the control of monosodium<br />
urate (MSU) crystal-stimulated inflammation. Dorian Haskard<br />
• Sequencial measurements of serum cartilage oligometric matrix protein (COMP)<br />
indicate a non-linear progression of knee osteoarthritis Mohammed Sharif<br />
• Neurovascular invasion at the osteochondral junction in osteoarthritis Sunita Suri<br />
• Cancellous bone changes in the proximal tibia of patients with knee osteoarthritis<br />
Elizabeth Messent<br />
• Long term outcome following total hip arthroplasty: a case controlled study<br />
Janet Cushnaghan<br />
Epidemiology Fintry<br />
Chair: Marwan Bukhari<br />
• Birth order as a determinant of osteoporosis risk: the Hert<strong>for</strong>dshire cohort study<br />
Elaine Dennison<br />
• Joint hypermobility is common and strongly genetically determined: results of a<br />
female twin study Alan Hakim<br />
• Association between dietary carotenoids and risk of developing inflammatory<br />
polyarthritis Dorothy Pattison<br />
• Young Investigator Award Winner: Predicting persistence of neck pain following a<br />
motor vehicle accident: a prospective study of persons attending emergency<br />
department Kate Atherton<br />
• Hypothalamic-pituitary-adrenal stress axis function – the relationship with chronic<br />
widespread pain and its antecedents: a population based study John McBeth<br />
• Is musculoskeletal pain more common now than 40 years ago? Results from two<br />
population-based cross-sectional studies John Mcbeth<br />
Vascular injury Tinto/Moorfoot<br />
Chair: George Kitas<br />
• Systemic rheumatoid vasculitis – facing extinction? Richard Watts<br />
• Young Investigator Award Winner: <strong>The</strong> haemoglobin scavenger receptor CD163<br />
mediates macrophage interleukin-10 and haem oxygenase-1 synthesis: an inducible<br />
cytoprotective pathway against haemoglobin-mediated oxidative vascular injury<br />
Pandelis Philippidis<br />
• Young Investigator Award Winner: Upregulation of membrane-bound<br />
complement regulatory proteins by atorvastatin protects vascular endothelium<br />
against complement-mediated injury during hypoxia-reoxygenation<br />
Anne Kinderlerer<br />
• Renal artery stenosis in hypertensive patients with antiphospholipid syndrome<br />
(APS): the effects of anticoagulation Shirish Sangle<br />
• Cardiovascular and cerebrovascular disease incidence and risk factors in<br />
ANCA-associated primary systemic vasculitis (AASV) John McLaren<br />
• Molecular profile of symptomatic and asymptomatic carotid plaques<br />
Eugene Halligan<br />
8
<strong>The</strong>rapeutics Pentland<br />
Chair: John Isaacs<br />
• <strong>The</strong> armada trial: efficacy and safety of adalimumab (humira ® ) over 30<br />
months in patients with active rheumatoid arthritis Oscar Segurado<br />
• Adalimumab (humira ® ) inhibits radiographic progression in rheumatoid<br />
arthritis (RA) patients with long-standing disease: data at two years<br />
Oscar Segurado<br />
• Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic<br />
resonance imaging study Ai Lyn Tan<br />
• Predictive value of synovial cytokine expression <strong>for</strong> response to<br />
anti-tumour-necrosis factor-α treatment in rheumatoid arthritis in<br />
clinical practice Maya Buch<br />
• A randomised, double-blind, placebo controlled multi-centre trial of<br />
combination therapy with methotrexate plus cyclosporine v methotrexate<br />
plus placebo in patients with active psoriatic arthritis A Fraser<br />
• A randomised controlled trial of intra-articular triamcinolone and/or<br />
physiotherapy in shoulder capsulitis Ian Ryans<br />
18:00 – 19:00 Welcome Buffet Reception Cromdale Hall<br />
19:00 – 20:00 Clinico-pathological Conference Pentland Suite<br />
Chair: David GI Scott, UK<br />
Discussant: Robert Thompson, Liverpool, UK<br />
Presenter: Kuntal Chakravarty, Rom<strong>for</strong>d, UK<br />
Wednesday 21 April 2004<br />
08:30 – 10:00 BSR Poster viewing session 1 Strathblane Hall<br />
10:00 – 11:00 BSR Poster discussions<br />
Cytokines and basic science Sidlaw<br />
Chairs: Andrew Cope and Iain McInnes<br />
Posters to be discussed: 7, 10, 3, 11, 28, 12, 2, 5<br />
Genomics Fintry<br />
Chairs: Anne Barton and Matthew Brown<br />
Posters to be discussed: 22, 24, 21, 23, 18, 26, 27, 13<br />
Osteoporosis and bone disease Tinto/Moorfoot<br />
Chairs: John Halsey and Jon Tobias<br />
Posters to be discussed: 89, 99, 82, 83, 100, 80, 95, 91<br />
Treatment of rheumatoid arthritis Pentland<br />
Chairs: Julie McHale and Bryan Williams<br />
Posters to be discussed: 52, 53, 31, 46, 29, 54, 70, 57<br />
11:00 – 11:30 Coffee Cromdale Hall<br />
9
11:30 – 13:00 BSR: Interface of rheumatology with the community<br />
Pentland/Sidlaw<br />
Chair: David GI Scott<br />
11:30 Community interface with secondary care Elaine Hay<br />
Increasingly, it is recognised that there is a significant gap in the provision of<br />
clinical care <strong>for</strong> patients with non-inflammatory and non-surgical<br />
musculoskeletal problems, who often access services in an ad-hoc manner.<br />
<strong>The</strong>re are a number of key principals to consider when developing a clinical<br />
service <strong>for</strong> such patients at the primary / secondary care interface.<br />
1. Delivering an effective and efficient musculoskeletal service that meets<br />
the needs of the community has less to do with geographical location of<br />
clinics than with developing a cohesive patient centred model of care.<br />
2. Local strategies need to be developed to breakdown barriers and<br />
facilitate coherent care between professions, between settings and<br />
organisations and between different models of care (medical model versus<br />
“patient centred” model).<br />
3. To be effective, the service must incorporate clinical services<br />
(“New Ways of Working” and cohesive clinical teams), training and<br />
education, and audit and research.<br />
Some <strong>for</strong>m of triage by practitioners with special interests (usually general<br />
practitioners or physiotherapists) is increasingly popular as a way to try to<br />
improve the efficiency and appropriateness of the referral process <strong>for</strong> patients<br />
with musculoskeletal problems. This approach has tangible benefits including<br />
reduced wait times, convenient access, high levels of patient satisfaction and<br />
increased conversion rate <strong>for</strong> surgery. However, it is important that practitioners<br />
with special interests work as part of a multidisciplinary team, providing an<br />
integrated service spanning primary and secondary care. <strong>The</strong> importance of<br />
robust, transparent procedures to ensure appropriate training and experience;<br />
evidence of continuing professional development; adequate clinical facilities,<br />
support and accountability as well as a commitment to clinical governance,<br />
audit and evaluation have recently been highlighted (A Musculoskeletal<br />
Clinical Framework <strong>for</strong> GPs with special interests<br />
www.doh.gov.uk/pricare/gp-specialinterests ).<br />
11:55 <strong>The</strong> GP’s perspective on the role of rheumatology Michael Dixon<br />
• How do we commission effectively? Primary and secondary care clinician<br />
leadership and frontline involvement in designing services. Ensuring cost<br />
effective use of services commissioned. Clinical leadership at the<br />
interface between secondary care and general practice.<br />
• Service redesign - how much rheumatology can be done in primary care?<br />
• Improving the patient experience - the role of PCTs and the impact of<br />
patient <strong>for</strong>ums and practice patient participation groups.<br />
• Patient choice - the effect on rheumatology services of moving the locus<br />
of control from Whitehall to the patient and his chosen practitioner.<br />
12:15 GPs with special interests in rheumatology Steven Longworth<br />
12:35 <strong>Rheumatology</strong> serving the community Carol Black<br />
<strong>The</strong> demographics of the population are changing, we are living longer and<br />
chronic diseases are on the increase. <strong>The</strong>se changes plus those embodied in<br />
shifting the balance of power require the rheumatological community to<br />
examine how, where and with whom care will be delivered in the future.<br />
10
11:30 – 13:00 BSR: Genetics <strong>for</strong> the terrified Tinto/Moorfoot<br />
Chairs: Robert Moots and Jane Worthington<br />
• <strong>The</strong> biology of genes Andrew Read<br />
This talk is <strong>for</strong> people who see a yawning chasm between the modern<br />
post-genome world view and their vague memories of the genetic code, and<br />
who are terrified because a crucial area of science seems to have run out of<br />
their reach. I will summarise the function of our DNA (only 2% codes <strong>for</strong><br />
protein), the structure of our genes and the significance of the many<br />
variations that exist between the DNA of different people. It will become<br />
apparent that, although we now have a ‘finished’ human genome sequence,<br />
we still understand rather little about how it works.<br />
• How can studies link genes to disease? Sally John<br />
Most common diseases of major public health impact have a complex<br />
aetiology in which many genetic and environmental factors may contribute<br />
to disease onset. Whilst mapping disease genes <strong>for</strong> Mendelian traits has<br />
been successful, mapping the genes <strong>for</strong> complex disease has been more<br />
challenging. <strong>The</strong> main reason <strong>for</strong> this, is that many genes, each conferring a<br />
small risk, often interacting with other genes and or environmental<br />
exposures are responsible <strong>for</strong> more complex traits.<br />
A case-control association study is the most efficient method of<br />
demonstrating a link between a gene and a disease. Well-designed<br />
association studies require careful consideration of the phenotype or<br />
outcome and appropriate selection of genetic markers. Common problems<br />
encountered in genetic association studies and methods to overcome them<br />
will be described.<br />
<strong>The</strong>re are now >5 million polymorphisms documented in the human<br />
genome, Understanding linkage disequilibrium and haplotypes on a genome<br />
wide basis will ensure we design more efficient and powerful association<br />
studies in the future.<br />
• Taking genetics back to the clinic <strong>for</strong> therapy of rheumatic diseases<br />
Yuti Chernajovsky<br />
Current advances in gene transfer and protein engineering methods enable<br />
the use of cytokine-inhibitors and inhibitory cytokine genes to treat<br />
polygenic diseases such as rheumatoid arthritis. Genetic engineering of cells<br />
ex vivo or direct in vivo therapeutic interventions have proven extremely<br />
useful to study local effects of immunomodulatory agents as well as being a<br />
safe and cost effective alternative therapy when compared with current<br />
protein therapies.<br />
11:30 – 13:00 BSR: Inherited defects of connective tissue Fintry<br />
Chair: Rodney Grahame<br />
11:30 Overview of key developments Michael Pope<br />
Connective tissue matrix is a very complex mixture of structural proteins,<br />
such as collagens, elastic components, proteoglycans etc, of particular<br />
relevance to specialties such as <strong>Rheumatology</strong>. This symposium illustrates<br />
the medical disorders caused by errors in some of those constituents.<br />
11
11:45 Collagen III and V mutations Anne de Paepe<br />
<strong>The</strong> Ehlers-Danlos syndrome groups a number of inherited connective tissue<br />
disorders in which skin and joint hyperlaxity, easy bruising, dystrophic scarring<br />
and generalized connective tissue fragility are prominent features. Mutations<br />
affecting the biosynthesis and structure of fibrillar collagens are causal in<br />
several EDS subtypes. One of the most severe subtypes, vascular EDS, is<br />
characterized by arterial fragility and reduced life expectancy due to vascular<br />
rupture and results from mutations in the gene encoding type III collagen.<br />
Approximately half of the patients with the classical <strong>for</strong>m of EDS, in which skin<br />
hyperextensibility and fragility are prominent, carry a mutation in one of the<br />
genes encoding type V collagen. <strong>The</strong> clinical and molecular aspects of these<br />
conditions as well as diagnostic and management issues will be discussed.<br />
12:05 Collagen II, XI and other mutations in Stickler syndrome Martin Snead<br />
Stickler syndrome <strong>for</strong>ms part of the spectrum of type II/XI collagen<br />
chondrodysplasias and is the commonest inherited cause of retinal detachment.<br />
12:25 Extracellular matrix mutations in the epiphyseal and other<br />
chondrodysplaysias Mike Briggs<br />
Multiple epiphyseal dysplasias are inherited bone diseases that are<br />
characterised by joint pain and stiffness and early onset osteoarthritis.<br />
Autosomal dominant <strong>for</strong>ms of these diseases are genetically heterogeneous<br />
and result from mutations in important cartilage structural proteins. Recent<br />
studies have contributed significantly to our understanding of the pathobiology<br />
of these relatively common diseases.<br />
12:45 One gene, many clinical consequences: the lessons from G proteins<br />
Paul Wordsworth<br />
G proteins fulfill a vital role in cell signaling pathways. Activating and<br />
inactivating mutations have been described in the alpha subunit. Depending on<br />
whether these are of maternal or paternal origin widely differing phenotypes<br />
may result (Albright’s hereditary osteodystrophy, progressive osseous<br />
heteroplasia, pseudohypoparathroidism). Somatic mosaicism <strong>for</strong> activating<br />
mutations results in polyostotic fibrous dysplasia (McCune Albright syndrome).<br />
Authorship acknowledgement: Lisa Miles<br />
13:00 – 14:00 Lunch Cromdale Hall<br />
BSR Biologics Register Open Meeting – progress update <strong>for</strong> BSR and<br />
BHPR members Tinto/Moorfoot<br />
14:00 – 16:00 BSR: Plenary oral presentations of abstracts Pentland/Sidlaw<br />
Chair: David GI Scott<br />
• Targeting B cells with rituximab: an effective and well tolerated treatment <strong>for</strong> active<br />
rheumatoid arthritis (RA) John Isaacs<br />
• Heberden’s nodes: what Heberden didn’t see – a high resolution MRI study of the<br />
micro-architectural abnormalities in early and established hand osteoarthritis<br />
Ai Lyn Tan<br />
• Psoriatic arthritis synovitis: a critical role <strong>for</strong> IL-15 and IL-18? David Kane<br />
• Young Investigator Award Winner: Very early rheumatoid arthritis is characterised<br />
by a unique and transient T cell and stromal cytokine profile Karim Raza<br />
• Moderate alcohol is good <strong>for</strong> women’s bones Frances Williams<br />
• Michael Mason Prize winner: Autoantibodies, lupus and the science of sabotage<br />
Anisur Rahman<br />
12
14:00 – 16:00 BHPR: Oral presentations of abstracts and presentation of arc medal<br />
Tinto/Moorfoot<br />
Chairs: Candy McCabe and Sarah Ryan<br />
• Conservative hand therapy treatments in rheumatoid arthritis (RA) –<br />
a randomised controlled trial Anne Chadwick<br />
• Pain is not always the priority – rheumatoid arthritis value other<br />
outcomes Sarah Hewlett<br />
• How does rheumatoid arthritis affect female patients’ ability to continue<br />
household activities. Results of the development and validation of a<br />
questionnaire Cathy Boys<br />
• Patients’ and rheumatologists’ different views on analgesia in RA<br />
Stella Howden<br />
• <strong>The</strong> patient’s experience of attending either a lupus or a scleroderma<br />
education <strong>programme</strong>: a qualitative evaluation Sue Brown<br />
• <strong>The</strong> future of shared care monitoring of DMARDS with the advent of the<br />
new general medical services GP contract – a survey in the Merthyr and<br />
Cynon valleys Elizabeth Thomas<br />
16:00 – 16:30 Tea Cromdale Hall<br />
16:30 – 17:30 Heberden Oration - What causes rheumatic diseases:<br />
nature vs nurture revisited Pentland Suite<br />
Orator: Prof Alan Silman, Manchester, UK<br />
Chair: Prof David GI Scott, Norwich, UK<br />
As a mark of distinction every year the BSR<br />
President appoints a Heberden Orator to give an<br />
hour keynote lecture at the BSR Annual Meeting.<br />
This tradition dates back to 1938 and the<br />
distinguished Orator is awarded a medal.<br />
This year the oration will be given by Alan Silman,<br />
Professor of Rheumatic Diseases Epidemiology at<br />
University of Manchester. He is also Director of<br />
the United Kingdom’s Arthritis Research<br />
Campaign Epidemiology Unit at the University<br />
of Manchester Medical School. Prof Silman’s interests are wide and cover<br />
genetics of rheumatoid arthritis, pregnancy and hormonal aspects of arthritis,<br />
the natural history of early arthritis, epidemiological studies of chronic pain<br />
syndromes, epidemiology of osteoporosis, Behçet’s disease and scleroderma.<br />
17:45 – 19:45 BSR Special Interest Groups<br />
• Clinical Trials Harris 2<br />
Convenor: Ernest Choy<br />
• Complex Intervention Trial Professor Paul Dieppe<br />
• Patient research partners: benefits, practicalities and challenges<br />
Dr Sarah Hewitt and Mrs Pam Richards who is a special guest as a<br />
patient research partner.<br />
• Update on EU Clinical Trials Directives Dr Sara Meredith<br />
13
• EMG / NCS Carrick 3<br />
Convenor: Ian Morris<br />
Chairman: Jumbo Jenner<br />
• Talk: Clinical Governance - experience with Peer Review so far Ian Morris<br />
• Discussion on Peer Review, with call <strong>for</strong> volunteers to undertake and receive<br />
• Review<br />
• Debate: What are the boundaries <strong>for</strong> Rheumatologists undertaking EMGs<br />
Jumbo Jenner and Rupa Bessant<br />
• Progress on CTS project and call <strong>for</strong> participants in the study: Rupa Bessant<br />
• Management of Ulnar nerve lesions – Ian Morris<br />
• Heritable Disorders of Connective Tissue Ochil 3<br />
Co-chairmen: Rodney Grahame, Howard Bird<br />
“New insights into the hypermobility syndromes” –<br />
short papers and discussion<br />
• Dysautonomia in JHS; specific to the disease or a common feature of<br />
deconditioning? Alan Hakim<br />
• Proprioceptive impairment in JHS and its restoration William Ferrell<br />
• Experience of hypermobility in a DGH paediatric rheumatology clinic<br />
Nathan Hasson<br />
• Is the JHS/EDSHM phenotype ubiquitous? Rodney Grahame<br />
• Sjögrens Syndrome Carrick 1 & 2<br />
Convenor: Simon Bowman<br />
Chairperson: Elizabeth Price<br />
• Managing the neurological complications of Sjögrens Syndrome<br />
Professor Patrick Venables<br />
• Managing lymphoma risk in Sjögrens Syndrome Dr Nurhan Sutcliffe<br />
• Managing pulmonary & renal complications of Sjögrens Syndrome<br />
Dr Ian Griffiths<br />
• Systemic lupus erythematosus Kilsyth<br />
Convenors: Bridget Griffiths and Ian Bruce<br />
• Maintenance therapy in patients with severe SLE - the BILAG RCT comparing<br />
azathioprine versus cyclosporin A: preliminary results Bridget Griffiths<br />
• Brief update on current multicentre studies in SLE patients Lead investigators<br />
• Are immunosuppressive drugs as safe as we think in pregnancy?<br />
Caroline Gordon<br />
• <strong>The</strong> use of rituximab in patients with SLE Michael Ehrenstein<br />
• Vasculitis Harris 1<br />
Convenor: David Carruthers<br />
1) Management update - Biological therapies in SNV<br />
Clinical case SpR presentation<br />
Literature review - anti-TNF and Rituximab Dr R Luqmani<br />
Discussion<br />
2) Current research update<br />
Clinical trials – HiCy Dr D Carruthers<br />
Assessment methodology - BVAS2003 Dr R Luqmani<br />
Genetic studies Dr R Watts<br />
Atheroma in SNV (Edin/Birm data) Dr J McLaren<br />
3) Any other business<br />
14
17:45 – 19:45 ARMA/BSR/SSR Event – All Welcome Pentland Auditorium<br />
A panel of service users, policy makers and health professionals will discuss the<br />
ARMA Standards of Care project and the need <strong>for</strong> strategies <strong>for</strong> musculoskeletal<br />
conditions. We are pleased to announce that the Rt. Hon. John Reid MP,<br />
Secretary of State <strong>for</strong> Health, is planning to join us <strong>for</strong> the event.<br />
20:00 – 21:30 Satellite symposia<br />
Abbott Immunology: What are your views on current anti-TNF<br />
therapy issues? Tinto/Moorfoot<br />
• Introduction from the chairman. Paul Emery<br />
• Implementing guidelines. Brian Hazleman<br />
• Funding considerations. Gabriel Panayi<br />
• Treatment goals and considerations. Duncan Porter<br />
• Screening and monitoring. David Isenberg<br />
• Cessation of therapy. Iain McInnes<br />
• Summary of key points. Paul Emery<br />
• Question and answer session.<br />
Novartis Pharmaceuticals UK Ltd: Delivering on the COX-2 promise:<br />
towards proven GI safety Sidlaw<br />
20:00 Chair’s welcome G. Nuki, Edinburgh, UK and C. Hawkey,<br />
Nottingham, UK<br />
20:05 Current issues with NSAIDs and COX-2s G. Nuki, Edinburgh, UK<br />
20:20 <strong>The</strong> emerging clinical profile of lumiracoxib<br />
A. Tyndall, Basel, Switzerland<br />
20:40 COX-2 selective inhibitors: learnings from large outcomes studies<br />
D. Walker, Newcastle, UK<br />
20:55 TARGET: the definitive outcomes study? C. Hawkey, Nottingham, UK<br />
21:15 Panel Q&A session<br />
20:25 Chair’s closing remarks G. Nuki, Edinburgh, UK and C. Hawkey,<br />
Nottingham, UK<br />
MSD Ltd: Controversies and Challenges in <strong>Rheumatology</strong> 2004<br />
To be held off-site at the Edinburgh Suite, Sheraton Grand Hotel, Edinburgh<br />
We would like to invite you on behalf of Merck Sharp & Dohme Limited to join<br />
Professor David Blake and Professor Bryan Williams along with a panel of UK<br />
rheumatologists <strong>for</strong> a clinical update followed by a battle of great (and not so<br />
great) minds in the quiz, ‘Controversies and Challenges in <strong>Rheumatology</strong>’.<br />
19:30 Buffet<br />
20:10 Welcome and introduction Chairmen<br />
20:15 Etoricoxib review – key clinical data Chairmen<br />
20:20 Questions from the audience Chairmen and Panel<br />
20:30 <strong>Rheumatology</strong> Quiz<br />
21:20 Satellite close<br />
Panel: Professor Paul Bacon, University Hospital Birmingham<br />
Professor Michael Doherty, City Hospital, Birmingham<br />
Dr Peter Hollingworth, Southmead Hospital, Bristol<br />
Professor Robert Moots, University Hospital Aintree, Liverpool<br />
Professor Gabriel Panayi, Guys Hospital, London<br />
Dr Usha Srinivasan, Princess of Wales Hospital, Bridgend<br />
Dr Doug Veale, St Vincent’s Hospital, Dublin<br />
15
Pfizer Pain Management: Hot Topics 3 – the third in a continuing series<br />
of symposia exploring the latest developments in rheumatology<br />
To be held off-site at the Main Hall, <strong>The</strong> Hub, Castlehill, Edinburgh<br />
• Chairman’s introduction Dr Frank McKenna, Manchester, UK<br />
• <strong>The</strong> impact, on individuals and populations, of the introduction of COX-2 inhibitors<br />
– the Ontario experience. Dr Muhammad Mamdani, Toronto, Canada<br />
• <strong>The</strong> role and relevance of both haematopoietic and mesenchymal stem cells in<br />
<strong>Rheumatology</strong> Prof Dennis McGonagle, Leeds, UK<br />
• Endothelial function in patients with coronary artery disease – can it be improved?<br />
Dr Frank Ruschitzka, Zurich, Switzerland<br />
Thursday 22 April 2004<br />
07:30 – 08:30 Meet the Expert Workshops<br />
<strong>The</strong>se workshops will be given by experienced clinicians in the chosen topic area<br />
and are intended to be in<strong>for</strong>mal, interactive sessions based on problem solving.<br />
<strong>The</strong> workshops are relevant to all clinicians, but especially to newly appointed<br />
consultants and SpRs.<br />
• Connective tissue disease – FULLY BOOKED Carrick 1<br />
Expert: David D’Cruz<br />
This interactive session will discuss selected patients with complex clinical problems<br />
that proved to be challenging in terms of either diagnosis or management. <strong>The</strong><br />
topics covered will include systemic lupus erythematosus, antiphospholipid<br />
syndrome and systemic vasculitis. At the end of the session participants will be able<br />
to develop their problem solving skills to improve their management of patients<br />
with multisystem autoimmune diseases.<br />
• Management of difficult rheumatoid arthritis – FULLY BOOKED Carrick 2<br />
Expert: Ernest Choy<br />
Whilst we have more options <strong>for</strong> treating patients with rheumatoid arthritis, the<br />
goal in management has also moved significantly. Delivering the best care <strong>for</strong><br />
patients with rheumatoid arthritis remains challenging. This “Meet the Expert”<br />
session will look that various therapeutic options available <strong>for</strong> managing difficult<br />
cases. Attendees are encouraged to bring their own examples <strong>for</strong> discussion at<br />
the session.<br />
• Paediatrics Carrick 3<br />
Expert: Clive Ryder<br />
Dr Clive Ryder has been a full time NHS paediatric rheumatologist <strong>for</strong> over 8 years.<br />
He is happy to discuss any aspects of the care of children with rheumatological<br />
conditions and to discuss recent advances in treatment and research. If no cases<br />
are received by the audience then sample cases will be presented which will<br />
address the difficulties of differential diagnosis, the impact of chronic disease in<br />
childhood and treatment options.<br />
16
• Respiratory - musculoskeletal comorbidity: a joint session with a<br />
rheumatologist and a chest physician Ochil 3<br />
Experts: George Kitas and Michael Cushley<br />
Pulmonary pathology is common in the connective tissue diseases and<br />
primary chest disease can also involve the joints. Diagnostic and treatment<br />
approaches may differ between the 2 disciplines and the evidence base is<br />
limited, so a combined approach may help. We will be presenting some<br />
examples <strong>for</strong> discussion and hope also to discuss cases submitted by<br />
the audience.<br />
Please note that there is an additional fee of £20 to attend a Meet the<br />
Expert workshop, and continental breakfast is included in this fee.<br />
Places are limited and are allocated on a first come, first served basis.<br />
To enquire about the availability of the workshops, please ask at the<br />
registration desk.<br />
08:30 – 10:00 BSR Poster viewing session 2 Strathblane Hall<br />
08:30 – 09:30 BHPR SIGs<br />
• Connective tissue disease Sidlaw<br />
08:30 Management of Sjögren’s Elizabeth Price<br />
08:50 Quality of life in Sjögren’s Simon Bowman<br />
09:10 Panel discussion on Sjogren’s<br />
• Osteoporosis Harris 1 & 2<br />
08:30 Chairperson opening Rachel Lewis<br />
08:35 Fracture Liason Service with in<strong>for</strong>mation on outline of the service,<br />
outcomes and case studies as requested by last years attendees<br />
Marine Fraser Bone and Metabolism unit,<br />
Western infirmary, Glasgow<br />
09:15 Questions<br />
09:25 Next years meeting<br />
• Rheumatoid arthritis Fintry<br />
Patient education - the New Forest experience. Heather Unsworth, Senior OT<br />
Anti-TNF agents - to switch or not to switch? - <strong>The</strong> Basingstoke story.<br />
Kate Wise, Nurse Specialist<br />
09:30 – 10:00 BHPR AGM Fintry<br />
10:00 – 10:30 Coffee Cromdale Hall<br />
10:30 – 12:30 BSR: Spondyloarthritis – recent advances in pathogenesis,<br />
imaging and treatment Tinto/Moorfoot/Kilsyth<br />
Chair: Andrew Keat<br />
• Why does HLA-B27 predispose to spondyloarthritis? Paul Bowness<br />
This talk will describe the biology of HLA-B27 and the cellular mechanisms<br />
by which it may cause inflammatory disease<br />
• CD4 T cells and spondyloarthritis – breaking the rules Hill Gaston<br />
<strong>The</strong> association between HLA-B27 and spondyloarthropathies is usually<br />
thought to imply a central role <strong>for</strong> CD8+ T lymphocytes in the pathogenesis<br />
of these diseases. This presentation will present evidence that CD4+ T cells<br />
can also be involved in recognition of HLA-B27, and the implications of<br />
these findings<br />
17
• Recent advances in spondyloarthritis imaging – is enthesitis the key?<br />
Dennis McGonagle<br />
Enthesitis on closely associated osteitis present at all sites of disease in the<br />
spondyloarthropathies are present in both axial and peripheral sites of disease in<br />
the spondyloarthropathy. This talk will be to review the imaging findings of<br />
enthesitis and the advantages and disadvantages of sonography in the assessment<br />
of enthesial related pathologies and will show how imaging has trans<strong>for</strong>med the<br />
understanding of these diseases.<br />
• Anti-TNF therapy <strong>for</strong> ankylosing spondylitis Jürgen Braun<br />
10:30 – 12:30 BSR: Muscle: the neglected organ in arthritis Fintry<br />
Chair: Andrew Lemmey<br />
• <strong>The</strong> concept of rheumatoid cachexia Laura Rall<br />
Patients with rheumatoid arthritis (RA) experience a loss of metabolically active<br />
tissue that we have termed ‘rheumatoid cachexia’. This loss of lean body mass is<br />
an important contributor to morbidity and mortality in RA. Many factors appear to<br />
contribute to rheumatoid cachexia, including catabolic cytokines, inadequate<br />
dietary intake, steroid effects, and decreased physical activity.<br />
• <strong>The</strong> consequences of sarcopenia – lessons from ageing Marco Narici<br />
Sarcopenia is regarded as a major cause of muscle weakness in ageing. Several<br />
factors are known to contribute to the development of sarcopenia and the<br />
associated impact on function. Loss of skeletal muscle fibres secondary to<br />
decreased numbers of motoneurons appears to be a major contributing influence,<br />
but other factors, including decreased physical activity, altered hormonal status,<br />
decreased total caloric and protein intake, inflammatory mediators, and changes in<br />
protein synthesis, are also involved. However, in ageing, the loss of muscle strength<br />
typically exceeds that of muscle size and this leads to a decrease in <strong>for</strong>ce-per unit<br />
area (muscle-quality). Although, this phenomenon is partly explained by a decrease<br />
in the <strong>for</strong>ce per unit area of muscle fibres (specific tension) and by a reduction in<br />
voluntary neural drive to the muscle, recent evidence suggests that changes in<br />
muscle architecture and in tendon mechanical properties may significantly<br />
contribute to this phenomenon. <strong>The</strong> present paper will present new findings in<br />
this field and will illustrate the role of myotendinous alterations, associated with<br />
sarcopenia, in the loss of muscle function in old age.<br />
• <strong>The</strong> role of exercise and other anabolic interventions Samuele Marcora<br />
Studies on the effects of resistance exercise, anabolic steroids, dietary amino acids<br />
supplementation and anti-TNF therapy on muscle wasting and physical function in<br />
rheumatoid arthritis patients will be presented and discussed.<br />
• Exercise in management of RA - safe, effective and efficient. Impossible?<br />
Oh ye of little faith Mike Hurley<br />
In order to convince the doubters, the safety and efficacy of exercise in improving<br />
pain and disability in RA is briefly reviewed. In order to confront the doubters, the<br />
difficulties of implementing clinical practicable exercise regimens, and how these<br />
might be addressed, are discussed. In order to blame the doubters, the vital role<br />
healthcare professionals play in helping patients help themselves is emphasised.<br />
18
10:30 – 12:30 BSR/BHPR session: <strong>The</strong> impact of illness Pentland/Sidlaw<br />
Chairs: Alan Silman and Krysia Dziedzic<br />
• <strong>The</strong> impact of arthritis Deborah Symmons<br />
This talk will describe the number of people with arthritis in the UK at the<br />
population, primary care and secondary care levels. It will examine the<br />
prevalence and risk factors <strong>for</strong> disability associated with arthritis and will<br />
explore the potential <strong>for</strong> primary and secondary prevention of arthritis<br />
associated symptoms.<br />
• <strong>The</strong> impact of illness from an individual perspective Ailsa Bosworth<br />
<strong>The</strong> impact of chronic disease on both the individual and their family is huge<br />
and at times overwhelming. My presentation will reflect on personal<br />
experience and also relate to the experience of NRAS members who have<br />
recently taken part in our second survey on the emotional and psychological<br />
impact of rheumatoid arthritis, entitled ‘Beyond the Pain’.<br />
• Illness beliefs of patients and spouses Maggie Carr<br />
This presentation explores beliefs about RA and examines the<br />
impact of any discordance in beliefs of patients and spouses on outcomes.<br />
• Common musculoskeletal pain in primary care: the example of<br />
knee pain and knee osteoarthritis in older adults George Peat<br />
Primary healthcare is the point of first presentation and on-going care <strong>for</strong><br />
the majority of people with musculoskeletal pain. Taking the example of<br />
knee pain and knee OA in older adults this presentation will consider issues<br />
related to the impact of illness in primary care and at their relation to the<br />
general population.<br />
12:30 – 14:30 Lunch Cromdale Hall<br />
BSR AGM (12:45 – 14:00) Fintry<br />
Lunch will be available <strong>for</strong> BSR AGM attendees after the meeting.<br />
14:30 – 16:30 BSR: Concurrent oral presentations of abstracts<br />
Health service and education research Tinto/Moofoot<br />
Chair: Lesley Kay<br />
• Improved access and targeting of musculoskeletal services: the teams<br />
<strong>programme</strong> Peter Maddison<br />
• Using the health assessment questionnaire and welfare benefits advice to<br />
help people disabled through arthritis to access financial support<br />
John Kirwan<br />
• RCT of patient-initiated review versus regular physician-initiated follow-up in<br />
• Development of e-learning tutorials in rheumatology: experience from the<br />
University of Bristol Robert Marshall<br />
• Competence based assessment of specialist registrars in rheumatology:<br />
assessment of out-patient consultation skills Caitlyn Dowson<br />
• Hospital services <strong>for</strong> low back pain: are they efficient? Michael Plant<br />
• Evaluation of an interactive intelligent telephone based monitoring system<br />
<strong>for</strong> patients with rheumatoid Rosie Hampson<br />
• Early physiotherapy management of back pain in primary care: a randomised<br />
clinical trial of physical treatments versus a brief pain management<br />
<strong>programme</strong> Elaine Hay<br />
19
Rheumatoid arthritis pathogenesis Fintry<br />
Chair: Chris Buckley<br />
• <strong>The</strong> balance of signalling molecules downstream of the notch receptor in<br />
CD4+CD25 high regulatory T-cells in RA resembles the balance observed in<br />
anergic cells Frederique Ponchel<br />
• Oxdative inactivation of CD45 phosphate contributes to the disregulation of<br />
T cells in RA Stephen Young<br />
• Angiopoietin 2 in inflammation, a primary role <strong>for</strong> angiogenesis in the invasive<br />
process? Ursula Fearon<br />
• Synovial HIF-2α expression is inversely related to tissue oxygen levels in<br />
inflammatory arthritis Peter Taylor<br />
• Bystander activated lymphocytes: a phenotypic comparison with rheumatoid<br />
synovial lymphocytes Jonathan Beech<br />
• Young Investigator Award Winner: <strong>The</strong> angiotensin-converting enzyme inhibitor<br />
quinapril suppresses inflammatory arthritis Nicola Dalbeth<br />
• Defects in the generation and function of regulatory T cells in rheumatoid arthritis:<br />
reversal by anti-TNFα therapy Claudia Mauri<br />
• Protease-activated receptor-2 is highly expressed in rheumatoid synovium<br />
Elizabeth Kelso<br />
Genomics Kilsyth<br />
Chair: Yuti Chernajovsky<br />
• Sequestosome 1 gene mutations in Paget’s Disease of bone lead to disregulated<br />
NFKB signalling Anna Daroszewska<br />
• OX40L, but not OX40, is associated with systemic lupus erythematosus<br />
Deborah Cunninghame<br />
• Heterogeneity amongst patients with chronic infantile neurological cutaneous<br />
and articular (CINCA) syndrome Ebun Aganna<br />
• High resolution linkage disequilibrium mapping identifies association to single<br />
nucleotide polymorphism markers mapping to a region of linkage on chromosome<br />
17q22 with rheumatoid arthritis Anne Barton<br />
• <strong>The</strong> BXSB interval on chromosome 13 (Bxs6) is necessary and sufficient <strong>for</strong> high<br />
titre gp70 autoantigen synthesis and concomitant autoantibody production<br />
Joanna Rankin<br />
• Microarray analysis of chromosome 1 congenic BXSB mice reveals novel<br />
lupus-susceptibility gene candidates Michelle Haywood<br />
• Young Investigator Award Winner: <strong>The</strong> IL-1 gene cluster is a major locus<br />
determining susceptibility to ankylosing spondylitis Andrew Timms<br />
Connective tissue diseases Sidlaw<br />
Chair: Neil McHugh<br />
• Upregulation of the monocyte chemoattractant protein-1 ligand-receptor axis in<br />
early stage diffuse cutaneous scleroderma Maria Teresa Carulli<br />
• A longitudinal analysis of skin sclerosis and organ-based endpoints in a cohort of<br />
early diffuse cutaneous systemic sclerosis Lynne Shand<br />
• Altered lipid raft expression and associated signalling in T lymphocytes from<br />
patients with systemic lupus erythematosus (SLE) Elizabeth Jury<br />
• Serological investigation of autoantibodies in 577 families with systemic lupus ery<br />
thematosus Timothy Vyse<br />
• Genetic dissection of BXSB lupus phenotype using mice congenic <strong>for</strong> chromosome<br />
1 demonstrates that separate intervals direct different aspects of disease<br />
Michelle Haywood<br />
20
• Reconstitution of C1q-deficiency with bone marrow deprived cells amelio<br />
rates the autoimmunity associated with C1q deficiency<br />
Josefina Cortes-Hernandez<br />
• Serological changes following B lymphocyte depletion therapy in systemic<br />
lupus erythematosus Maria Leandro<br />
• Quality of life and disability at presentation in polymyalgia rheumatica<br />
(PMR): results from a multi-centre prospective cohort study<br />
Andrew Hutchings<br />
14:30 – 16:30 BHPR: <strong>Rheumatology</strong> pain Pentland<br />
Chairs: Paul Creamer and Julia Taylor<br />
• Pain mechanisms Bruce Kidd<br />
Up to 85% of patients with chronic back pain and related disorders cannot<br />
be given a precise anatomical diagnosis. It is apparent that internal and<br />
external factors act in concert to produce sensitization of nociceptive/pain<br />
pathways at peripheral, spinal and cortical levels. This lecture will discuss the<br />
clinical implications of these changes and show how the evaluation and<br />
treatment of musculoskeletal pain may be facilitated using a<br />
mechanism-based approach.<br />
• Multidisciplinary team assessment and management of chronic pain<br />
Mike Shipley<br />
Chronic pain is difficult to manage. <strong>The</strong> way an experienced and<br />
multidisciplinary team including physicians, psychologists, physiotherapists<br />
and nurses assesses the patients and then encourages better coping<br />
strategies in groups of patients will be discussed.<br />
• Clinical assessment of fibromyalgia Sarah Ryan<br />
This presentation will focus on the clinical features of Fibromyalgia and the<br />
need <strong>for</strong> a biopsychosocial approach to assessment<br />
• Pain from a therapists perspective Kay Stevenson<br />
Kay will use a new referral pathway <strong>for</strong> patients with musculoskeletal disease<br />
to demonstrate how a multidisciplinary approach to patient care can<br />
improve patient outcomes and opportunities <strong>for</strong> healthcare professionals.<br />
She will also include a discussion on her role as a Consultant Physiotherapist<br />
and how this contributes to patient care<br />
16:30 – 17:00 Tea Cromdale Hall<br />
17:00 – 18:00 Heberden Round – Stepping stones in rheumatology Pentland Suite<br />
Prof Roger Sturrock, Glasgow, Scotland<br />
Chair: David GI Scott<br />
<strong>The</strong> Heberden Round was initiated in 1948 to<br />
the work of an individuals’ outstanding contribution to<br />
clinical rheumatology. <strong>The</strong> award traditionally took the<br />
<strong>for</strong>m of a ward round in the appointee’s own hospital.<br />
In 1999 it was decided that the Round would be<br />
incorporated into the BSR’s Annual Meeting to ensure<br />
greater exposure to the membership.<br />
21
This has proved to be a huge success and the one hour annual Heberden Round<br />
presentation remains a highlight within the rheumatology calendar.<br />
This year the round will be given by Roger Sturrock, McLeod/arc Professor of<br />
<strong>Rheumatology</strong>, Centre <strong>for</strong> Rheumatic Diseases, Glasgow, Scotland. Prof Sturrock has<br />
been President of the BSR and is currently Chairman of the Board of Trustees at the<br />
Arthritis Research Campaign.<br />
18:00 onwards Drinks reception, followed by dinner and ceilidh<br />
Museum of Scotland<br />
Friday 23 April 2004<br />
07:30 – 08:30 Wyeth sponsored fun run <strong>The</strong> Meadows Park, Edinburgh<br />
07:30 – 08:30 Christian Medical Fellowship breakfast meeting Harris 1<br />
08:30 – 10:00 BSR & BHPR Poster viewing session 3 Strathblane Hall<br />
10:00 – 11:00 BSR Poster Discussions<br />
Clinical aspects of rheumatoid arthritis Pentland<br />
Chairs: Hilary Cappell and Peter Dawes<br />
Posters to be discussed: 365, 343, 369, 367, 368, 372, 347, 344<br />
Connective tissue disease Sidlaw<br />
Chairs: Ian Bruce and Ariane Herrick<br />
Posters to be discussed: 262, 240, 252, 268, 217, 238, 234, 221<br />
Health service research and education Kilsyth<br />
Chairs: Andy Hassell and Deborah Symmons<br />
Posters to be discussed: 177, 199, 212, 167, 165, 151, 173, 189<br />
Spondyloarthropathies Tinto/Moorfoot<br />
Chairs: Gabrielle Kingsley and Roger Sturrock<br />
Posters to be discussed: 313, 296, 328, 320, 324, 306, 319, 312<br />
10:00 – 11:00 BHPR Poster prize and oral presentation of 3 abstracts Fintry<br />
Chairs: Lindsey Hawley and Margaret Somerville<br />
• “Clinic at home” an audit of a multidisciplinary service Yvonne Hough<br />
• Patient perception of reason <strong>for</strong> folic acid supplementation while on methotrexate<br />
<strong>for</strong> rheumatoid arthritis Moira McDonald<br />
• Winner of the NRAS Patients in Focus Award<br />
Setting up a home based patient self-administration subcutaneous methotrexate<br />
service <strong>for</strong> adults and children. Gill Jackson and Jo White<br />
11:00 – 11:30 Coffee Cromdale Hall<br />
22
11:30 – 12:30 BSR State of the Art Lecture -<br />
New therapies <strong>for</strong> autoimmune disease:<br />
anti-TNF and beyond Pentland/Sidlaw<br />
Prof Lawrence Steinman, Beckman Centre,<br />
Cali<strong>for</strong>nia, USA<br />
Chair: David Isenberg<br />
<strong>The</strong> State of the Art lecture is generally of broader<br />
interest, but relevant to rheumatologists, and is<br />
traditionally given by an invited lecturer who is<br />
eminent within their field. This year Lawrence<br />
Steinman, Professor of Neurology and<br />
Neurological Sciences at the Beckman Centre,<br />
Stan<strong>for</strong>d University, Cali<strong>for</strong>nia will give delegates a<br />
vision of the future with new biologics.<br />
Prof Steinman will describe how large scale profiles of gene transcripts from<br />
material taken from lesions has lead to the identification of new targets in<br />
autoimmunity. Some surprising new targets in Th1 autoimmunity including<br />
leptins, histamine receptors and enzymes in the cholesterol pathway will be<br />
discussed. <strong>The</strong> use of large scale profiling of the immune response to develop<br />
a “reverse genomic” approach to the antigen specific therapy of autoimmune<br />
disease, using suppressive DNA vaccines will be described.<br />
11:30 – 12:00 BHPR: Evidence based guidelines Fintry<br />
Speaker: Tom Kennedy<br />
Chairs: Alison Hammond and Bett Barrett<br />
This session will cover the principles, levels and evaluation tools used <strong>for</strong><br />
evidence based guidelines development. <strong>The</strong>re will be discussion of the BSR<br />
approach to standards, guidelines and audit.<br />
12:00 – 12:30 BHPR: Update on arc education initiative Fintry<br />
Speaker: Karen Mounce<br />
Chairs: Alison Hammond and Bett Barrett<br />
This flexible, modular, rheumatology education <strong>programme</strong> is nearing<br />
accreditation as a post-graduate certificate with a chosen university.<br />
<strong>The</strong> course will be open to all Allied Health Professionals, with a masters<br />
<strong>programme</strong> planned <strong>for</strong> subsequent development.<br />
12:30 – 13:00 Lunch Cromdale Hall<br />
13:00 – 14:30 Satellite symposium<br />
Schering Plough: “Beneath the Skin” Treatment goals <strong>for</strong> underlying<br />
disease in IMIDs Tinto<br />
• Welcome Dr Peter Taylor, Chair<br />
• Immunological Basis <strong>for</strong> IMID Professor Iain McInnes<br />
• Could healing of underlying damage now be a goal of treatment in<br />
Rheumatoid Arthritis? Dr Peter Taylor and Professor Paul Emery<br />
• Ankylosing Spondylitis and Inflammatory Bowel Disease – common<br />
treatment aims? Professor Subrata Ghosh<br />
• Questions<br />
• Thanks and close<br />
23
Additional Meetings<br />
Please note that all meetings with the exception of the RATs Meeting, BSR Standards, Audit and Guidelines<br />
Working Group Open Meeting, BSR Biologics Register Open Meeting, and the Christian Medial Fellowship<br />
Breakfast, are by invitation only.<br />
Date & Time Meeting Name Room<br />
Tuesday 20 April<br />
11:00 – 13:00 BSR External Relations Committee Ochil 3<br />
13:00 – 14:00 RATs Meeting (lunch provided) Kilsyth<br />
13:00 – 14:00 Academic <strong>Rheumatology</strong> Forum Carrick 1<br />
13:00 – 14:00 <strong>Rheumatology</strong> Editorial Board Meeting Carrick 2<br />
13:00 – 14:00 BSR Standards, Audit and Harris 1<br />
Guidelines Working Group Open Mtg<br />
16:00 – 18:00 BSRBR Management Committee Harris 1<br />
Wednesday 21 April<br />
10:00 – 11:00 BSR Clinical Affairs Committee Harris 1<br />
12:00 – 14:30 arc/BSR MIPA Clinical Trial Carrick 3<br />
13:00 – 13:45 BSR Biologics Register Open Mtg Tinto/Moorfoot<br />
14:00 – 16:00 ARMA Governance Meeting Harris 1<br />
Thursday 22 April<br />
12:45 – 14:00 BSR AGM Fintry<br />
Friday 23 April<br />
07:00 – 08:30 Fun Run – sponsored by Wyeth <strong>The</strong> Meadows Park<br />
07:30 – 08:30 Christian Medical Fellowship Breakfast Harris 1<br />
14:30 onwards <strong>The</strong> Raynaud’s & Scleroderma Association Moorfoot<br />
24
Concurrent Oral Sessions<br />
Tuesday 20 April 2004, 16:30 – 18:00<br />
Osteoarthritis and crystal diseases (OP1 – OP6) Sidlaw<br />
OP1 GAIN OF FUNCTION ANKH VARIANTS CAUSE BOTH FAMILIAL AND SPORADIC CALCIUM<br />
PYROPHOSPHATE DIHYDRATE CHONDROCALCINOSIS.<br />
Y Zhang 1,2 , K Johnson 3 , GG Russell 2 , BP Wordsworth 2 , AJ Carr 2 , RA Terkeltaub 3 , MA Brown 1,2 .<br />
1<br />
Wellcome Trust Centre <strong>for</strong> Human Genetics, Spondyloarthritis and Bone Disease Research Group,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 2 Institute of Musculoskeletal Sciences, the Botnar<br />
Centre, Nuffield Orthopaedic Centre, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 3 VA Medical<br />
Center, Division of <strong>Rheumatology</strong>, University of Cali<strong>for</strong>nia, San Diego, United States<br />
OP2 MONOCYTE-MACROPHAGE DIFFERENTIATION IN VIVO AND THE CONTROL OF<br />
MONOSODIUM URATE (MSU) CRYSTAL-STIMULATED INFLAMMATION.<br />
DR Yagnik, BJ Evans, C Landis, DO Haskard. Eric Bywaters Centre <strong>for</strong> Vascular Inflammation,<br />
Imperial College, London, United Kingdom<br />
OP3 SEQUENCIAL MEASUREMENTS OF SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN<br />
(COMP) INDICATE A NON-LINEAR PROGRESSION OF KNEE OSTEOARTHRITIS.<br />
M Sharif 1 , JR Kirwan 2 , R Granell 2 , S Clarke 2 . 1<br />
Department of Anatomy, University of Bristol, Bristol,<br />
United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary, Bristol, United Kingdom<br />
OP4 NEUROVASCULAR INVASION AT THE OSTEOCHONDRAL JUNCTION IN OSTEOARTHRITIS.<br />
SE Gill 1 , CS Bonnet 1 , S Suri 1 , D Wilson 2 , DA Walsh 1,2 . 1<br />
Academic <strong>Rheumatology</strong>, University of<br />
Nottingham, Nottingham, Nottinghamshire, United Kingdom; 2 Back Pain Unit, King’s Mill Hospital,<br />
Mansfield, Nottinghamshire, United Kingdom<br />
OP5 CANCELLOUS BONE CHANGES IN THE PROXIMAL TIBIA OF PATIENTS WITH KNEE<br />
OSTEOARTHRITIS.<br />
EA Messent, C Buckland-Wright. Applied Clinical Anatomy, King’s College London, London,<br />
United Kingdom<br />
OP6 LONG TERM OUTCOME FOLLOWING TOTAL HIP ARTHROPLASTY: A CASE CONTROL<br />
STUDY.<br />
J Cushnaghan 1 , I Reading 1 , P Byng 1 , D Coggon 1 , K Cox 1 , P Croft 2 , P Dieppe 3 , C Cooper 1 . 1<br />
MRC EEU,<br />
Southampton University, Southampton, United Kingdom; 2 Primary Care Sciences Research Centre,<br />
Keele University, Keele, United Kingdom; 3 MRC Health Services Research Collaboration, Bristol<br />
University, Bristol, United Kingdom<br />
Epidemiology (OP7 – OP12) Fintry<br />
OP7 BIRTH ORDER AS A DETERMINANT OF OSTEOPOROSIS RISK: THE HERTFORDSHIRE<br />
COHORT STUDY.<br />
E Dennison, H Syddall, A Aihie Sayer, H Gilbody, C Cooper. Medical Research Council<br />
Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hampshire,<br />
United Kingdom<br />
OP8 JOINT HYPERMOBILITY IS COMMON AND STRONGLY GENETICALLY DETERMINED:<br />
RESULTS OF A FEMALE TWIN STUDY.<br />
AJ Hakim 1,2,3 , R Grahame 2 , TD Spector 1 , AJ MacGregor 1 . 1<br />
<strong>The</strong> Twin Research Unit, St Thomas’<br />
Hospital, London, United Kingdom; 2 <strong>The</strong> Hypermobility Clinic, Centre <strong>for</strong> <strong>Rheumatology</strong>, University<br />
College London Hospitals, London, United Kingdom; 3 <strong>The</strong> Academic <strong>Rheumatology</strong> and<br />
Osteoporosis Unit, Whipps Cross University Hospital, London, United Kingdom<br />
25
OP9 ASSOCIATION BETWEEN DIETARY CAROTENOIDS AND RISK OF DEVELOPING<br />
INFLAMMATORY POLYARTHRITIS.<br />
DJ Pattison 1 , DPM Symmons 1 , M Lunt 1 , A Welch 2 , R Luben 2 , SA Bingham 3 , K-T Khaw 2 , NE Day 2 , AJ<br />
Silman 1 . 1 Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United<br />
Kingdom; 2 Department of Public Health & Primary Care, University of Cambridge, Cambridge, United<br />
Kingdom; 3 MRC Dunn Human Nutrition Unit, University of Cambridge, Cambridge, United Kingdom<br />
Young Investigator Award Winner<br />
OP10 PREDICTING PERSISTENCE OF NECK PAIN FOLLOWING A MOTOR VEHICLE ACCIDENT:<br />
A PROSPECTIVE STUDY OF PERSONS ATTENDING EMERGENCY DEPARTMENT.<br />
K Atherton 1 , GT Jones 1,2 , NJ Wiles 2,3 , AJ Silman 2 , FE Lecky 1 , SJ Hawes 4 , AJ Littlewood 1 , CJ Main 1 , GJ<br />
Macfarlane 1,2 . 1<br />
Unit of Chronic Disease Epidemiology, University of Manchester, Manchester, United<br />
Kingdom; 2 Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United<br />
Kingdom; 3 Division of Psychiatry, University of Bristol, Bristol, United Kingdom; 4 Department of<br />
Emergency Medicine, Wythenshawe Hospital, Manchester, United Kingdom<br />
OP11 HYPOTHALAMIC-PITUITARY-ADRENAL STRESS AXIS FUNCTION - THE RELATIONSHIP WITH<br />
CHRONIC WIDESPREAD PAIN AND ITS ANTECEDENTS: A POPULATION-BASED STUDY.<br />
J McBeth 1 , YH Chiu 1,5 , D Ray 2 , RK Morriss 3 , C Dickens 4 , A Gupta 1 , AJ Silman 1 , GJ Macfarlane 1,5 . 1<br />
ARC<br />
Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Endocrine Sciences Research<br />
Group, University of Manchester, Manchester, United Kingdom; 3 Department of Psychiatry, University of<br />
Liverpool, Liverpool, United Kingdom; 4 Department of Psychiatry, University of Manchester, Manchester,<br />
United Kingdom; 5 <strong>The</strong> Unit of Chronic Disease Epidemiology, University of Manchester, Manchester,<br />
United Kingdom.<br />
OP12 IS MUSCULOSKELETAL PAIN MORE COMMON NOW THAN 40 YEARS AGO?<br />
RESULTS FROM TWO POPULATION-BASED CROSS-SECTIONAL STUDIES.<br />
J McBeth 1 , EF Harkness 1 , AJ Silman 1 , GJ Macfarlane 1,2 . 1<br />
ARC Epidemiology Unit, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom; 2 <strong>The</strong> Unit of Chronic Diseases Epidemiology, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom<br />
Vascular injury (OP13 – OP18) Tinto/Moorfoot<br />
OP13 SYSTEMIC RHEUMATOID VASCULITIS - FACING EXTINCTION?<br />
RA Watts 1 , J Mooney 2 , SE Lane 2 , DGI Scott 2 . 1<br />
Department of <strong>Rheumatology</strong>, Ipswich Hospital NHS Trust,<br />
Ipswich, Suffolk, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Norfolk & Norwich University Hospital,<br />
Norwich, Norfolk, United Kingdom<br />
Young Investigator Award Winner<br />
OP14 THE HAEMOGLOBIN SCAVENGER RECEPTOR CD163 MEDIATES MACROPHAGE<br />
INTERLEUKIN-10 AND HAEM OXYGENASE-1 SYNTHESIS: AN INDUCIBLE CYTOPROTECTIVE<br />
PATHWAY AGAINST HAEMOGLOBIN-MEDIATED OXIDATIVE VASCULAR INJURY.<br />
P Philippidis, BJ Evans, JC Mason, KM Taylor, DO Haskard, C Landis. Eric Bywaters Centre <strong>for</strong> Vascular<br />
Inflammation, Imperial College, London, United Kingdom<br />
Young Investigator Award Winner<br />
OP15 UPREGULATION OF MEMBRANE-BOUND COMPLEMENT REGULATORY PROTEINS BY<br />
ATORVASTATIN PROTECTS VASCULAR ENDOTHELIUM AGAINST COMPLEMENT-MEDIATED INJURY<br />
DURING HYPOXIA-REOXYGENATION.<br />
AR Kinderlerer 1 , R Mankoff 1 , PH Maxwell 2 , DO Haskard 1 , JC Mason 1 . 1<br />
BHF Cardiovascular Medicine Unit,<br />
<strong>The</strong> Eric Bywaters Centre <strong>for</strong> Vascular Inflammation, Imperial College London, London, United Kingdom;<br />
2<br />
Renal Unit, Faculty of Medicine, Imperial College London, London, United Kingdom<br />
26
OP16 RENAL ARTERY STENOSIS IN HYPERTENSIVE PATIENTS WITH ANTIPHOSPHOLIPID SYN-<br />
DROME (APS): THE EFFECTS OF ANTICOAGULATION.<br />
S Sangle, D D’Cruz, M Khamashta, GRV Hughes. Lupus Research Unit, <strong>The</strong> Rayne Institute, St<br />
Thomas’ Hospital, London, United Kingdom<br />
OP17 CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS<br />
IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV).<br />
EM Salisbury 1 , JS McLaren 1 , DRW Jayne 2 , RA Luqmani 1 . 1<br />
Rheumatic Diseases Unit, University of<br />
Edinburgh, Edinburgh, United Kingdom; 2 Addenbrooke’s NHS Trust, Cambridge, United Kingdom<br />
OP18 MOLECULAR PROFILE OF SYMPTOMATIC AND ASYMPTOMATIC CAROTID PLAQUES.<br />
EP Halligan 1 , M Sintler 2 , A Mahmood 2 , J Butler 1 , J Vorha 2 , GD Kitas 3 , J Lunec 1 . 1<br />
Cancer Studies and<br />
Molecular Medicine, Univesity of Leicester, Leicester, Leicestershire, United Kingdom; 2 Vascular<br />
Surgery, Selloak Hospital, Birmingham, United Kingdom; 3 <strong>Rheumatology</strong>, Dudley Group of<br />
Hospitals NHS Trust, Dudley, United Kingdom<br />
THERAPEUTICS (OP19 – OP24) Pentland<br />
OP19 THE ARMADA TRIAL: EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA ® ) OVER 30<br />
MONTHS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS.<br />
ME Weinblatt 1 , EC Keystone 2 , DE Furst 3 , A Kavanaugh 4 , OG Segurado 5 , G Spencer-Green 6 , EK<br />
Chartash 6 . 1<br />
Brigham Women’s Hospital, Boston, MA, United States; 2 University of Toronto,<br />
Toronto, ON, Canada; 3 UCLA, Los Angeles, CA, United States; 4 <strong>The</strong> Center <strong>for</strong> Innovative <strong>The</strong>rapy,<br />
UCSD, San Diego, CA, United States; 5 Abbott Laboratories, Chicago, IL, United States; 6 Abbott<br />
Laboratories, Parsippany, NJ, United States<br />
OP20 ADALIMUMAB (HUMIRA ® ) INHIBITS RADIOGRAPHIC PROGRESSION IN RHEUMATOID<br />
ARTHRITIS (RA) PATIENTS WITH LONG-STANDING DISEASE: DATA AT TWO YEARS.<br />
E Keystone 1 , A Kavanaugh 2 , J Sharp 3 , G Spencer-Green 4 , OG Segurado 5 . 1<br />
University of Toronto,<br />
Toronto, ON, Canada; 2 <strong>The</strong> Centre <strong>for</strong> Innovative <strong>The</strong>rapy, UCSD, San Diego, CA, United States;<br />
3<br />
University of Washington, Seattle, WA, United States; 4 Abbott Laboratories, Parsippany, NJ,<br />
United States; 5 Abbott Laboratories, Chicago, IL, United States<br />
OP21 EFFICACY OF ANAKINRA IN ACTIVE ANKYLOSING SPONDYLITIS: A CLINICAL<br />
AND MAGNETIC RESONANCE IMAGING STUDY.<br />
AL Tan 1,3 , H Marzo-Ortega 1 , P O’Connor 2 , A Fraser 1 , P Emery 1 , D McGonagle 1,3 . 1<br />
Academic Unit of<br />
Musculoskeletal Disease, Leeds General Infirmary, Leeds, United Kingdom; 2 Department of<br />
Radiology, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of <strong>Rheumatology</strong>,<br />
Calderdale Royal Hospital, Halifax, United Kingdom<br />
OP22 PREDICTIVE VALUE OF SYNOVIAL CYTOKINE EXPRESSION FOR RESPONSE<br />
TO ANTI-TUMOUR-NECROSIS-FACTOR-α TREATMENT IN RHEUMATOID ARTHRITIS<br />
IN CLINICAL PRACTICE.<br />
MH Buch 1 , A English 1 , G Cunnane 2 , K Henshaw 1 , R Reece 1 , M Quinn 1 , SJ Bingham 1 , V Bejarano 1 ,<br />
P Emery 1 . 1<br />
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, West Yorkshire,<br />
United Kingdom; 2 Department of <strong>Rheumatology</strong>, St. James’ Hospital, Dublin, Ireland<br />
OP23 A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTI-CENTRE TRIAL OF<br />
COMBINATION THERAPY WITH METHOTREXATE PLUS CYCLOSPORIN V METHOTREXATE PLUS<br />
PLACEBO IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS.<br />
AD Fraser 1 , A van Kuyk 2 , R Westhovens 3 , Z Karim 1 , A Gerards 2 , RBM Landewe 4 , S Steinfeld 5 ,<br />
P Emery 1 , BAC Dijkmans 2 , DJ Veale 1 . 1<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University<br />
of Leeds, Leeds, West Yorkshire, United Kingdom; 2 VU University Medical Center, VU University,<br />
Amsterdam, <strong>The</strong> Netherlands; 3 Department of Rheuamtology, University of Leuven, Leuven,<br />
Belgium; 4 Department of <strong>Rheumatology</strong>, University Hospital Maastricht, Maastricht, <strong>The</strong><br />
Netherlands; 5 Department of Rheuamtology, Erasme University Hospital, Brussels, Belgium<br />
27
OP24 A RANDOMISED CONTROLLED TRIAL OF INTRA-ARTICULAR TRIAMCINOLONE<br />
AND/OR PHYSIOTHERAPY IN SHOULDER CAPSULITIS.<br />
I Ryans 1 , A Montgomery 2 , R Galway 2 , WG Kernohan 3 , R McKane 1 . 1<br />
Rhematology Department, <strong>The</strong> Ulster<br />
Hospital, Dundonald, Belfast, Northern Ireland, United Kingdom; 2 Physiotherapy Department, <strong>The</strong> Ulster<br />
Hospital, Dundonald, Belfast, Northern Ireland, United Kingdom; 3 Faculty of Life and Health Sciences,<br />
University of Ulster, Jordanstown, Northern Ireland, United Kingdom<br />
BSR Plenary Oral Session<br />
Wednesday 21 April 2004, 14:00 – 16:00<br />
BSR PLENARY SESSION (OP25 - OP30) Pentland/Sidlaw<br />
OP25 TARGETING B CELLS WITH RITUXIMAB: AN EFFECTIVE AND WELL TOLERATED<br />
TREATMENT FOR ACTIVE RHEUMATOID ARTHRITIS (RA).<br />
JD Isaacs 1 , P Emery 2 . 1<br />
Department of <strong>Rheumatology</strong>, University of Newcastle-upon-Tyne, Newcastle,<br />
Newcastle-upon-Tyne, United Kingdom; 2 Academic Unit of Musculoskeletal Disease, Department of<br />
<strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, United Kingdom<br />
OP26 HEBERDEN’S NODES: WHAT HEBERDEN DIDN’T SEE- A HIGH RESOLUTION MRI STUDY OF THE<br />
MICRO-ARCHITECTURAL ABNORMALITIES IN EARLY AND ESTABLISHED HAND OSTEOARTHRITIS.<br />
AL Tan 1 , A Grainger 2 , SF Tanner 3 , P Emery 1 , D McGonagle 1 . 1<br />
Academic Unit of Musculoskeletal Disease,<br />
University of Leeds, Leeds, United Kingdom; 2 Department of Radiology, Leeds General Infirmary, Leeds,<br />
United Kingdom; 3 Academic Unit of Medical Physics, University of Leeds, Leeds, United Kingdom<br />
OP27 PSORIATIC ARTHRITIS SYNOVITIS: A CRITICAL ROLE FOR IL-15 AND IL-18?<br />
DJ Kane 1 , A Gracie 2 , S Karanaman 2 , M Gogarty 3 , B Bresnihan 3 , O FitzGerald 3 , IB McInnes 2 .<br />
1<br />
<strong>Rheumatology</strong>, University of Newcastle, Newcastle, United Kingdom; 2 Centre <strong>for</strong> Rheumatic Diseases,<br />
Glasgow Royal Infirmary, Glasgow, United Kingdom; 3 <strong>Rheumatology</strong>, St. Vincent’s University Hospital,<br />
Dublin, United Kingdom<br />
Young Investigator Award Winner<br />
OP28 VERY EARLY RHEUMATOID ARTHRITIS IS CHARACTERISED BY A UNIQUE AND TRANSIENT<br />
T CELL AND STROMAL CYTOKINE PROFILE.<br />
K Raza 1 , SJ Curnow 1 , EJ Taylor 1 , KY Lee 2 , AN Akbar 3 , J Lord 1 , GD Kitas 4 , CD Buckley 1 , C Gordon 1 ,<br />
M Salmon 1 . 1<br />
Division of Immunity and Infection, MRC Centre <strong>for</strong> Immune Regulation, University of<br />
Birmingham, Birmingham B15 2TT, United Kingdom; 2 Department of Radiology, City Hospital, Dudley<br />
Road, Birmingham, B18 7QH, United Kingdom; 3 Department of Immunology and Molecular Pathology,<br />
Royal Free and University College Medical School, London, United Kingdom; 4 Department of<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, DY1 4SE, United Kingdom<br />
OP29 MODERATE ALCOHOL IS GOOD FOR WOMEN’S BONES.<br />
FMK Williams, LF Cherkas, TD Spector, AJ MacGregor. Twin Research and Genetic Epidemiology Unit,<br />
St Thomas’ Hospital, London, SE1 7EH, United Kingdom<br />
Michael Mason Prize Winner<br />
OP30 autoantibodies, lupus, and the science of sabotage<br />
A Rahman. Centre <strong>for</strong> <strong>Rheumatology</strong>, Department of Medicine, University College London,<br />
United Kingdom.<br />
28
BHPR Plenary Oral Session<br />
Wednesday 21 April 2004, 14:00 – 16:00<br />
BHPR PLENARY SESSION (OP31 – OP36) Tinto/Moorfoot<br />
OP31 CONSERVATIVE HAND THERAPY TREATMENTS IN RHEUMATOID ARTHRITIS (RA) -<br />
A RANDOMISED CONTROLLED TRIAL.<br />
AV Chadwick 1 , CS Simpson 2 , K Murray 2 , J Spicer 2 , D Mulherin 2 , PW Jones 3 , R Mullis 1,4 ,<br />
K Dziedzic 1,4 . 1<br />
Department of Physiotherapy Studies, Keele University, Keele, Staffs ST5 5BG,<br />
United Kingdom; 2 Department of Rehabilitation, Mid-Staf<strong>for</strong>dshire General Hospitals NHS Trust,<br />
Staf<strong>for</strong>d, Staffs, United Kingdom; 3 Department of Mathematics, Keele University, Keele, Staffs ST5<br />
5BG, United Kingdom; 4 Primary Care Sciences Research Centre, Keele University, Keele, Staffs ST5<br />
5BG, United Kingdom<br />
OP32 PAIN IS NOT ALWAYS THE PRIORITY - RHEUMATOID ARTHRITIS PATIENTS<br />
VALUE OTHER OUTCOMES.<br />
S Hewlett 1 , M Carr 2 , S Ryan 3 , J Kirwan 1 , P Richards 1 , P Creamer 4 , A Carr 5 , R Hughes 2 . 1<br />
Academic<br />
<strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom; 2 <strong>Rheumatology</strong> Department, St<br />
Peter’s Hospital, Chertsey, United Kingdom; 3 <strong>Rheumatology</strong> Department, Heywood Hospital, Stoke<br />
on Trent, United Kingdom; 4 <strong>Rheumatology</strong> Department, Southmead Hospital, Bristol, United<br />
Kingdom; 5 <strong>Rheumatology</strong> Department, Nottingham University, Nottingham, United Kingdom<br />
OP33 HOW DOES RHEUMATOID ARTHRITIS AFFECT FEMALE PATIENTS’ ABILITY<br />
TO CONTINUE HOUSEHOLD ACTIVITIES. RESULTS OF THE DEVELOPMENT AND<br />
VALIDATION OF A QUESTIONNAIRE.<br />
C Boys 1 , C Mayes 2 , A Young 2 , P Prouse 1 , A Stylianou 3 , J Done 3 . 1<br />
<strong>Rheumatology</strong> Department, North<br />
Hampshire Hospital, Basingstoke, Hampshire, United Kingdom; 2 <strong>Rheumatology</strong> Department, St<br />
Albans City Hospital, St Albans, Hert<strong>for</strong>dshire, United Kingdom; 3 Psychology Department, R&D<br />
Support Unit, University of Hert<strong>for</strong>dshire, Hatfield, Hert<strong>for</strong>dshire, United Kingdom<br />
OP34 PATIENTS’ AND RHEUMATOLOGISTS’ DIFFERENT VIEWS ON ANALGESIA IN RA.<br />
S Howden 1 , M Nicol 1 , DJ Martin 2 , D Jones 1 . 1<br />
Occupational <strong>The</strong>rapy Department, Queen Margaret<br />
University College, Edinburgh, Lothian, United Kingdom; 2 Physiotherapy Department, Queen<br />
Margaret University College, Edinburgh, Lothian, United Kingdom<br />
OP35 THE PATIENT’S EXPERIENCE OF ATTENDING EITHER A LUPUS OR A SCLERODERMA<br />
EDUCATION PROGRAMME: A QUALITATIVE EVALUATION.<br />
SJ Brown, NJ McHugh. RACE, Royal National Hospital <strong>for</strong> Rheumatic Diseases NHS Trust, Bath<br />
BA1 1RL, United Kingdom<br />
OP36 THE FUTURE OF SHARED CARE MONITORING OF DMARDS WITH THE ADVENT<br />
OF THE NEW GENERAL MEDICAL SERVICES GP CONTRACT - A SURVEY IN THE MERTHYR<br />
AND CYNON VALLEYS.<br />
E Thomas, F Hayes, C Rhys-Dillon. Department of <strong>Rheumatology</strong>, Prince Charles Hospital, Merthyr<br />
Tydfil, South Wales, United Kingdom<br />
29
Concurrent Oral Sessions<br />
Thursday 22 April 2004, 14:30 – 16:30<br />
HEALTH SERVICE AND EDUCATION RESEARCH (OP37 – OP44) Tinto/Moorfoot<br />
OP37 IMPROVED ACCESS AND TARGETING OF MUSCULOSKELETAL SERVICES:<br />
THE TEAMS PROGRAMME.<br />
P Maddison 1 , J Jones 1 , R Lewis 1 , L McSweeney 1 , C Norgain 1 , C Barton 1 , A Breslin 1 , J Fleur 1 , S Smith 1 ,<br />
C Thomas 1 , C Tillson 2 . 1<br />
<strong>Rheumatology</strong>, Orthopaedics, <strong>The</strong>rapy Services and Pain Management, Ysbyty<br />
Gwynedd, Bangor, Gwynedd, United Kingdom; 2 Gwynedd Local Health Board, Eryldon, Caernarfon,<br />
Gwynedd, United Kingdom<br />
OP38 USING THE HEALTH ASSESSMENT QUESTIONNAIRE AND WELFARE BENEFITS ADVICE TO HELP<br />
PEOPLE DISABLED THROUGH ARTHRITIS TO ACCESS FINANCIAL SUPPORT.<br />
C Langley 1 , DS Memel 1 , JR Kirwan 2 , J Pollock 3 , S Hewlett 2 , D Gubbay 4 , J Powell 3 . 1<br />
Air Balloon Surgery,<br />
Bristol, United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, University of Bristol, Bristol, United Kingdom;<br />
3<br />
Faculty of Health and Social Care, University of the West of England, Bristol, United Kingdom; 4 Barton<br />
Hill Advice Service, Bristol, United Kingdom<br />
OP39 RCT OF PATIENT-INITIATED REVIEW VERSUS REGULAR PHYSICIAN-INITIATED FOLLOW-UP IN<br />
RHEUMATOID ARTHRITIS, EXTENDED TO 6 YEARS.<br />
S Hewlett 1 , J Kirwan 1 , K Mitchell 1 , M Hehir 1 , J Pollock 2 , D Memel 3 , PS Blair 4 , M Perry 1 . 1<br />
Academic<br />
<strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom; 2 Faculty of Health and Social Care,<br />
University of the West of England, Bristol, United Kingdom; 3 Air Balloon Surgery, Bristol, United<br />
Kingdom; 4 Division of Child Health, University of Bristol, Bristol, United Kingdom<br />
OP40 DEVELOPMENT OF E-LEARNING TUTORIALS IN RHEUMATOLOGY: EXPERIENCE<br />
FROM THE UNIVERSITY OF BRISTOL.<br />
RW Marshall 1,2 , JR Kirwan 1 . 1<br />
<strong>Rheumatology</strong> Unit, University Department of Clinical Science at South<br />
Bristol, Bristol, BS2 8HW, United Kingdom; 2 <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, BA1 1RL, United Kingdom<br />
OP41 COMPETENCE BASED ASSESSMENT OF SPECIALIST REGISTRARS IN RHEUMATOLOGY:<br />
ASSESSMENT OF OUT-PATIENT CONSULTATION SKILLS.<br />
CM Dowson, AB Hassell. West Midland <strong>Rheumatology</strong> Services and Training Committee (WMRSTC),<br />
Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Stoke-on-Trent, North Staf<strong>for</strong>dshire, United Kingdom<br />
OP42 HOSPITAL SERVICES FOR LOW BACK PAIN : ARE THEY EFFICIENT?<br />
MJ Plant 1 , R Chadwick 3 , R Strachan 2 , M Murray 4 , E Carter 5 , S Puttick 5 , K Milligan 3 , C Greenough 4 .<br />
1<br />
<strong>Rheumatology</strong>, <strong>The</strong> James Cook University Hospital, Middlesbrough, United Kingdom; 2 Neurosurgery,<br />
<strong>The</strong> James Cook University Hospital, Middlesbrough, United Kingdom; 3 Pain Management, <strong>The</strong> James<br />
Cook University Hospital, Middlesbrough, United Kingdom; 4 Spinal Injuries, <strong>The</strong> James Cook University<br />
Hospital, Middlesbrough, United Kingdom; 5 Clinical Audit, <strong>The</strong> James Cook University Hospital,<br />
Middlesbrough, United Kingdom<br />
OP43 EVALUATION OF AN INTERACTIVE INTELLIGENT TELEPHONE BASED MONITORING<br />
SYSTEM FOR PATIENTS WITH RHEUMATOID.<br />
R Hampson, A Tierney, HA Capell, R Madhok. Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow,<br />
United Kingdom<br />
OP44 EARLY PHYSIOTHERAPY MANAGEMENT OF BACK PAIN IN PRIMARY CARE: A RANDOMISED<br />
CLINICAL TRIAL OF PHYSICAL TREATMENTS VERSUS A BRIEF PAIN MANAGEMENT PROGRAMME.<br />
EM Hay 1 , R Mullis 1 , M Lewis 1 , K Vohora 1 , C Main 2 , P Watson 3 , K Dzeidzic 1 , J Sim 1 , P Croft 1 . 1<br />
Primary Care<br />
Sciences Research Centre, Keele University, Keele, United Kingdom; 2 Department of Behavioral Medicine,<br />
Manchester University, Manchester, United Kingdom; 3 Department of Anaesthetics and Pain<br />
Management, University of Leicester, Leicester, United Kingdom<br />
30
RA PATHOGENESIS (OP45 – OP52) Fintry<br />
OP45 THE BALANCE OF SIGNALING MOLECULES DOWNSTREAM OF THE NOTCH RECEPTOR<br />
IN CD4+CD25 high REGULATORY T-CELLS IN RA RESEMBLES THE BALANCE OBSERVED IN<br />
ANERGIC CELLS.<br />
F Ponchel, SL Field, KE Snow, JD Isaacs, P Emery. Molecular Medicine Unit/<strong>Rheumatology</strong> Reserch<br />
Unit, University of Leeds, Leeds, West Yorkshire, United Kingdom<br />
OP46 OXDATIVE INACTIVATION OF CD45 PHOSPHATASE CONTRIBUTES TO THE<br />
DYSREGULATION OF T CELLS IN RA .<br />
DA Rider, AM McKendry, JE Goodall, SP Young. <strong>Rheumatology</strong>, University of Birmingham,<br />
Birmingham, West Midlands, United Kingdom<br />
OP47 ANGIOPOIETIN 2 IN INFLAMMATION, A PRIMARY ROLE FOR ANGIOGENESIS<br />
IN THE INVASIVE PROCESS?<br />
U Fearon 1 , T Markham 1 , RH Mullan 1 , L Golden-Mason 2 , T Duffy 1 , L Greenan 1 , B Bresnihan 1 ,<br />
O FitzGerald 1 , DJ Veale 1 . 1<br />
<strong>Rheumatology</strong>, St Vincents University Hospital and <strong>The</strong> Conway Institute,<br />
Dublin, Ireland; 2 Liver Unit, St Vincents University Hospital, Dublin, Ireland<br />
OP48 SYNOVIAL HIF-2a EXPRESSION IS INVERSELY RELATED TO TISSUE OXYGEN<br />
LEVELS IN INFLAMMATORY ARTHRITIS.<br />
V Sandhu 1 , D Peston 2 , A Sandisson 2 , PC Taylor 1 . 1<br />
Kennedy Institute of <strong>Rheumatology</strong> Division,<br />
Imperial College, London, United Kingdom; 2 Charing Cross Hospital, Department of Pathology,<br />
London, United Kingdom<br />
OP49 BYSTANDER ACTIVATED LYMPHOCYTES : A PHENOTYPIC COMPARISON WITH<br />
RHEUMATOID SYNOVIAL LYMPHOCYTES.<br />
J Beech, P Amjadi, S Owen, A Foey, F Brennan. Kennedy Institute of <strong>Rheumatology</strong> Division,<br />
Imperial College, London, United Kingdom<br />
Young Investigator Award Winner<br />
OP50 THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR QUINAPRIL SUPPRESSES<br />
INFLAMMATORY ARTHRITIS.<br />
N Dalbeth 1,2 , J Edwards 3 , MFC Callan 1,2 , FC Hall 1,4 . 1<br />
Weatherall Institute of Molecular Medicine,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 2 Department of Immunology, Imperial College<br />
London, London, United Kingdom; 3 Nuffield Department of Orthopaedic Surgery, Universty of<br />
Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 4 University of Cambridge School of Clinical Medicine,<br />
Addenbrooke’s Hospital, Cambridge, United Kingdom<br />
OP51 DEFECTS IN THE GENERATION AND FUNCTION OF REGULATORY T CELLS IN<br />
RHEUMATOID ARTHRITIS: REVERSAL BY ANTI-TNFα THERAPY.<br />
MR Ehrenstein, JG Evans, A Singh, S Moore, DA Isenberg, C Mauri. Department of Medicine,<br />
University College London, London, United Kingdom<br />
OP52 PAR-2 IN THE PATHOGENESIS OF JOINT INFLAMMATION.<br />
EB Kelso 1 , I Elias-Jones 1 , L Dunning 2 , JC Lockhart 2 , WR Ferrell 1 , MD Hollenberg 3 , R Plevin 4 . 1<br />
Centre<br />
<strong>for</strong> Rheumatic Diseases, University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Biological<br />
Sciences, University of Paisley, Glasgow, Scotland, United Kingdom; 3 Department of Pharmacology,<br />
University of Calgary, Canada; 4 Department of Physiology & Pharmacology, Strathyclyde University,<br />
Scotland.<br />
GENOMICS (OP53 – OP60) Kilsyth<br />
OP53 SEQUESTOSOME 1 GENE MUTATIONS IN PAGET’S DISEASE OF BONE LEAD<br />
TO DISREGULATED NFKB SIGNALLING.<br />
A Daroszewska, A Duthie, LJ Hocking, G Lucas, RJ van ‘t Hof, SH Ralston. Department of<br />
Medicine and <strong>The</strong>rapeutics, University of Aberdeen, Aberdeen, Aberdeenshire, United Kingdom<br />
31
OP54 OX40L, BUT NOT OX40, IS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS.<br />
DS Cunninghame Graham, TJ Vyse. <strong>Rheumatology</strong> Section, Imperial College, Hammersmith Campus,<br />
Eric Bywaters Centre, London, United Kingdom<br />
OP55 HETEROGENEITY AMONGST PATIENTS WITH CHRONIC INFANTILE NEUROLOGICAL CUTA-<br />
NEOUS AND ARTICULAR (CINCA) SYNDROME.<br />
E Aganna, 1 JE Davidson, 2 G Cleary, 2 JA Sills, 2 A Bybee, 3 E Drewe, 4 GA Hitman, 1 P Woo, 5 PN Hawkins, 3 MF<br />
McDermott. 1 1 Centre <strong>for</strong> Diabetes & Metabolic Medicine, Queen Mary School of Medicine and Dentistry,<br />
London, United Kingdom; 2 <strong>Rheumatology</strong>, Royal Liverpool Children’s Hospital, Alder Hey, Liverpool,<br />
United Kingdom; 3 Centre <strong>for</strong> Amyloidosis, Royal Free Hospital, London, United Kingdom; 4 Molecular and<br />
Clinical Immunology, Queen’s Medical Centre, Nottingham, United Kingdom; 5 <strong>Rheumatology</strong>, Child<br />
Health, University College, London, United Kingdom<br />
OP56 HIGH RESOLUTION LINKAGE DISEQUILIBRIUM MAPPING IDENTIFIES ASSOCIATION TO SINGLE<br />
NUCLEOTIDE POLYMORPHISM MARKERS MAPPING TO A REGION OF LINKAGE ON CHROMOSOME<br />
17Q22 WITH RHEUMATOID ARTHRITIS.<br />
A Barton 1 , D Ward 1 , S Eyre 1 , A Hinks 1 , A Silman 1 , E Culbert 2 , S John 3 , J Worthington 1 . 1<br />
ARC-EU, University<br />
of Manchester, Manchester, United Kingdom; 2 Astra-Zeneca Pharmceuticals Ltd, Alderley Park,<br />
Macclesfield, Cheshire, United Kingdom; 3 CIGMR, University of Manchester, Manchester, United Kingdom<br />
OP57 THE BXSB INTERVAL ON CHROMOSOME 13 (BXS6) IS NECESSARY AND SUFFICIENT FOR HIGH<br />
TITRE GP70 AUTOANTIGEN SYNTHESIS AND CONCOMITANT AUTOANTIBODY PRODUCTION.<br />
JM Rankin 1 , MEK Haywood 1 , A McDermott 1 , S Izui 2 , B Morley 1 . 1<br />
<strong>Rheumatology</strong> Section,<br />
<strong>The</strong> Eric Bywaters Centre, Imperial College, London, United Kingdom; 2 Department of Pathology,<br />
C.M.U, Geneva, Switzerland<br />
OP58 MICROARRAY ANALYSIS OF CHROMOSOME 1 CONGENIC BXSB MICE REVEALS<br />
NOVEL LUPUS-SUSCEPTIBILITY GENE CANDIDATES.<br />
MEK Haywood, J Rose, G Fu, MJ Walport, BJ Morley. <strong>Rheumatology</strong> Section, Eric Bywaters Centre,<br />
Imperial College, London, United Kingdom<br />
Young Investigator Award Winner<br />
OP60 THE IL1 GENE CLUSTER IS A MAJOR LOCUS DETERMINING SUSCEPTIBILITY TO<br />
ANKYLOSING SPONDYLITIS.<br />
AE Timms 1 , AM Crane 1 , A-M Sims 1 , H Cordell 2 , L Bradbury 1 , O Beynon 1 , GR Duff 5 , LR Cardon 4 , A Calin 3 ,<br />
P Wordsworth 1 , MA Brown 1 . 1<br />
Institute of Musculoskeletal Sciences, <strong>The</strong> Botnar Research Centre, Ox<strong>for</strong>d,<br />
United Kingdom; 2 Cambridge Institute of Medical Research, Addenbrookes Hospital, Cambridge, United<br />
Kingdom; 3 Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom; 4 Wellcome Trust<br />
Centre <strong>for</strong> Human Genetics, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 5 Division of Genomic<br />
Medicine, University of Sheffield, Sheffield, United Kingdom<br />
CONNECTIVE TISSUE DISEASE (OP61 – OP68) Sidlaw<br />
OP61 UPREGULATION OF THE MONOCYTE CHEMOATTRACTANT PROTEIN -1 LIGAND-RECEPTOR<br />
AXIS IN EARLY STAGE DIFFUSE CUTANEOUS SCLERODERMA.<br />
MT Carulli, V Ong, M Ponticos, X Shiwen, L Shand, DJ Abraham, CM Black, CP Denton. Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, Royal Free Hospital, London, United Kingdom<br />
OP62 A LONGITUDINAL ANALYSIS OF SKIN SCLEROSIS AND ORGAN-BASED ENDPOINTS<br />
IN A COHORT OF EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.<br />
LM Shand, M Hosseini, CM Black, CP Denton. Centre <strong>for</strong> <strong>Rheumatology</strong>, Royal Free and University<br />
College Medical School, London, United Kingdom<br />
32
OP63 ALTERED LIPID RAFT EXPRESSION AND ASSOCIATED SIGNALLING IN T LYMPHOCYTES<br />
FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).<br />
EC Jury 1 , PS Kabouridis 2 , F Flores-Borja 2 , RA Mageed 2 , DA Isenberg 1 . 1<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>,<br />
Royal Free and University College Medical School, University College London, London, United<br />
Kingdom; 2 Bone and Joint Research Unit, Bats and <strong>The</strong> London, Queen Mary’s School of Medicine<br />
and Dentistry, London, United Kingdom<br />
OP64 SEROLOGICAL INVESTIGATION OF AUTOANTIBODIES IN 577 FAMILIES WITH SYSTEMIC<br />
LUPUS ERYTHEMATOSUS.<br />
S Chadha, CA Roberton, P Charles, J Whittaker, TJ Vyse. 1 <strong>Rheumatology</strong> Section, Eric Bywaters<br />
Centre, Imperial College Faculty of Medicine, Hammersmith, London, United Kingdom; 2 Kennedy<br />
Institute of <strong>Rheumatology</strong>, Imperial College Faculty of Medicine, London, United Kingdom;<br />
3<br />
Epidemiology and Public Health, Imperial College Faculty of Medicine, St Mary’s, London, United<br />
Kingdom<br />
OP65 GENETIC DISSECTION OF BXSB LUPUS PHENOTYPE USING MICE CONGENIC<br />
FOR CHROMOSOME 1 DEMONSTRATES THAT SEPARATE INTERVALS DIRECT DIFFERENT<br />
ASPECTS OF DISEASE.<br />
MEK Haywood 1 , J Rose 1 , J Boyle 2 , AM McDermott 1 , JM Rankin 1 , S Izui 3 , MJ Walport 1 , BJ Morley 1 .<br />
1<br />
<strong>Rheumatology</strong> Section, Eric Bywaters Centre, Imperial College, London, United Kingdom;<br />
2<br />
Histopathology Department, Hammersmith Hospital, London, United Kingdom; 3 Department of<br />
Pathology, Centre Medical Universitaire, Geneva, Switzerland<br />
OP66 RECONSTITUTION OF C1q-DEFICIENCY WITH BONE MARROW DERIVED CELLS<br />
AMELIORATES THE AUTOIMMUNITY ASSOCIATED WITH C1q-DEFICIENCY.<br />
J Cortes-Hernandez 1 , L Fossati-Jimack 1 , S Izui 2 , F Petry 3 , M Loos 3 , MJ Walport 1 , M Botto 1 .<br />
1<br />
<strong>Rheumatology</strong> Section, Eric Bywaters Centre, Imperial College, London, London, United Kingdom;<br />
2<br />
Department of Pathology, University of Geneva, Geneva, Geneva, Switzerland; 3 Institute of<br />
Medical Microbiology and Hygiene, Johannes Gutenberg-University, Mainz, Mainz, Germany<br />
OP67 SEROLOGICAL CHANGES FOLLOWING B LYMPHOCYTE DEPLETION THERAPY<br />
IN SYSTEMIC LUPUS ERYTHEMATOSUS.<br />
MJ Leandro 1 , G Cambridge 1 , JCW Edwards 1 , M Teodorescu 2 , MR Ehrenstein 1 , DA Isenberg 1 .<br />
1<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London, London, United Kingdom; 2 <strong>The</strong>raTest Labs,<br />
Lombard, IL, United States<br />
OP68 QUALITY OF LIFE, FUNCTIONAL STATUS AND CLINICAL FEATURES AT PRESENTATION<br />
IN POLYMYALGIA RHEUMATICA(PMR): RESULTS FROM A MULTI-CENTRE PROSPECTIVE<br />
COHORT STUDY.<br />
B Dasgupta 1 , A Hutchings 1,2 , J Hollywood 1 , D Lamping 2 , C Pease 3 , K Chakravarty 4 , B Hazleman 5 ,<br />
B Silverman 5 , E Choy 6 , DGI Scott 7 , B Bourke 8 , N Gendi 9 . 1<br />
Southend Hospital, Westcliff-on-sea,<br />
United Kingdom; 2 London School of Hygiene & Tropical Medicine, London, United Kingdom;<br />
3<br />
Leeds General Infirmary, Leeds, United Kingdom; 4 Harold Wood Hospital, Rom<strong>for</strong>d, Essex, United<br />
Kingdom; 5 Addenbrookes Hospital, Cambridge, United Kingdom; 6 King’s College London, London,<br />
United Kingdom; 7 Norfolk & Norwich Hospital, Norwich, United Kingdom; 8 St George’s Hospital,<br />
London, United Kingdom; 9 Basildon Hospital, Basildon, Essex, United Kingdom.<br />
33
BHPR Oral Presentations<br />
Friday 23 April 2004, 10:00 – 11:00, Fintry<br />
OP69 “CLINIC AT HOME” AN AUDIT OF A MULTIDISCIPLINARY SERVICE.<br />
Y Hough, A Campbell, J Novak, AE Griffiths, VE Abernethy, MP Lynch. 1 <strong>Rheumatology</strong> Department,<br />
St Helens & Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom<br />
OP70 PATIENT PERCEPTION OF REASON FOR FOLIC ACID SUPPLEMENTATION WHILE ON<br />
METHOTREXATE FOR RHEUMATOID ARTHRITIS (RA).<br />
M McDonald, R Ramachandran, E Garrity, A Tierney, R Hampson, HA Capell, R Madhok. Centre <strong>for</strong><br />
Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom<br />
Poster <strong>View</strong>ing Session 1<br />
Wednesday 21 April 2004, 08:30 – 10:00<br />
CYTOKINS AND INFLAMMATOR MECHANISMS (1 – 5)<br />
1 TNF-α AND THE SPHINGOLIPID CASCADE: KEY PLAYERS IN THE SYSTEMIC INFLAMMATION AND<br />
ATHEROSCLEROSIS OF RA.<br />
LD Church, SP Young, PA Bacon. Department of <strong>Rheumatology</strong>, Division of Immunity and Infection,<br />
University of Birmingham, Birmingham, West Midlands, United Kingdom<br />
2 A NOVEL ROLE FOR SERUM AMYLOID-A (A-SAA) IN ANGIOGENESIS AND ADHESION MOLECULE<br />
EXPRESSION THROUGH AN NFKB-DEPENDENT SIGNAL TRANSDUCTION PATHWAY.<br />
RH Mullan, L Golden-Mason, T Markham, R O’Hara, O FitzGerald, B Bresnihan, DJ Veale, U Fearon.<br />
<strong>Rheumatology</strong>, St. Vincents University Hospital and <strong>The</strong> Conway Institute, Dublin, Ireland<br />
3 SYNDECAN-3 BINDS CXCL8 ON THE SYNOVIAL ENDOTHELIUM IN RHEUMATOID ARTHRITIS.<br />
AM Patterson 1 , L Gardner 1 , J Shaw 1 , E Loreau 2 , L Aguilar 2 , J Middleton 1 . 1<br />
LMARC, Keele University at<br />
Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom; 2 Endocube<br />
S.A.S., Prologue Biotech - BP-700, Rue Pierre et Marie Curie, 31319 Labege, France<br />
4 CHARACTERISATION OF THE RESPONSE TO SELF-hsp60 IN HEALTHY INDIVIDUALS.<br />
RC Duggleby 1 , MS Lillicrap 2 , JSH Gaston 1 , RA Whiston 1 . 1<br />
Medicine, University of Cambridge, Cambridge,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, Norfolk and Norwich University Hospital, Norwich, United Kingdom<br />
5 BYSTANDER-ACTIVATED LYMPHOCYTES IN INFLAMMATION: A NATURAL PROCESS?<br />
S Owen, P Amjadi, P Green, A Foey, F Brennan. Kennedy Institute of <strong>Rheumatology</strong> Division, Imperial<br />
College, London, United Kingdom<br />
CELL RECEPTOR-LIGAND INTERACTIONS (6 – 12)<br />
6 A ROLE FOR BOTH COMPLEMENT AND Fcγ RECEPTORS IN THE TRANSFER OF SOLUBLE IMMUNE<br />
COMPLEXES FROM ERYTHROCYTES TO MONOCYTE-DERIVED MACROPHAGES IN A DYNAMIC IN<br />
VITRO HUMAN MODEL.<br />
AL Hepburn 1 , JC Mason 2 , S Wang 2 , MJ Walport 1 , KA Davies 1 . 1<br />
<strong>Rheumatology</strong> Section, Imperial College<br />
London, Hammersmith Hospital, London, United Kingdom; 2 BHF Cardiovascular Medicine Unit, Imperial<br />
College London, Hammersmith Hospital, London, United Kingdom<br />
34
7 BIFUNCTIONAL ROLE FOR VEGF-INDUCED HEME OXYGENASE-1 IN VIVO:<br />
INDUCTION OF ANGIOGENESIS AND INHIBITION OF LEUKOCYTIC INFILTRATION.<br />
B Bussolati 1 , A Ahmed 2 , RC Landis 3 , F Di Carlo 1 , H Pemberton 1 , DO Haskard 3 , JC Mason 3 . 1<br />
Biology<br />
and Clinical Science, Torino University, Torino, Italy; 2 Reproductive and Vascular Biology,<br />
Birmingham University, Birmingham, United Kingdom; 3 <strong>The</strong> Eric Bywaters Centre, Imperial College<br />
London, Hammersmith Hospital, London, United Kingdom<br />
8 INVESTIGATION OF PLATELET GLYCOPROTEIN IIIa POLYMORPHISM IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS.<br />
AH Strang 1 , M McLaren 1 , A Rudd 1 , KD Morley 2 , JJF Belch 1 . 1<br />
Vascular Medicine, University of<br />
Dundee, Dundee, Tayside, United Kingdom; 2 <strong>Rheumatology</strong>, Ninewells Hospital, Dundee, Tayside,<br />
United Kingdom<br />
9 VEGF-INDUCED CYTOPROTECTION OF VASCULAR ENDOTHELIUM IS DIFFERENTIALLY REGU-<br />
LATED BY CYCLOSPORIN A AND RAPAMYCIN.<br />
JC Mason 1 , EA Lidington 1 , R Mankoff 1 , AR Kinderlerer 1 , M Ohba 2 , DO Haskard 1 . 1<br />
<strong>The</strong> Eric Bywaters<br />
Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom; 2 Institute of<br />
Molecular Oncology, Showa University, Tokyo, Japan<br />
10 LIGATION OF LEUKOCYTE FCγRII (CD32) BY AN ANTI-ENDOTHELIAL CELL (EC) ANTIBODY<br />
SYNERGISES WITH G-PROTEIN COUPLED RECEPTOR SIGNALLING TO AMPLIFY LEUKOCYTE<br />
ADHESION TO CYTOKINE-ACTIVATED UNDER PHYSIOLOGICAL FLOW.<br />
O Florey, JC Mason, DO Haskard. Eric Bywaters Centre, Imperial College, London, United Kingdom<br />
11 THE RA CANDIDATE SUSCEPTIBILITY GENE IkBL DOWNREGULATES<br />
INFLAMMATORY SIGNALLING.<br />
CD Ellis, D Mewar, FA Guesdon, AG Wilson. Division of Genomic Medicine, University of Sheffield,<br />
Sheffield, S Yorks, United Kingdom<br />
12 PERFORIN EXPRESSION IN EARLY INFLAMMATORY ARTHRITIS.<br />
CF Matthews 1 , P Maxwell 2 , GD Wright 1 , B Bresnihan 3 , O FitzGerald 3 , PW Hamilton 2 , MME Rooney 1 .<br />
1<br />
Department of <strong>Rheumatology</strong>, Musgrave Park Hospital, Belfast, County Antrim, United Kingdom;<br />
2<br />
Department of Quantitative Pathology, Queen’s University of Belfast, Belfast, County Antrim,<br />
United Kingdom; 3 Department of <strong>Rheumatology</strong>, St Vincent’s University Hospital, Dublin, Ireland<br />
GENOMICS (13 – 27)<br />
13 THE DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE S GENE IN<br />
PSORIATIC ARTHRITIS USING PYROSEQUENCING.<br />
E Korendowych 1 , NJ McHugh 1 , J Lewis 1 , J Ravindran 1 , PA Owen 1 , S Gaudieri 2 . 1<br />
Department of<br />
Research and Clinical Effectiveness, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United<br />
Kingdom; 2 Centre <strong>for</strong> Clinical Immunology and Biomedical Statistics, Royal Perth Hospital, Perth,<br />
WA, Australia<br />
14 INVESTIGATION OF CHROMOSOME 3q21 IN PSORIATIC ARTHRITIS.<br />
PYP Ho, J Bowes, S Eyre, P Bradburn, I Bruce, A Silman, J Worthington, A Barton.<br />
ARC-Epidemilogy Unit, University of Manchester, Manchester, United Kingdom<br />
15 INVESTIGATION OF CARD15 IN PATIENTS WITH PSORIATIC ARTHRITIS.<br />
PYP Ho, J Bowes, S Eyre, P Bradburn, I Bruce, A Silman, J Worthington, A Barton.<br />
ARC-Epidemiology Unit, University of Manchester, Manchester, United Kingdom<br />
16 FAILED TOTAL HIP REPLACEMENT CANDIDATE GENE ANALYSIS.<br />
HA Malik 2 , F Jury 1 , E Zeggini 1 , A Bayat 1 , WE Ollier 1 , PR Kay 2 . 1<br />
Centre <strong>for</strong> Integrated Genomic<br />
Medical Research, <strong>The</strong> University of Manchester, Manchester, United Kingdom; 2 <strong>The</strong> Centre <strong>for</strong><br />
Hip Surgery, Wrightington Hospital, Wigan, Lancashire, United Kingdom<br />
35
17 POLYMORPHISMS OF WISP3 AND SUSCEPTIBILITY TO JUVENILE IDIOPATHIC ARTHRITIS.<br />
RM Lamb 1 , E Zeggini 2 , BPRG Study Group, W Thomson 1 , R Donn 1 . 1<br />
ARC/EU, University of Manchester,<br />
Manchester, United Kingdom; 2 CIGMR, University of Manchester, Manchester,<br />
United Kingdom<br />
18 GENOME WIDE SCREEN ANALYSIS IN MULTIPLEX FAMILIES WITH PRIMARY HIP OSTEOARTHRITIS:<br />
SUGGESTIVE LINKAGE TO CHROMOSOMES 2, 10 AND 11.<br />
GK Meenagh 1 , J Nixon 1 , GD Wright 1 , AE Hughes 2 . 1<br />
Department of <strong>Rheumatology</strong>, Musgrave Park<br />
Hospital, Belfast, United Kingdom; 2 Department of Medical Genetics, Queen’s University Belfast, Belfast<br />
City Hospital Trust, Belfast, United Kingdom<br />
19 LACK OF ASSOCIATION BETWEEN CORTICOTROPHIN-RELEASING HORMONE<br />
LOCUS AND RHEUMATOID ARTHRITIS.<br />
A Julià 1 , D Gallardo 2 , F Vidal 2 , C Tomàs 1 , P Barceló 1 , M Vilardell 3 , S Marsal 1 . 1<br />
Unitat de Recerca de<br />
Reumatologia, Hospital General i Universitari Vall d’Hebron, Barcelona, Spain; 2 Centre de Transfusions i<br />
Banc de Teixits de Barcelona, Servei Català de la Salut, Barcelona, Spain; 3 Servei de Medicina Interna,<br />
Hospital General i Universitari Vall d’Hebron, Barcelona, Spain<br />
20 A FUNCTIONAL HAPLOTYPE OF THE PADI4 GENE ASSOCIATED WITH RA IN A JAPANESE<br />
POPULATION IS NOT ASSOCIATED IN A UK POPULATION.<br />
J Bowes 1 , S Eyre 1 , K Spreckley 1 , A Hinks 1 , S John 2 , J Worthington 1 , A Barton 1 . 1<br />
ARC-EU, University of<br />
Manchester, Manchester, United Kingdom; 2 University of Manchester, Manchester, United Kingdom<br />
21 FUNCTIONAL LYMPHOTOXIN α 5’ POLYMORPHIC VARIANTS INFLUENCE PROMOTER ACTIVITY<br />
IN RHEUMATOID ARTHRITIS.<br />
C Molloy 1 , C Adams 1 , G O’Donoghue 1 , H Mulcahy 1 , S Busteed 2 , K O’Rourke 1 , C Silke 1 , F Shanahan 3 , MG<br />
Molloy 2 , F O’Gara 1 . 1<br />
Biomerit Research Centre, Microbiology, National University of Ireland (NUI), Cork,<br />
Ireland; 2 <strong>Rheumatology</strong>, NUI, Cork, Ireland; 3Medicine, NUI, Cork, Ireland<br />
22 GENE EXPRESSION PROFILING OF ISCHAEMIC HEART DISEASE IN RHEUMATOID ARTHRITIS.<br />
EP Halligan 1 , J Butler 1 , M Evans 1 , M Cooke 1 , F Falciani 3 , MJ Banks 2 , J Lunec 1 , GD Kitas 2 . 1<br />
Cancer Studies<br />
and Molecular Medicine, University of Leicester, Leicester, Leicestershire, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom; 3 Biosciences, University<br />
of Birmingham, Birmingham, United Kingdom<br />
23 REFINEMENT OF THE CRH HAPLOTYPE IN RHEUMATOID ARTHRITIS.<br />
S Steer 1 , SA Fisher 2 , MS Fife 3 , B Lad 1 , J Grumley 1 , A Milicic 4 , P Wordsworth 4 , J Worthington 5 , ARC<br />
National Repository 5 , CM Lewis 2 . 1<br />
<strong>Rheumatology</strong>, Kings College, London, United Kingdom; 2 Division of<br />
Genetics and Development, Kings College, London, United Kingdom; 3 Paediatric and Adolescent<br />
<strong>Rheumatology</strong>, University College, London, United Kingdom; 4 <strong>Rheumatology</strong>, University of Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>d, United Kingdom; 5 ARC Epidemiology Unit, University of Manchester, Manchester,<br />
United Kingdom<br />
24 FINE MAPPING OF NOVEL SUSCEPTIBILITY GENES FOR RHEUMATOID ARTHRITIS IN<br />
THE TELOMERIC MHC.<br />
AL Coote, RF Kilding, MM Iles, AM Mcdermott, AG Wilson. Division of Genomic Medicine, <strong>The</strong><br />
University of Sheffield, Sheffield, United Kingdom<br />
25 ASSOCIATION OF MARKERS WITHIN THE FOXP3 GENE WITH RHEUMATOID ARTHRITIS (RA).<br />
A Hinks 1 , A Barton 1 , E Zeggini 2 , S Eyre 1 , S John 2 , J Worthington 1 . 1<br />
ARC-EU, University of Manchester,<br />
Manchester, United Kingdom; 2 CIGMR, University of Manchester, Manchester, United Kingdom<br />
36
26 ANALYSIS OF COMBINED US-UK RA WGS IDENTIFIES A SUSCEPTIBILITY LOCUS ON<br />
CHROMOSOME 1P.<br />
ND Shephard 1 , A Butterworth 1 , W Chen 2 , M Seldin 1 , A Silman 1 , B Ollier 3 , P Gregersen 4 , C Amos 2 ,<br />
S John 3 , J Worthington 1 . 1<br />
ARC Epidemiology Unit, University of Manchester, Manchester, United<br />
Kingdom; 2 Epidemiology and Biomathematics, University of Texas, Houston, TX, United States;<br />
3<br />
Centre <strong>for</strong> Integrated Genomic Medical Research, University of Manchester, Manchester, United<br />
Kingdom; 4 Division of Biology and Human Genetics, North Shore University Hospital, New York,<br />
United States<br />
27 WHOLE GENOME LINKAGE SCAN IN RA MULTICASE FAMILIES, USING 11,245 SNPS.<br />
S John 1 , N Shephard 2 , E Zeggini 1 , M Cao 3 , W Chen 3 , N Vasavda 4 , G Liu 3 , N Gibson 4 , K Jones 3 ,<br />
G Kennedy 3 , J Worthington 2 . 1<br />
Centre <strong>for</strong> Integrated Medical Genomic Research, University of<br />
Manchester, Manchester, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom; 3 Affymetrix, Inc., Santa Clara, CA, United States; 4Astrazeneca,<br />
Alderley Park, Macclesfield, United Kingdom<br />
RHEUMATOID ARTHRITIS: BIOLOGICS (28 – 47)<br />
28 IL-7 AND T-CELL DYSFUNCTION IN RA PATIENTS IN CLINICAL REMISSION.<br />
F Ponchel, AK Brown, SL Field, JD Isaacs, P Emery. Molecular Medicine Unit, <strong>Rheumatology</strong><br />
Research Unit, University of Leeds, Leeds, West Yorkshire, United Kingdom<br />
29 ASSESSMENT OF FUNCTIONAL STATUS AMONG PATIENTS WITH ACTIVE RHEUMATOID<br />
ARTHRITIS IN A DOUBLE-BLIND TRIAL OF ETANERCEPT AND METHOTREXATE, ALONE AND<br />
COMBINED (TEMPO TRIAL).<br />
D van der Heijde 1 , L Klareskog 2 , J DeJager 3 , A Gough 4 , J Kalden 5 , M Malaise 6 , E Martin Mola 7 ,<br />
K Pavelka 8 , J Sany 9 , L Settas 10 , J Wajdula 11 . 1<br />
U Hosp Maastricht, Maastricht, <strong>The</strong> Netherlands;<br />
2<br />
Karolinska Hosp, Stockholm, Sweden; 3 Gold Coast <strong>Rheumatology</strong>, Southport, Australia;<br />
4<br />
Harrogate District Hosp, Harrogate, United Kingdom; 5 U Erlangen-Nurnberg, Erlangen, Germany;<br />
6<br />
CHU Univ of Liege, Liege, Belgium; 7 La Paz Hosp, Madrid, Spain; 8 Inst of <strong>Rheumatology</strong>, Prague,<br />
Czech Republic; 9 Hosp Lapeyronie, Montpellier, France; 10 U <strong>The</strong>ssaloniki, <strong>The</strong>ssaloniki, Greece;<br />
11<br />
Wyeth Research, Collegeville, United States<br />
30 DOUBLE-BLIND COMPARATIVE STUDY OF RADIOGRAPHIC PROGRESSION OF<br />
ETANERCEPT (E) AND METHOTREXATE (MTX), ALONE AND COMBINED (E+MTX),<br />
IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (TEMPO TRIAL).<br />
D van der Heijde 1 , L Klareskog 2 , J DeJager 3 , A Gough 4 , J Kalden 5 , M Malaise 6 , E Martin Mola 7 ,<br />
K Pavelka 8 , J Sany 9 , L Settas 10 , J Wajdula 11 . 1<br />
U Hosp Maastricht, Maastricht, <strong>The</strong> Netherlands;<br />
2<br />
Karolinska Hosp, Stockholm, Sweden; 3 Gold Coast <strong>Rheumatology</strong>, Southport, Australia;<br />
4<br />
Harrogate District Hosp, Harrogate, United Kingdom; 5 U Erlangen-Nurnberg, Erlangen, Germany;<br />
6<br />
CHU Univ of Liege, Liege, Belgium; 7 La Paz Hosp, Madrid, Spain; 8 Inst <strong>Rheumatology</strong>, Prague,<br />
Czech Republic; 9 Hosp Lapeyronie, Montpellier, France; 10 U <strong>The</strong>ssaloniki, <strong>The</strong>ssaloniki, Greece;<br />
11<br />
Wyeth Research, Collegeville, United States<br />
31 SWITCHING BIOLOGICS AFTER INITIAL ANTI-TUMOUR-NECROSIS-FACTOR-α FAILURE;<br />
SUCCESS WITH FURTHER TNF-α ANTAGONISM BUT FAILURE ON SUBSEQUENT<br />
INTERLEUKIN-1 RECEPTOR ANTAGONIST.<br />
MH Buch, SJ Bingham, Y Seto, V Bejarano, M Rynne, D Bryer, J White, P Emery. Academic Unit of<br />
Musculoskeletal Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom<br />
32 LEVELS OF CIRCULATING sCD23 FOLLOWING B LYMPHOCYTE DEPLETION THERAPY<br />
IN RHEUMATOID ARTHRITIS.<br />
G Cambridge, MJ Leandro, A Bhatia, JCW Edwards. Centre <strong>for</strong> <strong>Rheumatology</strong>, University College<br />
London, Arthur Stanley House, London W1T 5NJ, United Kingdom<br />
37
33 FATAL EXACERBATION OF RHEUMATOID ARTHRITIS (RA) ASSOCIATED FIBROSING ALVEOLITIS<br />
IN THREE PATIENTS TREATED WITH AZATHIOPRINE AND INFLIXIMAB.<br />
AJK Ostor 1 , MF Somerville 2 , SE Lane 1 , AYN Lim 1 , AJ Crisp 1 , DGI Scott 2 . 1<br />
<strong>Rheumatology</strong> Department,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 <strong>Rheumatology</strong> Department, Norfolk and<br />
Norwich University Hospital, Norwich, United Kingdom<br />
34 RELATIONSHIP OF ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) TO PHARMACODYNAMIC<br />
(PD) IN RHEUMATOID ARTHRITIS (RA) PATIENTS DURING PHASE II/III CLINICAL TRIALS.<br />
R Granneman 1 , Y Zhang 1 , P Noertersheuser 2 , R Velagapudi 3 , W Awni 1 , C Locke 1 , O Segurado 1 , T Toward 4 .<br />
1<br />
Abbott Laboratories, Abbott Park, IL, United States; 2 Abbott Laboratories, Ludwigshafen, Germany;<br />
3<br />
Abbott Laboratories, Parsippany, NJ, United States; 4 Abbott Laboratories, Maidenhead, Berkshire,<br />
United Kingdom<br />
35 THE EFFECT OF DISEASE DURATION ON CLINICAL OUTCOMES FOLLOWING ADALIMUMAB<br />
(HUMIRA ® ) THERAPY IN RA.<br />
P Emery 1 , R Fleischmann 2 , V Strand 3 , WG Reiss 4 , G Spencer-Green 5 , OG Segurado 6 . 1<br />
University of Leeds,<br />
Leeds, United Kingdom; 2 Southwestern Medical Centre at Dallas - Radiant Research, University of Texas,<br />
Dallas, TX, United States; 3 Stan<strong>for</strong>d University, Portola Valley, CA, United States; 4 Abbott Laboratories,<br />
Parsippany, NJ, United States; 5Abbott Laboratories, Chicago, IL, United States<br />
36 BIOLOGICS IN CLINICAL PRACTICE - BETTER THAN EXPECTED?<br />
RN Jois, M Somerville, A Brooksby, K Gaffney, P Merry, DGI Scott. Department of <strong>Rheumatology</strong>,<br />
Norfolk and Norwich University Hospital, Norwich, United Kingdom<br />
37 ARE ALL ANTI-TNF AGENTS EQUAL? RESULTS OF MERSEY BIOLOGICS AUDIT.<br />
TC Barnes 1 , V Abernethy 2 . 1<br />
Dept <strong>Rheumatology</strong>, Royal Liverpool University Hospital, Liverpool, United<br />
Kingdom; 2 Dept <strong>Rheumatology</strong>, Whiston and St Helens Hospital, St. Helens, United Kingdom<br />
38 ANTI TNF: PATIENTS, POLITICS AND PRACTICALITIES OF ACCESS TO TREATMENT DURING<br />
THE LAST FOUR YEARS.<br />
MF Somerville, A Brooksby, K Gaffney, DGI Scott. <strong>Rheumatology</strong> Unit, Norfolk & Norwich University<br />
Hospital, Norwich, Norfolk, United Kingdom<br />
39 STEADY-STATE ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) FOLLOWING EVERY OTHER<br />
WEEK (EOW) DOSING OF 40mg SUBCUTANEOUS (SC) INJECTION, IN RHEUMATOID ARTHRITIS (RA)<br />
PATIENTS TREATED WITH AND WITHOUT CONCOMITANT METHOTREXATE (MTX).<br />
WM Awni 1 , P Cascella 2 , N Oleka 3 , RB Velagapudi 3 , H Kupper 4 , E Chartash 3 , R Granneman 1 ,<br />
OG Segurado 1 , TJ Toward 5 . 1 Abbott Laboratories, Abbott Park, IL, United States; 2 Drug Development<br />
Resources LLC, Mountain Lakes, NJ, United States; 3 Abbott Laboratories, Parsippany, NJ, United States;<br />
4<br />
Abbott Laboratories, Ludwigshafen, Germany; 5 Abbott Laboratories, Maidenhead, Berks,<br />
United Kingdom<br />
40 SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA ® ) PLUS METHOTREXATE (MTX)<br />
IN RHEUMATOID ARTHRITIS (RA) PATIENTS.<br />
MH Schiff 1 , M Weisman 2 , DE Furst 3 , A Kavanaugh 4 , G Spencer-Green 5 , OG Segurado 6 . 1<br />
Denver Arthritis<br />
Clinic, Denver, CO, United States; 2 Cedars-Sinai Medical Center, Los Angeles, CA, United States; 3 UCLA,<br />
Los Angeles, CA, United States; 4 <strong>The</strong> Center <strong>for</strong> Innovative <strong>The</strong>rapy, UCSD, San Diego, CA, United<br />
States; 5 Abbott Laboratories, Parsippany, NJ, United States; 6 Abbott Laboratories, Chicago, IL,<br />
United States<br />
41 HOW WELL DO WE IDENTIFY RHEUMATOID ARTHRITIS (RA) PATIENTS ELIGIBLE FOR ANTI-TNF<br />
IN OUR ROUTINE CLINICS?<br />
M Leach, S Christy-Kilner, B Pal, PA Sanders. Department of <strong>Rheumatology</strong>, South Manchester University<br />
Hospitals, Manchester, M20 2LR, United Kingdom<br />
38
42 THE OXFORD EXPERIENCE WITH THE USE OF INFLIXIMAB IN THE TREATMENT OF<br />
RHEUMATOID ARTHRITIS.<br />
ATY Chan, T Reed, J David. Department of <strong>Rheumatology</strong>, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d,<br />
United Kingdom<br />
43 ADALIMUMAB IN CLINICAL PRACTICE-INITIAL EXPERIENCE AT A SINGLE UK CENTRE.<br />
AN Bennett, P Peterson, N Banya, J Grumley, G Panayi, B Kirkham. Department of <strong>Rheumatology</strong>,<br />
Guy’s & St Thomas’ Hospital Trust, UK, London, United Kingdom<br />
44 THE USE OF BIOLOGIC AGENTS FOR SEVERE INFLAMMATORY ARTHRITIS IN<br />
NORTHERN IRELAND.<br />
SA Wright 1 , K Brown 1 , D McCracken 2 , AJ Taggart 1 . 1<br />
<strong>Rheumatology</strong>, Musgrave Park Hospital,<br />
Belfast, Northern Ireland, United Kingdom; 2 Clinical Governance, Musgrave Park Hospital, Belfast,<br />
Northern Ireland, United Kingdom<br />
45 ANALYSING DECISIONS ABOUT THE CHANGE IN A PATIENT’S CLINICAL CONDITION<br />
AFTER A TRIAL TREATMENT WITH TNF-α AGENTS.<br />
L O’Hare, N Sheehy, F Kee, A Bell, O Fitzgerald. 1 Psychology, Queens University, Belfast, United<br />
Kingdom; 2 Psychology, Queens University, Belfast, United Kingdom; 3 Epidemiology and Public<br />
Health, Queens University, Belfast, United Kingdom; 4 <strong>Rheumatology</strong>, Queens University, Belfast,<br />
United Kingdom; 5 <strong>Rheumatology</strong>, St Vincent’s Hospital, Dublin, Ireland<br />
46 OBSERVATIONAL STUDY OF THE ROUTINE USE OF ANTI-TNF DRUGS IN THE TREATMENT<br />
OF RHEUMATOID ARTHRITIS IN A UK SETTING: IMPACTS ON QUALITY OF LIFE AND MOOD.<br />
M Koutantji 1 , JR Smith 2 , M Adams 2 , A Brooksby 3 , M Somerville 3 , DGI Scott 2,3 . 1<br />
Department of<br />
Surgical Oncology & Technology, Imperial College London, London, United Kingdom; 2 School of<br />
Medicine, Health Policy & Practice, University of East Anglia, Norwich, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, Norfolk & Norwich Univesity Hospital NHS Trust, Norwich,<br />
United Kingdom<br />
47 PATIENTS’ EXPERIENCE OF ANTI-TNFα THERAPY IN RHEUMATOID ARTHRITIS:<br />
A QUALITATIVE STUDY.<br />
NJ Marshall 1 , G Wilson 1 , K Lapworth 2 , LJ Kay 1 . 1 Musculoskeletal Department, Newcastle upon Tyne<br />
Hospitals NHS Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2 Clinical Effectiveness<br />
Department, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, Tyne and Wear,<br />
United Kingdom<br />
RHEUMATOID ARTHRITIS: THERAPY (48 – 71)<br />
48 USE OF HERBAL AND OVER-THE-COUNTER REMEDIES AND POTENTIAL INTERACTIONS<br />
WITH CONVENTIONAL MEDICATION IN RHEUMATOLOGY OUTPATIENTS.<br />
WA Holden 1 , J Joseph 2 , L Williamson 3 . 1<br />
<strong>Rheumatology</strong>, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, Nuffield Orthopaedic Hospital, Ox<strong>for</strong>d, United Kingdom;<br />
3<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United Kingdom<br />
49 ULTRASONOGRAPHY PREDICTS RESPONSE TO INTRAMUSCULAR METHYLPREDNISOLONE<br />
AND HYDROXYCHLOROQUINE IN PATIENTS WITH INFLAMMATORY HAND PAIN.<br />
Z Karim, MA Quinn, RJ Wakefield, AK Brown, PG Conaghan, P Emery. Academic Unit of<br />
Musculoskeletal Medicine, Department of <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, West<br />
Yorkshire, United Kingdom<br />
50 THE REGIONAL VARIATION AND DIFFERENTIAL RESPONSE OF SYNOVITIS TO THERAPY IN<br />
KNEE JOINT DISEASE IN EARLY INFLAMMATORY ARTHRITIS.<br />
AL Tan 1 , LA Rhodes 2 , SF Tanner 2 , A Radjenovic 2 , R Reece 1 , P O’Connor 3 , P Emery 1 , D McGonagle 1 .<br />
1<br />
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom;<br />
2<br />
Academic Unit of Medical Physics, University of Leeds, Leeds, United Kingdom; 3 Department of<br />
Radiology, Leeds General Infirmary, Leeds, United Kingdom<br />
39
51 UNDERSTANDING NON-RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS:<br />
PREDICTING SUBSEQUENT OUTCOME.<br />
MH Buch, Y Seto, SJ Bingham, V Bejarano, D Bryer, J White, P Emery. Academic Unit of Musculoskeletal<br />
Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom<br />
52 AGGRESSIVE THERAPY WITH CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC<br />
DRUGS (DMARD) DOES NOT PREVENT DISEASE PROGRESSION IN PATIENTS WITH STABLE<br />
ESTABLISHED RHEUMATOID ARTHRITIS (RA): RESULTS OF A RANDOMISED OBSERVER-BLINDED<br />
CONTROLLED CLINICAL TRIAL.<br />
M Davis 1 , K Tricker 2 , C Roberts 3 , P Dawes 4 , A Hassell 4 , S Knight 5 , D Mulherin 6 , DL Scott 7 , D Symmons 2,5 .<br />
1<br />
Royal Cornwall NHS Trust, Truro, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom; 3 Biostatistics Group, University of Manchester, Manchester, United<br />
Kingdom; 4 University Hospital of North Staf<strong>for</strong>dshire NHS Trust, Stoke on Trent, United Kingdom; 5 East<br />
Cheshire NHS Trust, Macclesfield, United Kingdom; 6 Mid-Staf<strong>for</strong>dshire General Hospitals NHS Trust,<br />
Cannock, United Kingdom; 7 King’s College Hospital, London, United Kingdom<br />
53 ADDING LIGNOCAINE DOES NOT AFFECT SHORT OR MEDIUM-TERM OUTCOME IN<br />
INTRA-ARTICULAR STEROID INJECTIONS.<br />
C Rao, M Bukhari. Department of <strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster, Lancashire,<br />
United Kingdom<br />
54 RANDOMISED PLACEBO-CONTROLLED TRIAL OF INTRAMUSCULAR (IM) DEPOT<br />
METHYLPREDNISOLONE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS.<br />
EH Choy 1 , GH Kingsley 1 , B Khoshaba 1 , N Pipitone 1 , L Dolan 2 , P Pitt 3 , B Dasgupta 4 , GS Panayi 1 , DL Scott 1 .<br />
1<br />
Academic Department of <strong>Rheumatology</strong>, GKT School of Medicine, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Greenwich, United Kingdom; 3 <strong>Rheumatology</strong>, Farnborough<br />
Hospital, Farnborough, United Kingdom; 4 <strong>Rheumatology</strong>, Southend Hospital, Southend, United Kingdom<br />
55 IS IT POSSIBLE TO PREDICT WHICH PATIENTS WITH RHEUMATOID ARTHRITIS (RA)<br />
WILL DERIVE RHEUMATOLOGICAL BENEFIT FROM STATIN THERAPY?<br />
DW McCarey, N Sattar, R Hampson, R Madhok, IB McInnes, HA Capell. Centre <strong>for</strong> Rheumatic Diseases,<br />
Royal Infirmary, Glasgow, United Kingdom<br />
56 COMBINATION VS MONOTHERAPY FOR POOR PROGNOSIS RHEUMATOID ARTHRITIS:<br />
A LONG-TERM FOLLOW-UP STUDY.<br />
V Bejarano, C Philip, G Michael, K Heather, E Paul. Academic Unit of Musculoskeletal Disease, University<br />
of Leeds, Leeds, United Kingdom<br />
57 SYSTEMATIC REVIEW OF EFFECTIVENESS OF FIVE STRATEGIES TO PREVENT NSAID-INDUCED<br />
GASTROINTESTINAL TOXICITY.<br />
L Hooper 1 , TJ Brown 1 , RA Elliott 2 , K Payne 3 , C Roberts 4 , D Symmons 5 . 1<br />
Cochrane Oral Health Group,<br />
University of Manchester, Manchester, United Kingdom; 2 School of Pharmacy, Manchester University,<br />
Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital, Manchester, United<br />
Kingdom; 4 School of Epidemiology and Health Sciences, Manchester University, Manchester, United<br />
Kingdom; 5 ARC Epidemiology Unit, Manchester University, Manchester, United Kingdom<br />
58 DEMOGRAPHIC TRENDS IN 5 COHORTS OF RHEUMATOID ARTHRITIS (RA) PATIENTS ENROLLED<br />
IN PROSPECTIVE DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) STUDIES 1986-2003.<br />
S Irvine 1 , G Roberts 1 , R Madhok 1 , DR Porter 2 , JA Hunter 2 , IB McInnes 1 , HA Capell 1 . 1<br />
Centre <strong>for</strong> Rheumatic<br />
Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 <strong>Rheumatology</strong> Department, Gartnavel General<br />
Hospital, Glasgow, United Kingdom<br />
59 EFFECT OF GENDER ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) PRESCRIPTION<br />
IN RHEUMATOID ARTHRITIS (RA).<br />
E Morrison 1 , R Hampson 2 , A Tierney 2 , L MacKenzie 2 , HA Capell 2 . 1<br />
<strong>Rheumatology</strong>, Southern General<br />
Hospital, Glasgow, United Kingdom; 2 Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow,<br />
United Kingdom<br />
40
60 LEFLUNOMIDE - EXPERIENCE WITH 300 PATIENTS.<br />
PN Platt. <strong>Rheumatology</strong> Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom<br />
61 FREQUENCY AND TYPE OF PIGMENTATION IN PATIENTS RECEIVING MINOCYCLINE THER-<br />
PAY FOR RHEUMATOID ARTHRITIS (RA).<br />
G Roberts, HA Capell. Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United<br />
Kingdom<br />
62 THE USE AND MONITORING OF IMMUNE MODIFYING DRUGS IN DIFFERENT<br />
MEDICAL SPECIALITIES ACROSS WALES.<br />
H Cohen, C Aldridge, S Jones. Department of <strong>Rheumatology</strong>, University Hospital of Wales, Cardiff,<br />
S.Glamorgan, Wales, United Kingdom<br />
63 EFFICACY OF ARTROFOON IN RHEUMATOID ARHTRITIS: RESULTS OF A SIX-MONTH<br />
OPEN-LABEL STUDY.<br />
VI Petrov 1 , AR Babayeva 1 , JL Dugina 2 , AV Martyushev-Poklad 2 , MV Kachanova 2 , EV Tcherevkova 1 ,<br />
OI Epstein 2 , SA Sergeeva 2 . 1<br />
Volgograd Medical University, Volgograd, Russian Federation; 2 NPF<br />
“Materia Medica Holding”, Moscow, Russian Federation<br />
64 SINGLE-BLIND RANDOMISED TRIAL OF COMBINATION ANTIBIOTIC THERAPY IN<br />
RHEUMATOID ARTHRITIS.<br />
A Smith 1 , W Rogers 2 , J Soon-Shiong 2 , A Mitchell 2 , C Dore 3 , P Taylor 1 , C Mackworth-Young 1 .<br />
1<br />
Kennedy Institute of <strong>Rheumatology</strong>, London, United Kingdom; 2 Charing Cross Hospital, London,<br />
United Kingdom; 3 Statistics Department, MRC Clinical Trials Unit, London, United Kingdom<br />
65 AUDIT OF DRUG MONITORING FREQUENCY OF PATIENTS ON METHOTREXATE<br />
IN PRIMARY CARE COMPARED WITH HOSPITAL OUTPATIENTS CONTROLS.<br />
SK Pathare, NP Hurst. Rheumatic Diseases Unit, Western General Hospital, Edinburgh, Lothian,<br />
United Kingdom<br />
66 DMARDs TREATMENT AND BONE MINERAL DENSITY IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS.<br />
LA Taukumova, AV Smirnov. 1<br />
Clinical Pharmacology, Institute of <strong>Rheumatology</strong>, Moscow, Russian<br />
Federation; 2 Radiology, Institute of <strong>Rheumatology</strong>, Moscow, Russian Federation<br />
67 THERMAL INFRARED-REFLECTIVE WRIST SLEEVE FOR RHEUMATOID ARTHRITIS:<br />
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY.<br />
J Currey 1 , P Lightman 1 , K Chakravarty 2 , S Petty-Saphon 3 . 1<br />
<strong>Rheumatology</strong>, Princess Alexandra<br />
Hospital NHS Trust, Harlow, CM20 1QX, United Kingdom; 2 <strong>Rheumatology</strong>, Harold Wood Hospital,<br />
Harold Wood, RM3 0BE, United Kingdom; 3 Spine-issimus Ltd, Saffron Walden, CB11 4JT,<br />
United Kingdom<br />
68 SUBCUTANEOUS METHOTREXATE (SC-Mtx) ADMINISTRATION IN RHEUMATOLOGY<br />
CLINIC AND IN THE HOME - CLINICAL AND PATIENT PERSPECTIVES.<br />
G Burbage, A Mee, K Lim. Dept. of <strong>Rheumatology</strong>, Sherwood Forest Hospitals NHS Trust,<br />
Kings Mill Hospital, Nottinghamshire, United Kingdom<br />
69 THE USE OF PARENTERAL METHOTREXATE IN THE TREATMENT OF RHEUMATIC DISEASE.<br />
RK Moitra, JM Ledingham. <strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth,<br />
Hampshire, United Kingdom<br />
70 CAN INTRAMUSCULAR METHOTREXATE FOR THE TREATMENT OF RHEUMATOID AND<br />
OTHER INFLAMMATORY ARTHRITIS BE ADMINISTERED IN THE COMMUNITY?<br />
SK Williams, S Church, GR Clarke. Department of <strong>Rheumatology</strong>, Harold Wood Hospital,<br />
Rom<strong>for</strong>d, Essex, United Kingdom<br />
41
71 METHOTREXATE MONITORING: A COUNTRYWIDE ANALYSIS OF MONITORING POLICIES AMONG<br />
RHEUMATOLOGISTS AND DERMATOLOGISTS IN THE REPUBLIC OF IRELAND.<br />
JG Ryan 1 , J Barry 2 , J Bourke 2 , M Phelan 1 . 1<br />
Departments of <strong>Rheumatology</strong>, South Infirmary- Victoria<br />
Hospital, Cork, Ireland; 2 Dermatology, South Infirmary- Victoria Hospital, Cork, Ireland<br />
CARTILAGE BIOLOGY (72 – 76)<br />
72 A NOVEL INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS) INHIBITOR INFLUENCES AGGRECAN<br />
mRNA LEVELS IN OSTEOARTHRITIC (OA) CHONDROCYTES.<br />
JE Johnston 1 , SJ Millward-Sadler 1 , N Boughton-Smith 2 , G Nuki 1 . 1<br />
Osteoarthritis Research Lab, Edinburgh<br />
University, Edinburgh, Scotland, United Kingdom; 2 Research And Development, AstraZeneca,<br />
Loughborough, Leicestershire, United Kingdom<br />
73 EFFECTS OF MECHANICAL STIMULATION ON MAP KINASES IN NORMAL AND OSTEOARTHRITIC<br />
HUMAN ARTICULAR CHONDROCYTES.<br />
Y Zhou, SJ Millward-Sadler, NS Khan, DM Salter, G Nuki. Osteoarticular Research Group, Medical<br />
College, University of Edinburgh, Edinburgh EH8 9AG, Scotland, United Kingdom<br />
74 INTEGRIN DEPENDENT UP-REGULATION OF PROTEOGLYCAN SYNTHESIS IN CULTURED<br />
NORMAL HUMAN ARTICULAR CHONDROCYTES FOLLOWING MECHANICAL STIMULATION IS LOST<br />
IN CHONDROCYTES FROM PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS.<br />
M Maruo Holledge, SJ Millward-Sadler, NS Khan, DM Salter, G Nuki. Osteoarticular Research Group,<br />
Medical College, University of Edinburgh, Edinburgh EH8 9AG, Scotland, United Kingdom<br />
75 CHANGE IN SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP) AFTER TOTAL<br />
KNEE REPLACEMENT FOR OSTEOARTHRITIS (OA).<br />
M Sharif 1 , JR Kirwan 2 , R Granell 2 , S Clarke 2 . 1<br />
Department of Anatomy, University of Bristol, Bristol,<br />
United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary, Bristol, United Kingdom<br />
76 INCREASED EXPRESSION OF CATABOLIC CYTOKINES AND THEIR RECEPTORS IN EARLY<br />
EQUINE ARTICULAR CARTILAGE DAMAGE.<br />
MJ Trickett, M Sharif, MJ Perry, CJ Fuller. Anatomy, University of Bristol, Bristol, United Kingdom<br />
BONE BIOLOGY (77 – 79)<br />
77 TARTRATE-RESISTANT ACID PHOSPHATASE: A POTENTIAL TARGET FOR THERAPEUTIC GOLD.<br />
AR Hayman 1 , TM Cox 2 . 1<br />
Clinical Veterinary Science, University of Bristol, Bristol, BS40 5DU, United<br />
Kingdom; 2 Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, CB2 2QQ, United<br />
Kingdom<br />
78 LIGAMENTS AND BONE JOIN AT SACRAL AND ILIAC ENTHESES BY DISCONTINUOUS<br />
ATTACHMENT ZONES DEFINED BY TENASCIN AND TYPE VI COLLAGEN.<br />
L Fairbairn, SJ Millward-Sadler, DM Salter, DL Gardner. Pathology, University of Edinburgh, Edinburgh,<br />
United Kingdom<br />
79 COMPARATIVE ANALYSIS OF STRUCTURES WITHIN THE OSTEOARTHRITIC KNEE JOINTS REVEALS<br />
MESENCHYMAL PROGENITOR CELL (MPC) ACTIVITY IN ALL TISSUES, IMPLICATIONS FOR THE ROLE<br />
OF THE MICROENVIRONMENT IN REPAIR.<br />
A English 1 , EA Jones 1 , K Henshaw 1 , D Corscadden 1 , J Holdsworth 2 , T Chapman 3 , R Reece 1 , P Emery 1 ,<br />
D McGonagle 2 . 1<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University of Leeds, Leeds, Yorkshire,<br />
United Kingdom; 2 <strong>Rheumatology</strong> Department, Calderdale General Hospital, Halifax, Yorkshire, United<br />
Kingdom; 3 Orthopaedic Department, Calderdale General Hospital, Halifax, Yorkshire, United Kingdom<br />
42
BONE: GENES AND THE ENVIRONMENT (80 – 83)<br />
80 CADMIUM TOXICITY AND ITS HUMAN HEALTH IMPACT: A POSSIBLE CAUSE OF<br />
OSTEOMALACIA AND OSTEOPOROSIS IN POLLUTED AREAS.<br />
AA Elbeialy 1 , AM Bersy 2 , SM Zaky 3 , AM Kotb 4 , MM Emara 5 . 1<br />
<strong>Rheumatology</strong>, Al-Azhar Faculty of<br />
Medicine, Cairo, Cairo, Egypt; 2 Clinical Pathology, Al-Azhar Faculty of Medicine, Cairo, Cairo,<br />
Egypt; 3 Tropical Medicine, Al-Azhar Faculty of Medicine, Cairo, Cairo, Egypt; 4 Geophysics, Al-Azhar<br />
Faculty of Science, Cairo, Cairo, Egypt; 5 Chemistry, Al-Azhar Faculty of Science, Cairo, Cairo, Egypt<br />
81 POLYMORPHISMS OF THE TRANSFORMING GROWTH FACTOR β GENE ARE ASSOCIATED<br />
WITH BONE MASS AND INFANT GROWTH IN UK MEN BUT NOT WOMEN.<br />
E Dennison 1 , T Spector 2 , Y Mac 2 , T Andrew 2 , H Syddall 1 , C Cooper 1 . 1<br />
Medical Research Council<br />
Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United<br />
Kingdom; 2 Twin & Genetic Epidemiology Research Unit, St Thomas’ Hospital, London, United<br />
Kingdom<br />
82 LRP5 POLYMORPHISMS ARE LINKED AND ASSOCIATED WITH BONE MINERAL DENSITY.<br />
AM Koay 1 , PY Woon 1 , LJ Miles 1 , EL Duncan 2 , Y Zhang 1 , FAMOS Study Investigators 3 , JAH Wass 2 ,<br />
MA Brown 1,2 . 1<br />
Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>d, United Kingdom; 2 Metabolic Bone Unit, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United<br />
Kingdom; 3 Oxagen, Abingdon, United Kingdom<br />
83 VITAMIN D BINDING PROTEIN GENE (TAAA)n-Alu ELEMENT POLYMORPHISM AND ITS<br />
ASSOCIATION WITH BONE DENSITY AND OSTEOPOROSIS IN MEN.<br />
SP Tuck 1 , ZH Al-oanzi 1 , SS Varanasi 1 , N Raj 2 , GD Summers 2 , HK Datta 1 , RM Francis 1 . 1<br />
School of<br />
Clinical Medical Sciences, Medical School, Ubiversity of Newcastle, Newcastle upon Tyne,<br />
Newcastle, United Kingdom; 2 <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, Derbyshire,<br />
United Kingdom<br />
CONNECTIVE TISSUE BIOLOGY (84 – 85)<br />
84 ROLE OF THE RAS/MEK/ERK SIGNALING PATHWAY AND ITS INHIBITORY REGULATION BY<br />
PROSTANOIDS IN THE FIBROTIC/WOUND HEALING RESPONSE.<br />
R Stratton, H Penn, G Taguri, X Shiwen, CM Black, DJ Abraham, A Leask. Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, Royal Free and University College School of Medicine, Royal Free Campus, London,<br />
United Kingdom<br />
85 EXPRESSION AND REGULATION OF ‘AGGRECANASE’ ENZYMES (ADAMTS-1, -4, -5)<br />
IN TENDON PATHOLOGY.<br />
AN Corps 1 , RL Harrall 1 , AHN Robinson 2 , BL Hazleman 1 , GP Riley 1 . 1<br />
<strong>Rheumatology</strong> Research Unit,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Department of Orthopaedics &<br />
Trauma Surgery, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom<br />
CRYSTAL DEPOSITION DISEASE (86 – 87)<br />
86 BASIC CALCIUM PHOSPHATE CRYSTAL-INDUCED SECRETION OF PRO-INFLAMMATORY<br />
CYTOKINES BY HUMAN MONOCYTE/MACROPHAGES LEADING TO ENDOTHELIAL ACTIVATION<br />
MEDIATED THROUGH PROTEIN KINASE Cα AND ε, MEK-1/2 MAP KINASE AND NFKB<br />
INTRACELLULAR SIGNALING PATHWAYS.<br />
I Nadra 1 , JC Mason 1 , GM McCarthy 2 , C Landis 1 , DO Haskard 1 . 1<br />
Eric Bywaters Centre <strong>for</strong> Vascular<br />
Inflammation, Imperial College, London, United Kingdom; 2 Department of Clinical Pharmacology,<br />
Royal College of Surgeons, Dublin, United Kingdom<br />
87 THE CROWNING GLORY OF CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD)<br />
DEPOSITION DISEASE.<br />
JE Brockbank, M Akil, C Romanowski. Royal Hallamshire Hospital, Sheffield, United Kingdom<br />
43
BONE MINERAL DENSITY (88 – 104)<br />
88 REDUCED BONE MASS IN RHEUMATOID ARTHRITIS PATIENTS COMPARED WITH<br />
AGE-MATCHED CONTROLS.<br />
B Heidari, S Azizian. 1 Department of Medicine, Shaheed Beheshti Hospital, Babol University of Medical<br />
Sciences, Babol, Mazandarn, Islamic Republic of Iran; 2 Department of Medicine, Shaheed Beheshti<br />
Hospital, Babol, Mazandarn, Islamic Republic of Iran<br />
89 EFFECT OF MEDICAL RISK FACTORS, MUSCLE STRENGTH AND FALLS HISTORY ON<br />
FRACTURE INCIDENCE.<br />
S Vasireddy 1 , K Kayan 1 , T Jalava 2 , C McGurk 1 , L Reaney 1 , J Kanis 1 , E McCloskey 1 . 1<br />
University of Sheffield,<br />
Sheffield, United Kingdom; 2 Leiras Oy, Helsinki, Finland<br />
90 EFFECT OF MEDICAL RISK FACTORS ON DXA MEASUREMENTS AND METACARPAL<br />
RADIOGRAPHIC INDICES.<br />
S Vasireddy, L Reaney, D Charlesworth, JA Kanis, EV McCloskey. University of Sheffield, Sheffield,<br />
United Kingdom<br />
91 MATERNAL VITAMIN D STATUS AND BODY COMPOSITION IN LATE PREGNANCY PREDICT<br />
CHILDHOOD LUMBAR SPINE VOLUMETRIC BONE DENSITY AT 9 YEARS.<br />
NCW Harvey 1 , MK Javaid 1 , P Taylor 2 , SR Crozier 1 , CR Gale 1 , EM Dennison 1 , KM Godfrey 1 , C Cooper 1 . 1<br />
MRC<br />
Environmental Epidemiology Unit, Southampton, United Kingdom; 2 Medical Physics and Bioengineering,<br />
Southampton General Hospital, Southampton, United Kingdom<br />
92 RELATIONSHIPS BETWEEN SF-36 AND BONE MINERAL DENSITY: THE HERTFORDSHIRE<br />
COHORT STUDY.<br />
E Dennison, H Syddall, H Gilbody, C Statham, A Aihie Sayer, C Cooper. Medical Research Council<br />
Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom<br />
93 PEAK BONE MASS IN EUROPEAN AND SOUTH ASIAN WOMEN OF PAKISTANI MUSLIM ORIGIN.<br />
DK Roy 1 , CM Swarbrick 1 , Y King 1 , SR Pye 1 , JE Adams 2 , J Berry 3 , AJ Silman 1 , TW O’Neill 1 . 1<br />
Arthritis Research<br />
Campaign Epidemiology Unit, University of Manchester, Manchester, Greater Manchester, United<br />
Kingdom; 2 Department of Imaging Science and Biomedical Engineering, University of Manchester,<br />
Manchester, Greater Manchester, United Kingdom; 3 Department of Medicine, Manchester Royal<br />
Infirmary, Manchester, Greater Manchester, United Kingdom<br />
94 DOES FRACTURE RISK ASSESSMENT INFLUENCE GP TREATMENTS OF PATIENTS WITH<br />
LOW TRAUMA FRACTURES?<br />
J Christopher 1 , M Goodwin 2 , C Jones 3 , P Thompson 1 . 1<br />
<strong>Rheumatology</strong> Unit, Poole Hospital NHS Trust,<br />
Poole, Dorset, United Kingdom; 2 Orthopedic Unit, Poole Hospital NHS Trust, Poole, Dorset, United<br />
Kingdom; 3 Osteoporosis Dorset, Bournemouth, Dorset, United Kingdom<br />
95 VITAMIN D STATUS IN PATIENTS WITH PAGET’S DISEASE.<br />
G Chung 1 , RW Keen 1,2 . 1<br />
Metabolic Unit, Royal National Orthopaedic Hospital, Stanmore, Middx, United<br />
Kingdom; 2 Department of Medicine, University College London, London, United Kingdom<br />
96 SELF REPORT OVERESTIMATES TRUE HEIGHT LOSS: RESULTS FROM THE<br />
NEWCASTLE THOUSAND FAMILIES STUDY.<br />
F Birrell 1,2,3 , M Pearce 1 , R Francis 1,2 , L Parker 1 . 1<br />
School of Clinical Medical Sciences, University of Newcastle<br />
upon Tyne, Newcastle upon Tyne, United Kingdom; 2 Musculoskeletal Unit, Freeman Hospital, Newcastle<br />
upon Tyne, United Kingdom; 3 <strong>Rheumatology</strong>, Wansbeck General Hospital, Ashington, United Kingdom<br />
97 THE PREVALENCE AND DISTRIBUTION OF OSTEOPOROSIS IN PATIENTS WITH END-STAGE KNEE<br />
OSTEOARTHRITIS (OA): MORE EVIDENCE FOR OA MITIGATING LOCAL BONE LOSS.<br />
E Lingard 1,2 , A Khan 2 , F Birrell 1,2,3 , R Francis 1,2 , R Peaston 2 , A McCaskie 1,2 . 1<br />
School of Clinical Medical<br />
Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 2 Musculoskeletal<br />
Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 3 <strong>Rheumatology</strong>, Wansbeck General<br />
Hospital, Ashington, United Kingdom<br />
44
98 THE PREVALENCE AND DISTRIBUTION OF OSTEOPOROSIS IN PATIENTS WITH END-STAGE<br />
HIP OSTEOARTHRITIS (OA): EVIDENCE FOR OA MITIGATING LOCAL BONE LOSS.<br />
F Birrell 1,2,3 , E Lingard 1,3 , A Khan 3 , R Francis 1,3 , R Peaston 3 , A McCaskie 1,3 . 1<br />
School of Clinical<br />
Medical Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Wansbeck General Hospital, Ashington, United Kingdom; 3 Musculoskeletal Unit,<br />
Freeman Hospital, Newcastle upon Tyne, United Kingdom<br />
99 SIZE-ADJUSTED MATERNAL CALCANEAL QUS CHANGE DURING PREGNANCY<br />
AND NEONATAL BONE MASS.<br />
MK Javaid 1 , SR Crozier 1 , P Taylor 1 , HM Inskip 1 , KM Godfrey 1 , C Cooper 1 . 1<br />
MRC Environmental<br />
Epidemiology Unit, Southampton, Hampshire, United Kingdom; 2 Medical Physics and<br />
Bioengineering, Southampton General Hospital, Southampton, Hampshire, United Kingdom<br />
100 DIRECT ACCESS BONE DENSITOMETRY AND SIGN GUIDELINES IN OSTEOPOROSIS:<br />
A PRIMARY CARE PERSPECTIVE.<br />
C Mitchell 1 , V Rajagopal 2 , E Brankin 1 , J Wright 1 , R Munro 2 . 1<br />
Coatbridge Local Healthcare<br />
Co-Operative, Coatbridge, Lanarkshire, United Kingdom; 2 <strong>Rheumatology</strong> Dept, Wishaw General,<br />
Wishaw, Lanarkshire, United Kingdom<br />
101 DIRECT ACCESS BMD IN MEN - IS THE PICK UP BETTER THAN IN WOMEN?<br />
H Gunawardena 1 , ECS Wong 1 , ND Harris 2 , AK Bhalla 1 . 1<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom; 2 Clinical Measurements, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, United Kingdom<br />
102 CLINICIAN SATISFACTION WITH A NURSE-LED PERIPHERAL DEXA SCAN SERVICE.<br />
A Adebajo, J Hitchcock, L Campbell. <strong>Rheumatology</strong>, Barnsley District General Hoapital NHS Trust,<br />
Barnsley, South Yorkshire, United Kingdom<br />
103 ACCESS TO DXA INFLUENCES PRESCRIBING CHOICES IN PRIMARY CARE, BUT DOES NOT<br />
SUBSTANTIALLY INCREASE COST.<br />
V Robins 1 , SM Stebbings 2 , R Darling 3 , L McHugh 4 . 1<br />
Medical School, University of Bristol, Bristol,<br />
United Kingdom; 2 Musculo-Skeletal Directorate, Southmead Hospital, Bristol, United Kingdom;<br />
3<br />
Riverbank Medical Centre, Weston-Super-Mare, Somerset, United Kingdom; 4 18, Upper Oldfield<br />
Park Surgery, Bath, Avon, United Kingdom<br />
104 CALCANEAL DXA - A USEFUL SCREENING TOOL?<br />
SY Khan, A Wood, K Mackay. <strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth,<br />
United Kingdom<br />
OSTEOPOROSIS: TREATMENT (105 – 107)<br />
105 SYSTEMIC MASTOCYTOSIS MAY PRESENT WITH OSTEOPOROSIS WHICH IMPROVES<br />
WITH BISPHOSPHONATES.<br />
AYN Lim, AJK Ostor, SA Love, AJ Crisp. Departments of <strong>Rheumatology</strong> and Metabolic Bone<br />
Diseases, Addenbrookes Hospital, Cambridge, Cambs, United Kingdom<br />
106 THE EFFECT OF 90MG OF PAMIDRONATE GIVEN ANNUALLY ON BONE MINERAL<br />
DENSITY IN POST-MENOPAUSAL OSTEOPOROSIS.<br />
EW Thomas 1 , H Cohen 1 , J Morgan 2 , D Hampton 2 , JC Martin 2 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
University Hospital of Wales, Cardiff, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Royal<br />
Glamorgan Hospital, Llantrisant, Rhondda Cynon Taf, United Kingdom<br />
107 PERCUTANEOUS VERTEBROPLASTY - A NEW DIMENSION TO TREATMENT<br />
FOR COMPLICATED OSTEOPOROSIS?<br />
T Sikdar, P Mathew, D Dutta, A Hussein. 1 Department of Radiology, Princess Alexandra Hospital,<br />
Harlow, United Kingdom; 2 Department of Orthopaerdics, Princess Alexandra Hospital, Harlow,<br />
United Kingdom; 3 Department of Anaesthesia, Princess Alexandra Hospital, Harlow, United<br />
Kingdom; 4 Department of Orthopaerdics, Princess Alexandra Hospital, Harlow, United Kingdom<br />
45
OSTEOARTHRITIS (108 – 132)<br />
108 PREVALENCE OF GENETIC HAEMOCHROMATOSIS AND IRON OVERLOAD AMONGST<br />
PATIENTS ATTENDING RHEUMATOLOGY AND JOINT REPLACEMENT CLINICS.<br />
S Donnelly 1 , NG Joshi 2 , D Thornburn 2 , A Cook 3 , G Reid 2 , M Neilson 2 , AJ Stanley 2 , HA Capell 1 . 1<br />
Centre <strong>for</strong><br />
Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 Department of Gastroenterology, Royal<br />
Infirmary, Glasgow, United Kingdom; 3 Genetics Unit, Yorkhill Hospital, Glasgow, United Kingdom<br />
109 HAEMOCHROMATOSIS: IS IT WORTH LOOKING HARDER FOR IT?<br />
M Lloyd 1 , P Alton 2 , P Cusick 3 . 1<br />
Department of <strong>Rheumatology</strong>, Frimley Park Hospital, Frimley, Surrey,<br />
United Kingdom; 2 Department of Haematology, Frimley Park Hospital, Frimley, Surrey, United Kingdom;<br />
3<br />
Department of Clinical Biochemistry, Frimley Park Hospital, Frimley, Surrey, United Kingdom<br />
110 RADIOGRAPHIC FEATURES OF LUMBAR DISC DEGENERATION AND BONE MINERAL<br />
DENSITY IN MEN AND WOMEN.<br />
SR Pye 1 , DM Reid 2 , R Smith 2 , JE Adams 3 , AJ Silman 1 , TW O’Neill 1 . 1<br />
ARC Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2 Department of Medicine and <strong>The</strong>rapeutics, University of<br />
Aberdeen, Aberdeen, United Kingdom; 3 Clinical Radiology, Imaging Science and Biomedical Engineering,<br />
University of Manchester, Manchester, United Kingdom<br />
111 AEROBIC WALKING OR STRENGTHENING EXERCISE FOR OSTEOARTHRITIS OF THE KNEE?<br />
A SYSTEMATIC REVIEW.<br />
E Roddy, W Zhang, M Doherty. Academic <strong>Rheumatology</strong>, Nottingham City Hospital, Nottingham,<br />
United Kingdom<br />
112 EULAR RECOMMENDATIONS 2003: AN EVIDENCE BASED MEDICINE APPROACH TO<br />
THE MANAGEMENT OF KNEE OSTEOARTHRITIS.<br />
KM Jordan 1 , NK Arden 1 , M Doherty 2 , P Dieppe 3 , K Gunther 3 , H Hauselmann 3 , G Herrero-Beaumont 3 ,<br />
P Kaklamanis 3 , S Lohmander 3 , B Leeb 3 , M Lequesne 3 , B Mazieres 3 , E Martin-Mola 3 , K Pavelka 3 ,<br />
A Pendleton, 3 L Punzi 3 , U Serni 3 , B Swoboda 3 , G Verbruggen 3 , I Zimmerman-Gorska 3 , B Bannwarth 3 JWJ<br />
Bijlsma 3 , M Dougados 4 . 1<br />
MRC EEU, Southampton General Hospital, Southampton, Hampshire SO16<br />
6YD, United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, City Hospital, Nottingham, United Kingdom;<br />
3<br />
EULAR OA Task Force, Standing Committee <strong>for</strong> International Clinical Studies Including <strong>The</strong>rapeutic<br />
Trials (ESCISIT), Paris, France; 4 Institut de Rhumatologie, Hardy B, Hopital Cochin, 27, rue du Faubourg<br />
Saint-Jacques, 75014 Paris, France<br />
113 A COMPARISON OF QUANTITATIVE AND SEMI-QUANTITATIVE MRI SYNOVITIS SCORES<br />
IN KNEE OSTEOARTHRITIS.<br />
LA Rhodes 1 , AJ Grainger 2 , AM Keenan 3 , P Emery 3 , PG Conaghan 3 . 1<br />
Department of Medical Physics,<br />
University of Leeds, Leeds, West Yorkshire, United Kingdom; 2 Department of Radiology, University of<br />
Leeds, Leeds, West Yorkshire, United Kingdom; 3 Department of <strong>Rheumatology</strong>, Leeds General Infirmary,<br />
Leeds, West Yorkshire, United Kingdom<br />
114 HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS (OA): A COCHRANE REVIEW.<br />
N Bellamy, Jr 1 , J Campbell 2 , T Gee 1 , V Robinson 3 , G Wells 3 , R Bourne 2 . 1<br />
Centre of National Research on<br />
Disability and Rehabilitation Medicine (CONROD), University of Queensland, Herston, Brisbane,<br />
Queensland, Australia; 2 University of Western Ontario, London, ON, Canada; 3 University of Ottawa,<br />
Ottawa, ON, Canada<br />
46
115 EVIDENCE-BASED RECOMMENDATIONS FOR THE ROLE OF EXERCISE IN THE<br />
MANAGEMENT OF OSTEOARTHRITIS (OA) OF THE HIP OR KNEE.<br />
E Roddy 1 , W Zhang 1 , M Doherty 1 , N Arden 2 , J Barlow 3 , F Birrell 4 , A Carr 1 , K Chakravarty 5 , J Dickson 6 ,<br />
E Hay 7 , G Hosie 6 , M Hurley 8 , K Jordan 2 , C McCarthy 9 , M McCurdo 10 , J Mead 11 , S Mockett 12 , J<br />
Nixon 13 , S O’Reilly 14 , G Peat 7 , A Pendleton 15 , S Richards 16 . 1<br />
Academic <strong>Rheumatology</strong>, Nottingham<br />
City Hospital, United Kingdom; 2 <strong>Rheumatology</strong>, Southampton General Hospital, United Kingdom;<br />
3<br />
Interdisciplinary Research Centre in Health, Coventry University, United Kingdom; 4 <strong>Rheumatology</strong>,<br />
University of Newcastle-upon-Tyne, United Kingdom; 5 <strong>Rheumatology</strong>, Haroldwood Hospital,<br />
Rom<strong>for</strong>d, United Kingdom; 6 Primary Care <strong>Rheumatology</strong> <strong>Society</strong>, United Kingdom; 7 Primary Care<br />
Sciences Research Centre, Keele University, United Kingdom; 8 Rehabilitation Research Unit, Kings<br />
College, London, United Kingdom; 9 <strong>The</strong> Centre <strong>for</strong> Rehabilitation Science, Manchester Royal<br />
Infirmary, United Kingdom; 10 Aging and Health, University of Dundee, United Kingdom; 11 Clinical<br />
Effectiveness, <strong>The</strong> Chartered <strong>Society</strong> of Physiotherapy, United Kingdom; 12 Physiotherapy Education,<br />
University of Nottingham, United Kingdom; 13 <strong>British</strong> Hip <strong>Society</strong>, <strong>The</strong> Royal College of Surgeons,<br />
United Kingdom; 14 <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, United Kingdom; 15 <strong>Rheumatology</strong>,<br />
Belfast City Hospital, United Kingdom; 16 <strong>Rheumatology</strong>, Poole Hospital NHS Trust, United Kingdom<br />
116 RADIOGRAPHIC ASSESSMENT OF SEVERE JOINT DAMAGE IN OSTEOARTHRITIS.<br />
P Dieppe 1 , S Williams 1 , I Watt 1 , P Gregg 2 , P Juni 1 . 1<br />
MRC HSRC, University of Bristol, Bristol, United<br />
Kingdom; 2 <strong>British</strong> Orthopaedic Association, Royal College of Surgeons, London, United Kingdom<br />
117 A RANDOMIZED, DOUBLE-BLIND COMPARISON OF THE EFFICACY AND SAFETY OF<br />
VALDECOXIB 10 mg AND ROFECOXIB 25 mg IN INDIAN PATIENTS WITH OSTEOARTHRITIS.<br />
A Desai 1 , S Jagtap 2 , C Ballary 1 . 1<br />
Medical, Glenmark, Mumbai, Maharashtra, India; 2 Orthopaedics,<br />
Grant Medical College and J.J. Hospital, Mumbai, Maharashtra, India<br />
118 EFFICACY AND TOLERABILITY OF LUMIRACOXIB IN PATIENTS WITH OSTEOARTHRITIS:<br />
A POOLED ANALYSIS.<br />
R Fleischmann 1 , F Berenbaum 2 , V Sloan 3 , A Moore 4 , A Couturier 3 . 1<br />
University of Texas<br />
Southwestern Medical Center, Dallas, TX, United States; 2 Pierre and Marie Curie<br />
University-Saint-Antoine Hospital, Paris, France; 3 Novartis Pharmaceuticals Corporation,<br />
East Hanover, NJ, United States; 4 Novartis Pharma AG, Basel, Switzerland<br />
119 DOES GRADING IMPROVE BY OVERLAYING AN ACETATE LINE DRAWING ATLAS<br />
DIRECTLY OVER A RADIOGRAPH?<br />
CE Wilkinson, A Carr, M Doherty. Academic <strong>Rheumatology</strong>, University of Nottingham,<br />
Nottingham, United Kingdom<br />
120 RELATIONSHIP BETWEEN HEBERDEN’S NODES AND THE UNDERLYING<br />
RADIOGRAPHIC CHANGE.<br />
A Thaper, W Zhang, S Doherty, G Wright, M Doherty. Academic <strong>Rheumatology</strong>, Clinical Sciences<br />
Building, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom<br />
121 COMPARISON OF INVESTIGATOR-REPORTED AND PATIENT-REPORTED ADVERSE EVENT<br />
SEVERITY RATINGS AND THEIR RELATION TO OVERALL HEALTH AND QUALITY OF LIFE.<br />
PS Tugwell 1 , JJ Clinch 2 , JZ Shainhouse 3 , BA Kristjansson 4 , GA Wells 5 . 1<br />
Centre <strong>for</strong> Global Health,<br />
University of Ottawa, Ottawa, ON, Canada; 2 Clinical Epidemiology Program, Ottawa Health<br />
Research Institute, Ottawa, ON, Canada; 3 Clinical Research, Dimethaid Health Care Ltd., Markham,<br />
ON, Canada; 4 School of Psychology, University of Ottawa, Ottawa, ON, Canada; 5 Department of<br />
Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada<br />
122 THE A.C.T.I.V.E. (ARTHRITIS CARE TOWARDS IMPROVED VITALITY AND ENDURANCE)<br />
TRIAL: AN OBSERVATIONAL STUDY ON THE IMPACT OF VIOXX ® (ROFECOXIB) 12.5 mg OR<br />
25 mg/DAY ON PAIN CONTROL AND PHYSICAL FUNCTION IN ELDERLY PATIENTS WITH<br />
OSTEOARTHRITIS SYMPTOMS<br />
NR Bastien, 1 JJ Mansi, 1 A Turcotte. 2 1 Clinical Research, Merck Frosst Canada & Co., Kirkland, QC,<br />
Canada; 2 Centre de l’osteoporose et de Rhumatologie de Quebec, Sainte-Foy, QC, Canada<br />
47
123 EFFECT OF LUMIRACOXIB ON BLOOD PRESSURE AND FLUID RETENTION:<br />
A POOLED ANALYSIS.<br />
R Hirschberg 1 , O Della Casa Alberighi 2 , G Hoexter 2 . 1<br />
Harbor-UCLA Medical Center, Torrance, CA,<br />
United States; 2 Novartis Pharma AG, Basel, Switzerland<br />
124 DOES INCREASING THE GRADES OF THE KNEE OSTEOARTHRITIS LINE DRAWING ATLAS<br />
IMPROVE IT’S CLINIMETRIC PROPERTIES?<br />
CE Wilkinson, A Carr, M Doherty. Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham,<br />
United Kingdom<br />
125 CAN BASELINE CLINICAL SIGNS OF INFLAMMATION AND/OR SENSITIVE C-REACTIVE<br />
PROTEIN MEASUREMENT IDENTIFY RESPONDERS TO NSAIDs IN KNEE OA.<br />
A Sanghvi 1 , M Sharif 1 , I Al-Salem 2 , B Hameed 2 , JR Kirwan 2 . 1<br />
Department of Anatomy, University of<br />
Bristol, Bristol, United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary, Bristol,<br />
United Kingdom<br />
126 THE EFFECTS OF EARLY ENVIRONMENT AND GENE INTERACTIONS ON SPINAL OSTEOARTHRITIS.<br />
KM Jordan, H Syddall, EM Dennison, C Cooper, NK Arden. MRC Environmental Epidemiology Unit,<br />
Southampton General Hospital, Southampton, Hampshire, United Kingdom<br />
127 CARTILAGE OLIGOMERIC MATRIX PROTEIN AND AGGRECAN IN SYNOVIAL FLUID FROM<br />
PATIENTS WITH OSTEOARTHRITIS: MARKERS OF LOCAL OR SYSTEMIC CHARACTERISTICS?<br />
DF McWilliams 1 , Y Reehana 1 , B Carolyn 1 , D Michael 1 , H Dick 2 , S Tore 2,3 , Z Weiya 1 . 1<br />
Academic<br />
<strong>Rheumatology</strong>, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom;<br />
2<br />
Dept Cell and Molecular Biology, Lund University, Lund, Sweden; 3 Dept <strong>Rheumatology</strong>,<br />
Lund University, Lund, Sweden<br />
128 SERUM BIOMARKERS IN MEDIAL TIBIOFEMORAL AND PATELLOFEMORAL<br />
OSTEOARTHRITIS OF THE KNEE.<br />
M Sharif 1 , JR Kirwan 2 , B Quilty 2 , S Clarke 2 , R Granell 2 , V Lock 2 , J Johansen 3 . 1<br />
Deopartment of Anatomy,<br />
University of Bristol, Bristol, United Kingdom; 2 Academic <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary,<br />
Bristol, United Kingdom; 3 Department of <strong>Rheumatology</strong>, University of Copenhagen, Copenhagen,<br />
Denmark<br />
129 CRP LEVELS ARE RAISED IN PATIENTS WITH LONGSTANDING OSTEOARTHRITIS<br />
WHEN COMPARED WITH NORMAL CONTROLS.<br />
N Kumar, NJ Marshall, D Neely, SS Furniss, PN Platt, DJ Walker. 1<br />
Department of <strong>Rheumatology</strong>,<br />
Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Department of<br />
Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of<br />
Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom<br />
130 EVALUATION OF PATIENT SATISFACTION FOLLOWING TOTAL KNEE JOINT REPLACEMENT FOR<br />
OSTEOARTHRITIS.<br />
EA Lingard, KA Bettinson, AW McCaskie, ID Griffiths. Musculoskeletal Unit, Freeman Hospital, Newcastle<br />
upon Tyne, United Kingdom<br />
131 EXPRESSION PROFILING USING MICOARRAY TECHNOLOGY OF FAILED TOTAL<br />
HIP REPLACEMENTS.<br />
HA Malik 2 , B Rash 1 , N Delcroix 1 , P Day 1 , A Bayat 1 , WE Ollier 1 , PR Kay 2 . 1<br />
Centre <strong>for</strong> Integrated Genomic<br />
Medical Research, <strong>The</strong> University of Manchester, Manchester, United Kingdom; 2 Centre <strong>for</strong> Hip Surgery,<br />
Wrightington Hospital, Wigan, Lancashire, United Kingdom<br />
132 THE USE OF NON WEIGHT BEARING NEUROMUSCULAR EXERCISES IN ACUTE ANKLE<br />
LIGAMENT INJURY REHABILITATION.<br />
SH Voules, DW Hodgkinson. 1 Physiotherapy Department, Ipswich Hospital NHS Trust, Ipswich, Suffolk,<br />
United Kingdom; 2 Emergency Department, Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom<br />
48
FIBROMYALGIA (133 – 140)<br />
133 TREATMENT OF FIBROMYALGIA WITH THE DOPAMINE AGONIST ROPINIROLE:<br />
A PILOT, PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL.<br />
AJ Holman 1 , RR Myers 1 , AM Gray 2 . 1<br />
<strong>Rheumatology</strong>, Pacific <strong>Rheumatology</strong> Associates, Renton, WA,<br />
United States; 2 Neurology & GI, GlaxoSmithKline, RTP, NC, United States<br />
134 PSYCHOLOGICAL STATUS IN PATIENTS WITH FIBROMYALGIA SYNDROME.<br />
SV Koliadenko, MA Stanislavchuk. <strong>Rheumatology</strong>, National Medical University, Vinnycia, Ukraine<br />
135 POWER SPEKTRUM ANALYSIS OF HEART RATE VARIABILITY IN THE PATIENTS<br />
WITH FIBROMYALGIA.<br />
MA Stanislavchuk 1 , VM Khomenko 2 . 1<br />
<strong>Rheumatology</strong>, Vinnytsia National Medical University,<br />
Vinnytsia, Ukraine; 2 <strong>Rheumatology</strong>, Vinnytsia District Hospital, Vinnytsia, Ukraine<br />
136 BODY COMPOSITION, PHYSICAL FUNCTION AND DISABLITY IN FEMALE ADULT<br />
PATIENTS WITH FIBROMYALGIA SYNDROME.<br />
KR Cowan 1 , SM Marcora 1 , JJ Jones 2 , PJ Maddison 2 , AB Lemmey 1 . 1<br />
School of Sport, Health and<br />
Exercise Sciences, University of Wales, Bangor, Gwynedd, United Kingdom; 2 Department of<br />
<strong>Rheumatology</strong>, Gwynedd Hospital, Bangor, Gwynedd, United Kingdom<br />
137 IS FIBROMYALGIA A UNIQUE RHEUMATIC DISORDER?<br />
GM Papadimitriou, KM Sotiriadou. 1 Internal Medicine Dept. University of Athens, Rheumatologist<br />
- Prof. University of Athens, Athens, Attiki, Greece; 2 Psychiatric Unit AGIOS Andreas Hospital,<br />
Psychiatrist Director of Psychiatric Unit, Patras, Ahaia, Greece<br />
138 IS THERE A LINK BETWEEN FIBROMYALGIA, HYPERVENTILATION SYNDROME AND<br />
OBSTRUCTIVE SLEEP APNOEA?<br />
AM Scott-Russell 1 , A Williams 2 , CA Dunne 1 . 1<br />
<strong>Rheumatology</strong> Department, Christchurch Hospital,<br />
Bournemouth, Dorset, United Kingdom; 2 Thoracic Department, Royal Bournemouth Hospital,<br />
Bournemouth, Dorset, United Kingdom<br />
139 A PILOT STUDY TO ESTABLISH THE BENEFITS OF A MULTIDISCIPLINARY FIBROMYALGIA<br />
PROGRAMME.<br />
W Farren, D Shead, F Caven, C Kemp, B Yates, R Mepstead, B Roychowdhury. Physiotherapy<br />
Department, Cumberland Infirmary, Carlisle, Cumbria, United Kingdom<br />
140 DO PATIENTS WITH FIBROMYALGIA UNDERGO UNNECESSARY OPERATIONS?<br />
AJ Kinder 1 , PT Dawes 2 , D Clement 3 , C Hollows 2 . 1<br />
Department of <strong>Rheumatology</strong>, Leicester Royal<br />
Infirmary, Leicester, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Staf<strong>for</strong>dshire <strong>Rheumatology</strong><br />
Centre, Stoke-on-Trent, United Kingdom; 3 Research and Development, University Hospital of North<br />
Staf<strong>for</strong>dshire, Stoke-on-Trent, United Kingdom<br />
SOFT TISSUE RHEUMATISM (141 – 145)<br />
141 PROGNOSTIC INDICATORS OF OUTCOME IN SHOULDER PAIN: RESULTS FROM<br />
AN ANALYSIS OF TWO PRAGMATIC, PRIMARY CARE-BASED RANDOMISED TRIALS.<br />
E Thomas 1,2 , DAWM van der Windt 2 , N Smidt 2 , K Dziedzic 1 , PR Croft 1 , LM Bouter 2 , EM Hay 1,3 .<br />
1<br />
Primary Care Sciences Research Centre, Keele University, Keele, North Staf<strong>for</strong>dshire, United<br />
Kingdom; 2 EMGO Institute, Vrije Universiteit, Amsterdam, <strong>The</strong> Netherlands; 3 Staf<strong>for</strong>dshire<br />
<strong>Rheumatology</strong> Centre, <strong>The</strong> Haywood, Stoke-on-Trent, North Staf<strong>for</strong>dshire, United Kingdom<br />
142 GENERAL PRACTITIONERS ATTITUDES AND TRAINING IN ASSESSMENT AND<br />
MANAGEMENT OF SHOULDER PAIN - A QUESTIONAIRRE STUDY.<br />
I Ryans 1 , S McCann 2 , O McNally 2 , WG Kernohan 3 , D MacAuley 4 , R McKane 1 . 1<br />
<strong>Rheumatology</strong><br />
Department, Ulster Hospital, Dundonald, Belfast, Co Down, United Kingdom; 2 Institute of<br />
Postgraduate Medical and Health Sciences, University of Ulster, Northern Ireland, United Kingdom;<br />
3<br />
Faculty of Life and Health Sciences, University of Ulster, Jordanstown, Northern Ireland, United<br />
Kingdom; 4 Department of Epidemiology, <strong>The</strong> Queen’s University, Belfast, United Kingdom<br />
49
143 THE EPIDEMIOLOGY OF ADHESIVE CAPSULITIS AMONG WORKING-AGED ADULTS<br />
IN THE GENERAL POPULATION.<br />
KE Walker-Bone 1 , IC Reading 2 , KT Palmer 2 , D Coggon 2 , C Cooper 2 . 1<br />
<strong>Rheumatology</strong> Department, Brighton<br />
and Sussex Medical School, Falmer, Brighton, East Sussex, United Kingdom; 2 MRC Environmental<br />
Epidemiology Unit, Southampton General Hospital, Southampton, Hampshire, United Kingdom<br />
144 ULTRASOUND EVALUATION OF SHOULDER PAIN AND RESTRICTION IN THE ELDERLY.<br />
J Rees1, I Wamuo1, W Jan2, T Gibson1. 1Department of <strong>Rheumatology</strong>, Guy’s and St Thomas’<br />
Hospital, London, United Kingdom; 2Department of Radiology, Guy’s and St Thomas’ Hospital, London,<br />
United Kingdom<br />
145 ROLE OF ULTRASOUND GUIDED INJECTION OF SOFT TISSUE AND JOINTS AS A DIAGNOSTIC<br />
AND THERAPEUTIC PROCEDURE IN OUT-PATIENT BASED RHEUMATOLOGY PRACTICE.<br />
T Sikdar, K Chakravarty. 1<br />
Department of Radiology, Princess Alexandra Hospital, Harlow, United<br />
Kingdom; 2 Department of <strong>Rheumatology</strong>, Harold Wood Hospital, Harold Wood, United Kingdom<br />
PSYCHOLOGY (146 – 150)<br />
146 QUALITATIVE EVALUATION OF A PROGRAMME TO IMPROVE SELF-EFFICACY IN RA PATIENTS.<br />
J Taylor 1 , H Allen 2 , A Hayden 3 , R Baker 2 , C Musslewhite 4 , D Freshwater 4 , P Thompson 1 . 1 <strong>Rheumatology</strong><br />
Unit, Poole Hospital NHS Trust, Poole, Dorset, United Kingdom; 2 Dorset Research and Development<br />
Support Unit, Poole Hospital, Poole, Dorset, United Kingdom; 3 ISECCA, <strong>The</strong> Surgery, Ringwood Rd,<br />
Dorset, United Kingdom; 4 Instutute of Health and Community Studies, Bournemouth University,<br />
Bournemouth, Dorset, United Kingdom<br />
147 COPING STRATEGIES USED BY PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
R Belcher 1 , B Vernon 1 , LJ Kay 2 . 1<br />
<strong>The</strong> Medical School, University of Newcastle, Newcastle upon Tyne, Tyne<br />
& Wear, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Newcastle Hospitals NHS Trust, Newcastle<br />
upon Tyne, Tyne & Wear, United Kingdom<br />
148 DISABILITY, ANXIETY, AND DEPRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS,<br />
PSORIASIS, AND CONTROL SUBJECTS.<br />
MJ Bridges 1 , NJ Reynolds 2 , LJ Kay 1 . 1<br />
Department of <strong>Rheumatology</strong>, Newcastle Hospital NHS Trust,<br />
Newcastle-upon-Tyne, Tyne and Wear, United Kingdom; 2 Department of Dermatology, University of<br />
Newcastle, Newcastle-upon-Tyne, Tyne and Wear, United Kingdom<br />
149 DEPRESSION IS MORE COMMON IN RHEUMATOID ARTHRITIS PATIENTS WITH A<br />
CARDIOVASCULAR COMORBIDITY: A CASE-CONTROLLED INVESTIGATION.<br />
GJ Treharne 1,2 , ED Hale 2 , AC Lyons 3 , DA Booth 1 , MJ Banks 2,4 , N Erb 2 , K Douglas 2 , DL Mitton 2,5 , GD Kitas 1,2,6 .<br />
1<br />
School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 3 School<br />
of Psychology, Massey University, Albany Campus, Auckland, New Zealand; 4 Department of Cardiology,<br />
Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 5 School of Health<br />
Sciences, University of Birmingham, Birmingham, United Kingdom; 6 Department of <strong>Rheumatology</strong>,<br />
University of Birmingham, Birmingham, United Kingdom<br />
150 SEASONALITY AND CHANGES IN DEPRESSION, DISABILITY AND PHYSICAL SYMPTOMS OF<br />
RHEUMATOID ARTHRITIS: A LONGITUDINAL STUDY.<br />
GJ Treharne 1,2 , AC Lyons 3 , DA Booth 1 , GD Kitas 1,2,4 . 1<br />
School of Psychology, University of Birmingham,<br />
Birmingham, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust,<br />
Dudley, United Kingdom; 3 School of Psychology, Massey University, Albany Campus, Auckland, New<br />
Zealand; 4 Department of <strong>Rheumatology</strong>, University of Birmingham, Birmingham, United Kingdom<br />
50
Poster <strong>View</strong>ing Session 2<br />
Thursday 22 April 2004, 08:30 – 10:00<br />
HEALTH SERVICES RESEARCH (151 – 188)<br />
151 TRIAL EXCLUSIONS CAN DAMAGE OUR HEALTH: THE EXAMPLE OF NSAIDs.<br />
P Dieppe 1 , C Bartlett 1 , S Morrant 2 , T MacDonald 2 , P Davey 2 . 1<br />
MRC HSRC, University of Bristol,<br />
Bristol, United Kingdom; 2 MEMO, University of Dundee, Dundee, United Kingdom<br />
152 THE INFLUENCE OF RESOURCE LIMITATIONS ON THE USE OF BIOLOGIC AGENTS IN<br />
SOUTH WEST ENGLAND.<br />
SE Knights, H Averns. 1 Department of <strong>Rheumatology</strong>, North Bristol NHS Trust, Bristol, United<br />
Kingdom; 2 Department of <strong>Rheumatology</strong>, North Devon District Hospital, Barnstaple, North Devon,<br />
United Kingdom<br />
153 COST EFFECTIVENESS OF PREVENTION OF NSAID-INDUCED GASTROINTESTINAL TOX I C I T Y.<br />
RA Elliott 1 , L Hooper 2 , K Payne 3 , TJ Brown 2 , C Roberts 4 , D Symmons 5 . 1<br />
School of Pharmacy,<br />
Manchester University, Manchester, United Kingdom; 2 Cochrane Oral Health Group, University of<br />
Manchester, Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital,<br />
Manchester, United Kingdom; 4 School of Epidemiology and Health Sciences, University of<br />
Manchester, Manchester, United Kingdom; 5 ARC Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom<br />
154 COX II SELECTIVE INHIBITORS VERSUS TRADITIONAL NSAIDS: ARE WE<br />
USING THEM APPROPRIATELY?<br />
WF Ng, A Hall, A Steuer. <strong>Rheumatology</strong>, Wexham Park Hospital, Slough, SL2 4HL, United<br />
Kingdom<br />
155 A SURVEY OF 1152 PATIENTS ON NSAIDS - ARE ‘NICE’ GUIDELINES BEING FOLLOWED<br />
FOR PRESCRIBING COX-II INHIBITORS AND THE IMPLICATIONS FOR CLINICAL GOVERNANCE.<br />
J Francis, A Samanta, FE Nichol. Department of <strong>Rheumatology</strong>, University Hospitals of Leicester<br />
NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom<br />
156 THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA ® ) IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS: A UK ANALYSIS.<br />
N Bansback 1 , A Brennan 1 , N Sengupta 2 , F Pang 3 . 1<br />
School of Health and Related Research,<br />
University of Sheffield, Sheffield, South Yorkshire, United Kingdom; 2 Center <strong>for</strong> Pharmaceutical<br />
Appraisal & Outcomes Research, Abbott Laboratories Inc., Chicago, IL, United States; 3 Clinical<br />
Research, Abbott Laboratories Ltd., Maidenhead, Berkshire, United Kingdom<br />
157 A REGIONAL AUDIT OF THE USE OF COX-2 SELECTIVE NON-STEROIDAL<br />
ANTI-INFLAMMATORY DRUGS (NSAIDS) IN RHEUMATOLOGY CLINICS IN THE WEST<br />
MIDLANDS, ACCORDING TO NICE GUIDELINES.<br />
AN Price-Forbes 1 , R Callaghan 2 , ME Allen 2 , IF Rowe 1 . West Midlands <strong>Rheumatology</strong> Services and<br />
Training Committee. 1 <strong>Rheumatology</strong>, Worcestershire Royal Hospital, Worcester, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Walsgrave Hospital, Coventry, United Kingdom<br />
158 EVALUATION OF THE COST-EFFECTIVENESS OF ETORICOXIB IN PATIENTS AT RISK<br />
OF GI COMPLICATIONS IN THE UK.<br />
A Moore 1 , C Phillips 2 , J Pellissier 3 , S Crespi 4 , E Hunsche 5 . 1<br />
Pain Research, University of Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>d, United Kingdom; 2 School of Health Science, University of Wales, Swansea, United<br />
Kingdom; 3 Health Economic Statistics, Merck & Co., Inc., Blue Bell, PA, United States; 4 Ernest<br />
Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States; 5 Outcomes Research,<br />
Merck & Co., Inc., Whitehouse Station, NJ, United States<br />
51
159 A SURVEY OF LONG-TERM NSAID USE IN PRIMARY CARE 1993 TO 2003: INDICATIONS,<br />
SIDE EFFECTS, AND COMPARISON WITH NICE GUIDELINES.<br />
T Leanne 1 , M John 1 , Q David 1 , T Paul 2 . 1<br />
Institute of Health and Community Studies, Bournemouth<br />
University, Bournemouth, Dorset, United Kingdom; 2 <strong>Rheumatology</strong> Unit, Poole Hospital NHS Trust, Poole,<br />
Dorset, United Kingdom<br />
160 NON-STEROIDAL ANTI-INFLAMMATORY USE IN GENERAL OUTPATIENT RHEUMATOLOGY<br />
SERVICE, AN AUDIT. ARE WE FOLLOWING DOCUMENTED GUIDELINES FOR PRESCRIBING<br />
COX2 AGENTS?<br />
N Quillinan, E O’Carroll, A Akadiri, G Kearns, P O’Connell. Department of <strong>Rheumatology</strong>, Beaumont<br />
Hospital, Dublin, Ireland<br />
161 REGIONAL AUDIT OF ANTI-TNF USE IN RHEUMATOID ARTHRITIS - ESSEX EXPERIENCE.<br />
K Chakravarty, T Bashir. <strong>Rheumatology</strong>, Harold Wood Hospital, Rom<strong>for</strong>d, Essex, United Kingdom<br />
162 A RESOURCE UTILISATION STUDY COMPARING HUMIRA ® (ADALIMUMAB) WITH REMICADE ®<br />
(INFLIXIMAB) FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS.<br />
B Hazleman 1 , A Ostor 1 , V Gurmin 2 , A Strickson 2 , F Pang 2 . 1<br />
School of Clinical Medicine, University of<br />
Cambridge, Cambridge, Cambridgeshire, United Kingdom; 2 Medical Division, Abbott Laboratories Ltd.,<br />
Maidenhead, Berkshire, United Kingdom<br />
163 RHEUMATOLOGY PATIENT PREFERENCES FOR TIMING AND LOCATION OF OUTPATIENT CLINICS.<br />
KMJ Douglas 1 , T Potter 1 , K Obrenovic 2 , D Mitton 1 , GD Kitas 1 . 1<br />
<strong>Rheumatology</strong> Department, Dudley Group<br />
Hospitals, Dudley, West Midlands, United Kingdom; 2 Audit Department, Dudley Group Hospitals, Dudley,<br />
West Midlands, United Kingdom<br />
164 PRIORITY SETTING FOR TJR.<br />
EA Fargher, K Payne, LM Davies. Health Economics Research at Manchester (HER@M), University of<br />
Manchester, Manchester, United Kingdom<br />
165 COPYING LETTERS TO PATIENTS - AN OUTPATIENT QUESTIONNAIRE.<br />
SA Young Min, C Heycock, J Hamilton, C Kelly. <strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead,<br />
Tyne & Wear, United Kingdom<br />
166 MUSCULOSKELETAL SERVICE PROVISION IN THE UK - A SNAPSHOT.<br />
AK Gilbert, J Reeback, S Edwards. <strong>Rheumatology</strong>, ARMA (Arthritis and Musculoskeletal Alliance,<br />
41 Eagle Street, London, United Kingdom<br />
167 THE USE OF SOOTHING CLASSICAL MUSIC IN OUTPATIENTS WAITING AREA TO DECREASE THE<br />
LEVEL OF ANXIETY AND INCREASE RELAXATION IN RHEUMATOLOGY OUTPATIENTS.<br />
GA Hamad, L Williamson. 1 <strong>Rheumatology</strong> Department, Great Western Hospital, Swindon, Wiltshire,<br />
United Kingdom; 2 <strong>Rheumatology</strong> Department, Great Western Hospital, Swindon, Wiltshire,<br />
United Kingdom<br />
168 DRUG MONITORING CLINICS ? - A THING OF THE PAST. GUIDED SELF MANAGEMENT IS THE<br />
WAY FORWARD.<br />
R Chengebroyen, T Bashir, K Chakravarty. <strong>Rheumatology</strong>, Harold Wood Hospital, Rom<strong>for</strong>d, Essex,<br />
United Kingdom<br />
169 TOUCH SCREEN COLLECTION OF RA OUTCOME DATA IN CLINIC -<br />
A FEASIBLE AND VALID OPTION?<br />
MC Greenwood, AJ Hakim, DV Doyle. Academic <strong>Rheumatology</strong> and Osteoporosis Unit, Whipps Cross<br />
University Hospital, London, United Kingdom<br />
170 E-MAIL FACILITIES FOR PATIENTS AND GENERAL PRACTITIONERS: INNOVATIVE<br />
SERVICE DEVELOPMENT AT SOUTH MANCHESTER.<br />
B Pal. <strong>Rheumatology</strong>, Withington, Manchester, United Kingdom<br />
52
171 PRESCRIBING FOLLOWING OSTEOPOROTIC FRACTURE: DOES A PATIENT AND GENERAL<br />
PRACTITIONER CENTRED APPROACH INCREASE PRESCRIBING?<br />
SL Hider 1 , AA Ismail 1 , G Cook 3 , B Todd 2 , J Rogers 3 , A Hamilton 3 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
Stepping Hill Hospital, Stockport, United Kingdom; 2 Department of Orthopaedics, Stepping Hill<br />
Hospital, Stockport, United Kingdom; 3 Department of Epidemiology, Stepping Hill Hospital,<br />
Stockport, United Kingdom<br />
172 THE COST EFFECTIVENESS AND ACCEPTABILITY OF SHARED CARE VS HOSPITAL<br />
TREATMENT FOR PATIENTS WITH MILD, STABLE, ESTABLISHED RHEUMATOID ARTHRITIS (RA).<br />
PK O’Neill 1 , EA Fargher 1 , K Tricker 1,2 , DPM Symmons 2 , LM Davies 1 . 1<br />
Health Economics Research at<br />
Manchester (HER@M), University of Manchester, Manchester, United Kingdom; 2 ARC<br />
Epidemiology Unit, University of Manchester, Manchester, United Kingdom<br />
173 THE USE OF A POINT-OF-CARE SYSTEM FOR CRP MEASUREMENT IN A<br />
RHEUMATOLOGY CLINIC.<br />
S Busteed 1 , K Hayden 2 , M Lawrence 1 , I Watson 2 , R Thompson 1 . 1<br />
<strong>Rheumatology</strong>, University Hospital<br />
Aintree, Liverpool, Merseyside, United Kingdom; 2 Biochemistry, University Hospital Aintree,<br />
Liverpool, Merseyside, United Kingdom<br />
174 INTER- AND INTRAOBSERVER VARIABILITY OF A NON-INSTRUMENTED,<br />
STANDARDISED PHYSICAL EXAMINATION IN A PRIMARY CARE POPULATION OF OLDER<br />
ADULTS WITH KNEE PROBLEMS.<br />
LRJ Wood 1 , GM Peat 1 , R Wilkie 1 , E Thomas 1 , EM Hay 1,2 , J Sim 1 . 1 Primary Care Sciences Research<br />
Centre, Keele University, Keele, Newcastle-under-Lyme, Staffs, United Kingdom; 2 Staf<strong>for</strong>dshire<br />
<strong>Rheumatology</strong> Centre, Haywood Hospital, Stoke-on-Trent, Staffs, United Kingdom<br />
175 THE IMPACT AND IMPLICATIONS OF NEW TREATMENTS IN ARTHRITIS: VALIDATION OF A<br />
QUESTIONNAIRE TO MEASURE THE ‘REAL LIFE’ EFFECTIVENESS OF MEDICATION.<br />
AJ Carr 1 , RA Hughes 2 , K Vincent 2 , M Carr 2 , C Thwaitesv. 1<br />
Academic <strong>Rheumatology</strong>, University of<br />
Nottingham, Nottingham, United Kingdom; 2 <strong>Rheumatology</strong>, Ash<strong>for</strong>d and St Peter’s Hospital,<br />
Chertsey, United Kingdom<br />
176 REGIONAL VARIATIONS IN SELF-REPORTED LONGSTANDING MUSCULOSKELETAL<br />
CONDITIONS ARE ONLY PARTLY EXPLAINED BY SOCIAL CLASS: RESULTS FROM THE GENERAL<br />
HOUSEHOLD SURVEY.<br />
AM Clarke, DPM Symmons. Arthritis Research Campaign Epidemiology Unit, School of<br />
Epidemiology and Health Sciences, University of Manchester, Manchester, United Kingdom<br />
177 CAN THE RHEUMATOID ARTHRITIS QUALITY OF LIFE QUESTIONNAIRE BE EXTENDED TO<br />
PROVIDE GREATER INSIGHT INTO SPECIFIC PATIENT CONCERNS WITHOUT LOSING VALIDITY?<br />
MC Greenwood, AJ Hakim, DV Doyle. Academic <strong>Rheumatology</strong> and Osteoporosis Unit, Whipps<br />
Cross University Hospital, London, United Kingdom<br />
178 THE IMPACT OF SOCIAL DEPRIVATION ON HEALTH RELATED QUALITY OF LIFE AND<br />
FUNCTIONAL DISABILITY IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS.<br />
M Harrison 1 , K Tricker 2 , L Davies 2 , C Roberts 1 , D Symmons 1 . 1<br />
ARC Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2 Health Economics Research at Manchester, University<br />
of Manchester, Manchester, United Kingdom; 3 Clinical Trials Unit, University of Manchester,<br />
Manchester, United Kingdom<br />
179 WHY WONT RESIDENTIAL HOME RESIDENTS WEAR HIP PROTECTORS?<br />
C Jones 1 , T Villar 2 , A Dawson 3 , P Thompson 2 . 1<br />
Osteoporosis Dorset, Bournemouth, Dorset, United<br />
Kingdom; 2 Poole Hospital NHS Trust, Poole, Dorset, United Kingdom; 3 Dorset Health Authority,<br />
Verwood, Dorset, United Kingdom<br />
53
180 DEGREE OF FUNCTIONAL DISABILITY DETERMINES THE USEFULNESS OF SPECIFIC<br />
HEALTH UTILITY MEASURES IN RA.<br />
AG Witney 1,2 , M Tavakoli 3 , K Vincent 4 , T Gareth 2 , DL Scott 4 , KD George 1,2 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
University of Birmingham, Birmingham, West Midlands, United Kingdom; 2 Department of <strong>Rheumatology</strong>,<br />
Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom; 3 Department of Management, University<br />
of St Andrews, St Andrews, Fife, United Kingdom; 4 Department of <strong>Rheumatology</strong>, King’s College,<br />
London, London, United Kingdom<br />
181 ELBOW ASSESSMENT TOOL - DEVELOPMENT AND VALIDATION.<br />
P Sathyamoorthy, GJ Kemp, A Rawal, V1 Raynor, S1 Frostick. Department of Musculoskeletal Science,<br />
Royal Liverpool University Hospital, Liverpool, Mersey, United Kingdom<br />
182 PREDICTORS OF PRIMARY CARE CONSULTATION FOR KNEE-RELATED DISORDERS.<br />
A PROSPECTIVE STUDY.<br />
K Jordan, C Jinks, PR Croft. Primary Care Sciences Research Centre, Keele University, Keele, Staffs,<br />
United Kingdom<br />
183 SHOULDER AND KNEE PAIN: HOW WELL DO BSR ATTENDEES APPRECIATE PATIENT PRIORITIES?<br />
- THE SHEEP STUDY REVISITED.<br />
S Clarke 1 , DJ Sharp 2 , M Calnan 1 , PA Dieppe 1 . 1<br />
MRC Health Services Research Collaboration, University of<br />
Bristol, Bristol, Avon, United Kingdom; 2 Division of Primary Health Care, University of Bristol, Bristol,<br />
Avon, United Kingdom<br />
184 SINGLE PATIENT TRIALS IN RHEUMATOLOGY.<br />
S Brookes 1 , C Paterson 1 , C Pope 1 , P Creamer 2 , J Haines 2 , P Dieppe 1 . 1<br />
MRC HSRC, University of Bristol,<br />
Bristol, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Southmead Hospital, Bristol, United Kingdom<br />
185 IS VIDEO ANALYSIS OF CLINICAL INTERVENTIONS IN TREATMENT TRIALS VALUABLE?<br />
EXPERIENCES FROM A LOW BACK PAIN STUDY.<br />
R Mullis 1 , K Dziedzic 1 , M Lewis 1 , V Cooper 2 , C Main 3 , P Watson 4 , P Croft 1 , E Hay 1 . 1<br />
Primary Care Sciences<br />
Research Centre, University of Keele, Keele, Staf<strong>for</strong>dshire, United Kingdom; 2 Department of Postgraduate<br />
Medicine, University of Keele, Keele, Staf<strong>for</strong>dshire, United Kingdom; 3 Department of Behavioural<br />
Medicine, University of Manchester/Hope Hospital, Sal<strong>for</strong>d, United Kingdom; 4 Department of<br />
Anaesthesia and Pain Management, University of Leicester, Leicester, United Kingdom<br />
186 SERVICE BARRIERS AND FACILITATORS TO IMPROVED MANAGEMENT OF OSTEOARTHRITIS.<br />
JA Chard 1 , PA Dieppe 1 , M Calnan 1 , P Conaghan 2 . 1<br />
MRC Hsrc, Department of Social Medicine, University<br />
of Bristol, Bristol, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds,<br />
United Kingdom<br />
187 ISSUES OF GENERALISABILITY IN RANDOMISED CLINICAL TRIALS.<br />
M Lewis, R Mullis, J Hill, C Vohora, KS Dziedzic, EM Hay. Primary Care Sciences Research Centre, Keele<br />
University, Keele, Staf<strong>for</strong>dshire, United Kingdom<br />
188 IMPROVED QUALITY OF REPORTING OF RANDOMIZED TRIALS IN EUROPEAN RHEUMATOLOGY<br />
JOURNALS PROMOTING CONSORT GUIDELINES.<br />
EA Sushchuk 1 , NN Stepanova 2 . 1<br />
Department of Hospital <strong>The</strong>rapeutics, Volgograd State Medical<br />
University, Volgograd, Russian Federation; 2 <strong>Rheumatology</strong> Department, Teaching City Hospital No.25,<br />
Volgograd, Russian Federation<br />
EPIDEMIOLOGY (189 – 196)<br />
189 PREDICTING THE ONSET OF NECK PAIN (WHIPLASH) FOLLOWING A MOTOR VEHICLE ACCIDENT.<br />
NJ Wiles 1,3 , GT Jones 1,2 , AJ Silman 1 , GJ Macfarlane 1,2 . 1<br />
ARC Epidemiology Unit, University of Manchester,<br />
Manchester, United Kingdom; 2 Unit of Chronic Disease Epidemiology, University of Manchester,<br />
Manchester, United Kingdom; 3 Division of Psychiatry, University of Bristol, Bristol, United Kingdom<br />
54
190 THE PREVALENCE OF RHEUMATOID ARTHRITIS IN RURAL EGYPT.<br />
RR Abdel-Tawab 1 , AM Abdel-Nasser 1 , JA Mahmoud 1 , A Sammy 2 , M Abdel-Fattah 3 . 1<br />
<strong>Rheumatology</strong><br />
& Rehabilitation, Minia University, Minia, Egypt; 2 Radiology, Minia University, Minia, Egypt;<br />
3Epidemiology, Minia University, Minia, Egypt<br />
191 PREVALENCE OF HAND PROBLEMS AND HAND PAIN IN OLDER PEOPLE:<br />
A SURVEY OF THE GENERAL POPULATION IN NORTH STAFFORDSHIRE.<br />
K Dziedzic, E Thomas, S Hill, R Wilkie, G Peat, P Croft. Primary Care Sciences Research Centre,<br />
Keele University, Keele, Newcastle, Staffs, United Kingdom<br />
192 ASSOCIATION OF HAND PARAESTHESIA WITH SPECIFIC JOB TASKS: RESULTS FROM<br />
A POPULATION STUDY IN NORTH STAFFORDSHIRE, UK.<br />
RJ Lacey, M Lewis, J Sim. Primary Care Sciences Research Centre, Keele University, Keele, Staffs<br />
ST5 5BG, United Kingdom<br />
193 A STUDY INTO THE INCIDENCE OF CANCER IN A COHORT OF PATIENTS WITH PRIMARY<br />
SJOGREN’S SYNDROME.<br />
MN Lazarus, DA Isenberg. Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London, London,<br />
United Kingdom<br />
194 THE CHANGING PROFILE OF RHEUMATOLOGY ADMISSIONS IN A DISTRICT<br />
GENERAL HOSPITAL OVER THREE DECADES.<br />
NJ Allen 2 , JC Belfield 1 , GC Zaphiropolous 1 , K Chaudhuri 1 . 1<br />
Department of <strong>Rheumatology</strong>, University<br />
Hospitals of Coventry and Warwickshire, Coventry, Warwickshire, United Kingdom; 2 Department<br />
of <strong>Rheumatology</strong>, Kingston Hospital, Kingston, Surrey, United Kingdom<br />
195 PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS.<br />
WF Ng, A Hall, A Steuer. <strong>Rheumatology</strong>, Wexham Park Hospital, Slough, SL2 4HL, United Kingdom<br />
196 LATERAL EPICONDYLITIS AMONG THE GENERAL POPULATION: A CASE-CONTROL STUDY.<br />
KE Walker-Bone 1 , KT Palmer 2 , IC Reading 2 , D Coggon 2 , C Cooper 2 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
Brighton and Sussex Medical School, Brighton, East Sussex, United Kingdom; 2 MRC Environmental<br />
Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom<br />
NON-INFLAMMATORY MUSCULOSKELETAL DISORDERS (197 – 202)<br />
197 MUSCULO-SKELETAL REFLEX DYSFUNCTION IN THE JOINT HYPERMOBILITY SYNDROME.<br />
WR Ferrell 1 , RH Baxendale 2 , M Kusel 2 , N Tennant 3 , RD Sturrock 1 . 1<br />
Centre <strong>for</strong> Rheumatic Diseases,<br />
University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Institute of Biomedical & Life<br />
Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom; 3 Physiotherapy, Royal<br />
Infirmary, Glasgow, Scotland, United Kingdom<br />
198 HIGH PREVALENCE OF JOINT HYPERMOBILITY SYNDROME IN CLINIC REFERRALS<br />
TO A NORTH LONDON COMMUNITY HOSPITAL.<br />
R Grahame 1,2 , AJ Hakim 1,3 . 1<br />
<strong>The</strong> Hypermobility Clinic, Centre <strong>for</strong> <strong>Rheumatology</strong>, University College<br />
London Hospitals, London, United Kingdom; 2 <strong>Rheumatology</strong>, Willesden Community Hospital,<br />
London, United Kingdom; 3 <strong>The</strong> Academic <strong>Rheumatology</strong> and Osteoporosis Unit, Whipps Cross<br />
University Hospital, London, United Kingdom<br />
199 ‘REPETITIVE STRAIN INJURY’ IS RARE AMONG WORKING-AGED ADULTS AND IS NOT<br />
ASSOCIATED WITH KEYBOARD USE.<br />
KE Walker-Bone 1 , IC Reading 2 , KT Palmer 2 , D Coggon 2 , C Cooper 2 . 1<br />
<strong>Rheumatology</strong> Department,<br />
Brighton and Sussex Medical School, Brighton, East Sussex, United Kingdom; 2 MRC Environmental<br />
Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom<br />
55
200 CAUSES OF MUSCULOSKELETAL CHEST PAIN IN PATIENTS ADMITTED TO HOSPITAL<br />
WITH POSSIBLE MYOCARDIAL INFARCTION.<br />
J How, G Volz, J Hamilton, C Heycock, C Kelly. Medicine and <strong>Rheumatology</strong>, Queen Elizabeth Hospital,<br />
Gateshead, Tyne and Wear, United Kingdom<br />
201 SHOULD ALL PATIENTS WITH CARPAL TUNNEL SYNDROME BE SCREENED<br />
FOR THYROID DISEASE?<br />
E Suresh, IM Morris. 1 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Kettering General Hospital, Kettering, United Kingdom<br />
202 TO SCAN OR NOT TO SCAN? THAT IS THE QUESTION....<br />
S Bawa 1 , K Gaffney 1 , PG Kitchener 2 . 1<br />
Department of <strong>Rheumatology</strong>, Norfolk & Norwich University<br />
Hospital NHS Trust, Norwich, Norfolk, United Kingdom; 2 Department of Radiology, Norfolk & Norwich<br />
University Hospital NHS Trust, Norwich, Norfolk, United Kingdom<br />
EDUCATION RESEARCH (203 – 215)<br />
203 FACTORS INFLUENCING PATIENT’S PERCEPTION OF RISK ASSOCIATED WITH TAKING NSAIDs<br />
FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS.<br />
AM Metcalfe 1 , CM Clif<strong>for</strong>d 1 , P Jobanputra 2 . 1<br />
School of Health Sciences, University of Birmingham,<br />
Birmingham, West Midlands, United Kingdom; 2 <strong>Rheumatology</strong> Dept., Selly Oak Hospital, University<br />
Hospital Birmingham (Teaching) NHS Trust, Birmingham, West Midlands, United Kingdom<br />
204 PATIENTS HAVE POSITIVE PERCEPTIONS OF INVOLVEMENT IN STRUCTURED MEDICAL<br />
STUDENT TEACHING.<br />
MS Lillicrap, V Dagley, AC Howe. School of Medicine, Health Policy and Practice, University of East<br />
Anglia, Norwich, United Kingdom<br />
205 AN EXPERT CONSENSUS OF APPROPRIATE PRACTICE AND COMPETENCY-BASED LEARNING<br />
OUTCOMES FOR RHEUMATOLOGISTS PERFORMING MUSCULOSKELETAL ULTRASONOGRAPHY.<br />
AK Brown 1 , RJ Wakefield 1 , Z Karim 1 , PJ O’Connor 2 , TE Roberts 3 , PG Conaghan 1 , A Grainger 2 , P Emery 1 .<br />
1<br />
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 2 Department of<br />
Radiology, Leeds General Infirmary, Leeds, United Kingdom; 3 Medical Education Unit, School of<br />
Medicine, University of Leeds, Leeds, United Kingdom<br />
206 AN EXPERIENCE OF OSTEOPOROSIS EDUCATION SESSIONS.<br />
JT Morgan 1 , JC Martin 1 , R Tyrell 2 . 1<br />
<strong>Rheumatology</strong>, Pontypridd & Rhondda NHS Trust, Royal Glamorgan &<br />
Dewi Sant Hospital, Wales, United Kingdom; 2 Physiotherapy, Pontypridd & Rhondda NHS Trust, Royal<br />
Glamorgan & Dewi Sant Hospital, Wales, United Kingdom<br />
207 THE EFFICACY OF A SELF-MANAGEMENT INTERVENTION FOR HOSPITAL OUTPATIENTS<br />
WITH CHRONIC RA.<br />
TJ Pimm 1 , MA Byron 2 , DM Curson 1 , S Hill 1 , GH Aikman 1 , CH Bam<strong>for</strong>d 1 , JA Hall 1 , JA Weinman 3 .<br />
1<br />
Department of <strong>Rheumatology</strong>, Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust,<br />
Aylesbury, United Kingdom; 2 Centre <strong>for</strong> Medical Education, University of Bristol, Bristol, United Kingdom;<br />
3<br />
Department of Psychology (at Guy’s), Institute of Psychiatry, London, United Kingdom<br />
208 CAN A SINGLE (RHEUMATOLOGY) REVISION SESSION HELP STUDENTS IN THEIR FINAL<br />
YEAR EXAMINATIONS?<br />
RW Marshall 1,2 , S Clarke 3 , D Coady 4 , JR Kirwan 1 . 1<br />
<strong>Rheumatology</strong> Unit, University Department of Clinical<br />
Science at South Bristol, Bristol, BS2 8HW, United Kingdom; 2 <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, BA1 1RL, United Kingdom; 3 MRC / HSRC, Canynge Hall, Whiteladies Road,<br />
Bristol, BS8 2PR, United Kingdom; 4 <strong>Rheumatology</strong>, Freeman Hospital, Newcastle-upon-Tyne,<br />
United Kingdom<br />
56
209 DO PATIENTS AND RHEUMATOLOGISTS HAVE THE SAME UNDERSTANDING OF WHAT IS<br />
SAID IN A CONSULTATION?<br />
MG Lee 3 , AG Witney 1,2 , GD Kitas 1,2 . 1<br />
Department of <strong>Rheumatology</strong>, University of Birmingham,<br />
Birmingham, West Midlands, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Dudley Group of<br />
Hospitals NHS Trust, Dudley, United Kingdom; 3 School of Computer Science, University of<br />
Birmingam, Birmingham, West Midlands, United Kingdom<br />
210 RELATIONSHIP BETWEEN PERCEIVED CONFIDENCE AND ACTUAL PERFORMANCE IN<br />
AN OBJECTIVE STRUCTURED CLINICAL EXAMINATION OF SHOULDER AND KNEE JOINT<br />
ASSESSMENT.<br />
P Vivekananda-Schmidt 1 , DA Coady 2 , M Lewis 1 , MJ McLean 3 , L Kay 2 , D Walker 2 , AB Hassell 1 .<br />
1<br />
Primary Care Sciences Research Centre, Keele University, Keele, Staf<strong>for</strong>dshire, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 3 <strong>The</strong><br />
Institute <strong>for</strong> the Advancement of University Learning, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, Ox<strong>for</strong>dshire,<br />
United Kingdom<br />
211 PERCEIVED CONFIDENCE AMONGST SENIOR HOUSE OFFICERS (SHOs) IN UNDERTAKING<br />
A REGIONAL MUSCULOSKELETAL EXAMINATION.<br />
DA Coady 1 , N McKay 2 , V Saravanan 3 , LJ Kay 1 . 1<br />
<strong>Rheumatology</strong>, Freeman Hospital, Newcastle upon<br />
Tyne, NE7 7DN, United Kingdom; 2 <strong>Rheumatology</strong>, Sunderland Royal Infirmary, Sunderland, Tyne<br />
and Wear, United Kingdom; 3 <strong>Rheumatology</strong>, Queen Elizabeth, Gateshead, Tyne and Wear,<br />
United Kingdom<br />
212 REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM (REMS): THE CORE<br />
SET OF CLINICAL SKILLS FOR MEDICAL STUDENTS.<br />
DA Coady, LJ Kay, DJ Walker. <strong>Rheumatology</strong>, Freeman Hospital, Newcastle upon Tyne, NE7 7DN,<br />
United Kingdom<br />
213 EVALUATION OF A “REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM”<br />
(REMS) TEACHING VIDEO AMONGST FINAL YEAR MEDICAL STUDENTS IN TWO MEDICAL<br />
SCHOOLS.<br />
DA Coady 1 , RW Marshall 3,4 , S Clarke 2 , J Kirwan 4 , L Kay 1 , D Walker 1 . 1<br />
<strong>Rheumatology</strong>, Freeman<br />
Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom; 2 MRC / HSRC, Canynge Hall,<br />
Whiteladies Road, Bristol, BS8 2PR, United Kingdom; 3 <strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, BA1 1RL, United Kingdom; 4 <strong>Rheumatology</strong> Unit, University Department<br />
of Clinical Science at South Bristol, Bristol, BS2 8HW, United Kingdom<br />
214 DOES A REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM (REMS) VIDEO<br />
DESIGNED FOR MEDICAL STUDENTS CONTAIN ENOUGH DETAIL FOR GENERAL PRACTICE<br />
REGISTRARS (GPRs)?<br />
EM Wise 2 , DA Coady 1 , LJ Kay 1 , DJ Walker 1 . 1<br />
Department of <strong>Rheumatology</strong>, <strong>The</strong> Freeman Hospital,<br />
Newcastle upon Tyne, United Kingdom; 2 Northumbria Vocational Training Scheme, Newcastle<br />
upon Tyne, United Kingdom<br />
215 THE USE OF PROSPECTIVE DIARIES TO CAPTURE WHICH MUSCULOSKELETAL<br />
CONDITIONS GENERAL PRACTICE REGISTRARS (GPRs) SEE.<br />
EM Wise 1 , DA Coady 2 , TD Van Zwanenberg 1 , DJ Walker 3 . 1<br />
<strong>Rheumatology</strong> Department,<br />
Musculoskeletal Unit, <strong>The</strong> Freeman Hospital, Newcastle upon Tyne, United Kingdom;<br />
2<br />
Northumbria Vocational Training Scheme, Newcastle upon Tyne, United Kingdom; 3 Department<br />
of General Practice, Postgraduate Institute <strong>for</strong> Medicine & Dentistry, Newcastle upon Tyne,<br />
United Kingdom<br />
57
SCLERODERMA (216 – 233)<br />
216 OXIDISED LOW DENSITY LIPOPROTEIN AND HOMOCYSTEINAEMIA ARE RISK FACTORS FOR<br />
MACROVASCULAR DISEASE IN SYSTEMIC SCLEROSIS.<br />
M Ho 2 , AH Strang 1 , M McLaren 1 , F Daly 1 , C Eastmond 3 , G Nuki 4 , JJF Belch 1 . 1<br />
University Department of<br />
Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom; 2 Dept. of <strong>Rheumatology</strong>,<br />
Northampton General Hospital NHS Trust, Northampton, United Kingdom; 3 Dept. of <strong>Rheumatology</strong>,<br />
Aberdeen Royal Infirmary, Aberdeen, United Kingdom; 4 Rheumatic Diseases Unit, Western General<br />
Hospital, Edinburgh, United Kingdom<br />
217 CTGF: A POTENTIAL MARKER OF FIBROSIS IN SCLERODERMA?<br />
M Dziadzio 1 , W Usinger 2 , H Penn 1 , C Black 1 , D Abraham 1 , C Denton 1 , R Stratton 1 . 1<br />
<strong>Rheumatology</strong>, Royal<br />
Free Hospital, London, United Kingdom; 2 FibroGen, San Francisco, CA, United States<br />
218 QUALITY OF LIFE WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS.<br />
AE Gliddon 1 , CJ Dore 2 , PJ Maddison 3 , the Quins Trial Study Group. 1 School of Sport, Health & Exercise<br />
Science, University of Wales, Bangor, Bangor, Gwynedd, United Kingdom; 2 MRC Clinical Trials Unit,<br />
London, United Kingdom; 3 <strong>Rheumatology</strong> Department, Ysbyty Gwynedd Hospital, Bangor, Gwynedd,<br />
United Kingdom<br />
219 A PILOT STUDY ASSESSING THE RESPONSE OF SINGLE DOSE SILDENAFIL CITRATE (VIAGRA)<br />
IN THE TREATMENT OF RAYNAUDS’ PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS.<br />
N Kumar 1 , J Allen 2 , A Murray 2 , B Griffiths 1 . 1<br />
Department of <strong>Rheumatology</strong>, Musculoskeletal Unit,<br />
Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Regional Medical Physics Department,<br />
Freeman Hospital, Newcastle-upon-Tyne, United Kingdom<br />
220 PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS - SCREENING GUIDELINES IN PRACTISE.<br />
S Busteed, RJ Moots, RN Thompson. <strong>Rheumatology</strong>, University Hospital Aintree, Liverpool, Merseyside,<br />
United Kingdom<br />
221 PULMONARY ARTERIAL HYPERTENSION IN FIBROTIC AND NON-FIBROTIC SSC PATIENTS -<br />
RESPONSE TO THERAPY.<br />
A Kawald, M Williams, C Elliott, CM Black, GJ Coghlan. 1 Department of Academic <strong>Rheumatology</strong>, Royal<br />
Free Hospital, London NW3 2QG, United Kingdom; 2 Department of Cardiology, Royal Free Hospial,<br />
London NW3 2QG, United Kingdom<br />
222 A COMPARISON OF FINGER AND EARLOBE OXIMETRY IN PATIENTS WITH SYSTEMIC SCLEROSIS.<br />
K Isdale 1 , BR O’Driscoll 2 , AL Herrick 1 . 1<br />
University of Manchester Rheumatic Diseases Centre, Hope<br />
Hospital, Sal<strong>for</strong>d, United Kingdom; 2 Respiratory Medicine, Hope Hospital, Sal<strong>for</strong>d, United Kingdom<br />
223 CALCINOSIS IN SYSTEMIC SCLEROSIS - ARE WE UNDERESTIMATING ITS PREVALENCE?<br />
K Brennan 1 , S Jackson 2 , AL Herrick 1 . 1<br />
University of Manchester Rheumatic Diseases Centre, Hope<br />
Hospital, Sal<strong>for</strong>d, United Kingdom; 2 Radiology, Hope Hospital, Sal<strong>for</strong>d, United Kingdom<br />
224 RENAL INVOLVEMENT IN INDIAN SCLERODERMA PATIENTS - A SINGLE CENTER STUDY.<br />
R Gupta 1 , R Grover 1 , V Marwaha 1 , VK Singhal 2 . 1<br />
Clinical Immunology & <strong>Rheumatology</strong> Service,<br />
Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India; 2 <strong>Rheumatology</strong><br />
Department, Army Hospital (Research & Referral), New Delhi, Delhi, India<br />
225 MONOCYTE CHEMOATTRACTANT PROTEIN-3 (MCP-3) OVEREXPRESSION IN SCLERODERMA:<br />
REGULATION BY TGFβ.<br />
VH Ong, M Carulli, G Lindahl, S Xu, DJ Abraham, CM Black, CP Denton. Centre <strong>for</strong> <strong>Rheumatology</strong>, Royal<br />
Free and University College Medical School, London, United Kingdom<br />
226 DNA BINDING-ACTIVITY OF CCAAT-BINDING FACTOR (CBF) IS STRONGLY ENHANCED IN<br />
ACTIVATED LUNG FIBROBLASTS FROM PATENTS WITH SYSTEMIC SCLEROSIS.<br />
GE Lindahl 1 , X Shiwen 1 , RC Chambers 2 , CP Denton 1 , DJ Abraham 1 , CM Black 1 , GJ Laurent 2 .<br />
1<br />
<strong>Rheumatology</strong>, Royal Free and UCL Medical School, London, United Kingdom; 2 Centre <strong>for</strong> Respiratory<br />
Research, Dept Medicine, UCL Medical School, London, United Kingdom<br />
58
227 DYSREGULATED METALLOPROTEINASE EXPRESSION IN A TRANSGENIC MOUSE<br />
MODEL OF SCLERODERMA.<br />
CP Denton 1 , K Lazaridis 2 , X Shiwen 1 , DJ Abraham 1 , A Chantry 2 , D Edwards 2 , CM Black 1 . 1<br />
Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, Royal Free and University College Medical School, Hampstead, London, United<br />
Kingdom; 2 School of Biological Sciences, University of East Anglia, Norwich, United Kingdom<br />
228 GENE EXPRESSION PROFILING DELINEATES CONSTITUTIVELY ACTIVATED TARGETS OF<br />
TGFβ IN A TRANSGENIC MODEL OF SCLERODERMA.<br />
CP Denton, G Lindahl, VH Ong, X Shiwen, E Renzoni, DJ Abraham, CM Black. Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, Royal Free and University College Medical School, Hampstead, London,<br />
United Kingdom<br />
229 DYSREGULATION OF THE EXPRESSION OF TGFβ ACCESSORY RECEPTORS IN THE<br />
SSC FIBROBLAST.<br />
AM Holmes, X Shi-Wen, CM Black, DJ Abraham. <strong>Rheumatology</strong> Dept., UCL-Royal Free Campus,<br />
London, United Kingdom<br />
230 SYNERGISTIC ENHANCEMENT OF MATRIX REMODELING IN LUNG FIBROBLASTS AFTER<br />
CO-STIMULATION WITH ET-1 AND THROMBIN: IMPLICATIONS FOR PULMONARY FIBROSIS<br />
IN SCLERODERMA.<br />
X Shiwen 1 , A Leask 1 , CP Denton 1 , M Eastwood 2 , R Stratton 1 , A Holmes 1 , R duBois 3 , DJ Abraham 1 ,<br />
CM Black 1 . 1<br />
<strong>Rheumatology</strong>, Royal Free and University College Medical School, London, United<br />
Kingdom; 2 Tissue Engineering Research, University of Westminster, London, United Kingdom;<br />
3<br />
Interstitial Lung Disease Unit, Imperial College School of Medicine, London, United Kingdom<br />
231 THE ROLE OF TH3 (TGF-β PRODUCING) T CELLS IN SYSTEMIC SCLEROSIS.<br />
NG Taguri, M Ponticos, DJ Abraham, CM Black. Centre <strong>for</strong> <strong>Rheumatology</strong>, Royal Free and<br />
University College Medical School, London, United Kingdom<br />
232 ENDOTHELIN-1 PROMOTES MYOFIBROBLAST INDUCTION THROUGH THE ETA<br />
RECEPTOR VIA RAC/PI3 KINASE/AKT AND CONTRIBUTES TO THE CONTRACTILE PHENOTYPE<br />
OF SCLERODERMA FIBROBLASTS.<br />
A Leask 1 , X Shi-wen 1 , CP Denton 1 , A Holmes 1 , M Eastwood 2 , E Renzoni 3 , M Dashwood 1 , RM<br />
duBois 3 , CM Black 1 , DJ Abraham 1 . 1<br />
<strong>Rheumatology</strong>, Royal Free and University College Medical<br />
School, London, United Kingdom; 2 Tissue and Engineering Research, University of Westminster,<br />
London, United Kingdom; 3 Interstitial Lung Disease Unit, Imperial College of Medicine, London,<br />
United Kingdom<br />
233 MICROVASCULAR PERICYTES EXPRESS THE MESENCHYMAL STEM CELL MARKER<br />
STRO-1 AND THE FIBROBLAST SPECIFIC ANTIGEN, THY-1.<br />
VS Rajkumar, CM Black, DJ Abraham. <strong>Rheumatology</strong>, Royal Free & University College Medical<br />
School, London, United Kingdom<br />
INFLAMMATORY MUSCLE DISEASE (234 – 235)<br />
234 INTER-RATER RELIABILITY OF TWO DISEASE ACTIVITY ASSESSMENT TOOLS IN PATIENTS<br />
WITH IDIOPATHIC INFLAMMATORY MYOPATHY.<br />
SM Sultan 1 , E Allen 2 , C Oddis 3 , J Vencovsky 4 , I Lundberg 5 , DA Isenberg 1 . 1<br />
<strong>Rheumatology</strong>, University<br />
College London, London, United Kingdom; 2 Medical Statistics, University College London, London,<br />
United Kingdom; 3 University of Pittsburgh, Pittsburgh, United States; 4 Institute of <strong>Rheumatology</strong>,<br />
Prague, Czech Republic; 5 Karolinska Institute, Stockholm, Sweden<br />
235 DIFFERENCES ARE DEMONSTRATED IN THE ASSOCIATION OF MALIGNANCY BETWEEN<br />
POLYMYOSITIS AND DERMATOMYOSITIS.<br />
H Chinoy 1 , F Salway 2 , SJ Alan 2 , OE William 2 , CG Robert 1 . 1<br />
Rheumatic Diseases Centre, Hope<br />
Hospital, Sal<strong>for</strong>d, Lancs, United Kingdom; 2 ARC Epidemiology Unit, Stop<strong>for</strong>d Building, University<br />
of Manchester, Manchester, Lancs, United Kingdom<br />
59
SJÖGREN’S SYNDROME (236 – 239)<br />
236 HEALTH CARE USAGE IN PRIMARY SJÖGREN’S SYNDROME.<br />
R Callaghan 1 , A Prabu 1 , C Gordon 1 , A Clarke 2 , S Bowman 1 . 1<br />
<strong>Rheumatology</strong> Department, Division of<br />
Immunity & Infection, <strong>The</strong> University of Birmingham, Birmingham, United Kingdom; 2 Department of<br />
Medicine, McGill University, Montreal, QC, Canada<br />
237 A STUDY INTO THE INCIDENCE OF AUTOIMMUNE DISEASES IN A COHORT OF PATIENTS<br />
WITH PRIMARY SJOGREN’S SYNDROME.<br />
MN Lazarus, DA Isenberg. Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London, London,<br />
United Kingdom<br />
238 SYMPTOMS OF OCULAR AND ORAL DRYNESS IN AN UNSELECTED POPULATION OF PATIENTS<br />
ATTENDING A RHEUMATOLOGY CLINIC.<br />
G Hamad, E Price. Department of <strong>Rheumatology</strong>, Great Western Hospital, Swindon, Wiltshire,<br />
United Kingdom<br />
239 HLA GENOTYPES IN PRIMARY SJÖGREN’S SYNDROME COMPARED TO A NORTH EAST OF<br />
ENGLAND CONTROL GROUP.<br />
C Morley 1 , V Carter 2 , G Cavanagh 2 , NJ Marshall 1 , ID Griffiths 1 . 1<br />
<strong>Rheumatology</strong> Department, Freeman<br />
Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2 Histocompatibility and<br />
Immunogenetics Department, National Blood Service, Newcastle upon Tyne, Tyne and Wear,<br />
United Kingdom<br />
SLE AND ANTIPHOSPHOLIPID SYNDROME (240 – 264)<br />
240 SPONTANEOUS AUTOIMMUNITY AND ITS EPISTATIC MODIFICATION IN 129 AND C57BL/6 MICE<br />
- IMPLICATIONS FOR AUTOIMMUNITY DESCRIBED IN GENE-TARGETED MICE.<br />
J Cortes-Hernandez, AE Bygrave, KL Rose, J Warren, TH Cook, MJ Walport, T Vyse, M Botto.<br />
<strong>Rheumatology</strong> Section, Eric Bywaters Centre, Imperial College, London, London, United Kingdom<br />
241 TNF HAPLOTYPES WITH SEROLOGICAL SUBSETS OF SLE.<br />
NJ McHugh 1 , PA Owen 2 , B Cox 2 , J Dunphy 2 , KI Welsh 3 . 1<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, Bath, Banes, United Kingdom; 2 BIRD Diagnostics, Bath Institute <strong>for</strong> Rheumatic<br />
Diseases, Bath, Banes, United Kingdom; 3 Clinical Genomics, National Heart and Lung Institute, London,<br />
United Kingdom<br />
242 A COMBINATION OF LOSS OF SLE SUSCEPTIBILITY INTERVALS AND ACQUISITION OF<br />
SUPPRESSOR LOCI RESULTS IN DISEASE RESISTANCE IN BXSB/LONG-LIVED MICE.<br />
MEK Haywood 1 , J Rose 1 , S Izui 2 , BJ Morley 1 . 1<br />
<strong>Rheumatology</strong> Section, Eric Bywaters Centre, Imperial<br />
College, London, United Kingdom; 2 Department of Pathology, Centre Medical Universitaire, Geneva,<br />
United Kingdom<br />
243 RE-THROMBOSIS AND BLEEDING IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS ON<br />
ORAL ANTICOAGULATION AT A TARGET INR 2.0-3.0. A LONGITUDINAL COMPARISON WITH<br />
PATIENTS WITH INHERITED THROMBOPHILIA AND AORTIC VALVE REPLACEMENTS.<br />
PRJ Ames 1 , A Ciampa 2 , M Maurizio 3 , S Giovanna 3 , B Vincenzo 3 , I Luigi 3 . 1<br />
Academic Department of<br />
<strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, United Kingdom; 2 Unita’ Semplice di Emostasi e<br />
Trombosi, Ospedale A. Moscati, Avellino, Italy; 3 Unita’ Semplice di Emostasi e Trombosi, Ospedale A<br />
Cardarelli, Naples, Italy<br />
244 COELIAC ARTERY STENOSIS AND ANTIPHOSPHOLIPID ANTIBODIES.<br />
G Obermoser, IS Lau, S Sangle, D D’Cruz, GRV Hughes. Lupus Research Unit, <strong>The</strong> Rayne Institute,<br />
St Thomas’ Hospital, London, United Kingdom<br />
60
245 CARDIOVASCULAR RISK FACTORS IN ANTIPHOSPHOLIPID SYNDROME WITH<br />
HYPERTENSION AND RENAL ARTERY STENOSIS.<br />
N Horwood, S Sangle, DP D’Cruz, MA Khamashta, I Abbs, GRV Hughes. Lupus Research Unit,<br />
Rayne Institute, St Thomas’ Hospital, London SE1 7EH, United Kingdom<br />
246 SURVEY OF ATTITUDES AND OPINIONS HELD BY PATIENTS WITH SLE AT NORTHWICK<br />
PARK HOSPITAL.<br />
J Andrews, U Martin, CS Higgens. Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex,<br />
United Kingdom<br />
247 PREVALENCE OF HYPERTENSION IN 600 PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME.<br />
S Sangle, D D’Cruz, M Khamashta, GRV Hughes. Lupus Research Unit, <strong>The</strong> Rayne Institute, St<br />
Thomas’ Hospital, London, United Kingdom<br />
248 LIVEDO RETICULARIS, PREGNANCY MORBIDITY AND NEGATIVE ANTIPHOSPHOLIPID<br />
ANTIBODIES: A PRELIMINARY REPORT.<br />
S Sangle, D D’Cruz, GRV Hughes. Lupus Research Unit, <strong>The</strong> Rayne Institute, St Thomas’ Hospital,<br />
London, United Kingdom<br />
249 CARDIAC LUPUS - MANY SHADES OF ONE COLOUR.<br />
M Fonseka, M Nisar. <strong>Rheumatology</strong>, Queen’s Hospital, Burton-on-Trent, United Kingdom<br />
250 HYPERTENSION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME.<br />
MA Baron, Y Karim, MJ Cuadrado, L Bertolaccini, MA Khamashta, GRV Hughes. 1 Lupus Research<br />
Unit, St. Thomas’ Hospital, London, England, United Kingdom; 2 Immunology Department, St.<br />
Thomas’ Hospital, London, England, United Kingdom; 3 Lupus Research Unit, St. Thomas’ Hospital,<br />
London, England, United Kingdom; 4 Lupus Research Unit, St. Thomas’ Hospital, London, England,<br />
United Kingdom; 5 Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom;<br />
6<br />
Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom<br />
251 PREMATURE CARDIOVASCULAR DISEASE IN SLE: A STUDY FROM A TERTIARY<br />
REFERRAL CENTRE.<br />
S Nair, DP D’Cruz, MA Khamashta, GRV Hughes. Lupus Research Unit, Rayne Institute,<br />
St.Thomas’s Hospital, London, United Kingdom<br />
252 A MULTICENTRE RANDOMISED CONTROLLED TRIAL OF CYCLOSPORIN A (CYA) VERSUS<br />
AZATHIOPRINE (AZA) IN PATIENTS WITH SEVERE SLE: AN INTERIM ANALYSIS.<br />
B Griffiths 1 , P Emery 2 , D Isenberg, M Akil, R Thompson, P Maddison, I Griffiths 1 , A Lorenzi 2 ,<br />
S Miles 2 , D Situnayake 3 , LS Teh, M Plant, C Hallengrew, K Chakravarty, T Tait, C Gordon 3 .<br />
1<br />
Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2 Academic Unit<br />
of <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of<br />
<strong>Rheumatology</strong>, University of Birmingham, Birmingham, United Kingdom<br />
253 THE PREVALENCE OF AN ABNORMAL ANKLE-BRACHIAL INDEX IN PRIMARY<br />
ANTIPHOSPHOLIPID SYNDROME.<br />
MA Baron, DP D’Cruz, MA Khamashta, GRV Hughes. <strong>The</strong> Lupus Research Unit, <strong>The</strong> Rayne<br />
Institute, St Thomas’ Hospital, London, United Kingdom<br />
254 AUDIT ON CARDIOVASCULAR RISK IN SLE.<br />
FM Erkeller-Yuksel 1 , HD Sinclair 2 , JA Griffin 1 , MR Persey 1 , J MacGowan 2 . 1<br />
<strong>Rheumatology</strong>, Chase<br />
Farm Hospital, Enfield, Middlesex, United Kingdom; 2 <strong>Rheumatology</strong>, North Middlesex University<br />
Hospital, London, United Kingdom<br />
255 ARTERIAL DISEASE IN ANTIPHOSPHOLIPID SYNDROME WITH HYPERTENSION AND RENAL<br />
ARTERY STENOSIS: A STUDY OF ENDOTHELIN LEVELS.<br />
N Horwood, S Sangle, K Mepani, ML Bertolaccini, D D’Cruz, MA Khamashta, I Abbs, GRV Hughes.<br />
Lupus Research Unit, <strong>The</strong> Rayne Institute, St Thomas’ Hospital, London SE1 7EH, United Kingdom<br />
61
256 DOES ANTINUCLEAR ANTIBODY ELISA MISS SIGNIFICANT CONNECTIVE TISSUE DISEASE ?<br />
AYN Lim, G Maguire, G Wood, DS Kumararatne, JSH Gaston. 1 Department of <strong>Rheumatology</strong>,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Department of Clinical Immunology,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 3 Department of Clinical Immunology,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 4 Department of Clinical Immunology,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 5 Department of <strong>Rheumatology</strong>,<br />
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom<br />
257 DOUBLE BLIND, CROSSOVER, RANDOMISED TRIAL COMPARING LOW MOLECULAR WEIGHT<br />
HEPARIN VERSUS PLACEBO IN THE TREATMENT OF CHRONIC HEADACHE IN PATIENTS WITH<br />
ANTIPHOSPHOLIPID ANTIBODIES.<br />
G Sanna 1 , MJ Cuadrado 2 , M Sharief 3 , MA Khamashta 4 , GRV Hughes 5 . 1<br />
<strong>Rheumatology</strong>, Homerton<br />
University Hospital, London, England, United Kingdom; 2 Lupus Rearch Unit, St. Thomas’ Hospital,<br />
London, England, United Kingdom; 3 Neurology, St. Thomas’ Hospital, London, England, United Kingdom;<br />
4<br />
Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom; 5 Lupus Research Unit,<br />
St. Thomas’ Hospital, London, England, United Kingdom<br />
258 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND QUALITY OF LIFE IN SYSTEMIC<br />
LUPUS ERYTHEMATOSUS.<br />
S Khanna 1 , H Pal 2 , RM Pandey 3 , R Handa 4 . 1<br />
All India Institute of Medical Sciences, New Delhi, India;<br />
2<br />
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India; 3 Department of<br />
Biostatistics, All India Institute of Medical Sciences, New Delhi, India; 4 Department of Medicine, All India<br />
Institute of Medical Sciences, New Delhi, India<br />
259 PREVALENCE OF ANTITHYROID ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME.<br />
P Harrison 1 , GT Swana 2 , MR Swana 3 , ML Bertolaccini 1 , MA Khamashta 1 , DP D’Cruz 1 , GRV Hughes 1 . 1 Lupus<br />
Research Unit, <strong>The</strong> Rayne Institute, London, United Kingdom; 2 Immunology Department, St.Thomas’<br />
Hospital, London, United Kingdom; 3 Immunology Department, University College London Hospital,<br />
London, United Kingdom<br />
260 ATYPICAL CO-LOCALISATION OF CD45 AND LYN TO LIPID RAFT SIGNALLING DOMAINS<br />
CORRELATES WITH B-LYMPHOCYTE HYPER RESPONSIVENESS IN PATIENTS WITH LUPUS.<br />
F Flores-Borja 1 , PS Kabouridis 1 , E Jury 2 , D Isenberg 2 , RA Mageed 1 . 1<br />
Bone and Joint Research Unit,<br />
St Bartholomew’s and <strong>The</strong> Royal London, Queen Mary School of Medicine, London, United Kingdom;<br />
2<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London, London, United Kingdom<br />
261 A SINGLE MUTATION OF AN ARGININE RESIDUE ALTERS THE BINDING AFFINITY OF A HUMAN<br />
MONOCLONAL ANTIBODY TO DIFFERENT ANTIGENS.<br />
N Lambrianides 1,2 , A Rahman 1,2 , L Mason 2 , D Latchman 1 , D Isenberg 2 . 1<br />
Medical Molecular Biology Unit,<br />
Institute of Child Health, University College London, London, United Kingdom; 2 Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom<br />
262 ANTIBODIES AGAINST OXIDISED THE COMPLEX LOW DENSITY LIPOPROTEIN-BETA - 2 -<br />
G LYCOPROTEIN-I MAY HAVE A PRO- ATHEROGENIC ROLE IN PRIMARY ANTIPHOSPHOLIPID SYNDROME.<br />
PRJ Ames 1 , J Delgado-Alves 2 , D Lopez 3 , L Lopez 3 , E Matsuura 4 , A Margarita 5 , L Iannaccone 5 ,<br />
V Brancaccio 5 . 1<br />
Academic Department of <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, United<br />
Kingdom; 2 Department of Internal Medicine, Curry Cabral Hospital, Lisbon, Portugal; 3 Science and<br />
Research, Corgenix Ltd, Denver, CO, United States; 4 Department of Biochemistry, Okayama School of<br />
Medicine, Okayama, Japan; 5 Angiohaemostasis Unit, Ospedale A. Cardarelli, Naples, Italy<br />
263 STABLE TRANSFECTION OF CHO CELLS TO EXPRESS WHOLE HUMAN IgG ANTIPHOSPHOLIPID<br />
ANTIBODIES.<br />
N Lambrianides 1,2 , I Giles 1,2 , D Latchman 1 , D Isenberg 2 , A Rahman 1,2 . 1<br />
Medical Molecular Biology Unit,<br />
Institute of Child Health, University College London, London, United Kingdom; 2 Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom<br />
62
264 TREATMENT OF REFRACTORY LUPUS NEPHRITIS WITH B LYMPHOCYTE DEPLETION.<br />
MJ Leandro, MR Ehrenstein, JCW Edwards, J Manson, G Cambridge, DA Isenberg. Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom<br />
VASCULITIS (265 – 270)<br />
265 PREDICING TEMPORAL ARTERITIS IN PEOPLE WITH PRESENTING POLYMYALGIC<br />
SYMPTOMS.<br />
CT Pease, G Haugeberg, AW Morgan, BB Bhakta. Academic Unit of Musculoskeletal Disease,<br />
University of Leeds, Leeds, United Kingdom<br />
266 PREDICTING DURATION OF ORAL PREDNISOLONE TREATMENT IN PEOPLE WITH<br />
POLYMYALGIA RHEUMATICA.<br />
CT Pease, G Haugeberg, BB Bhakta. 1 Academic Unit of Musculoskeletal Disease, University of<br />
Leeds, Leeds, United Kingdom; 2 Academic Unit of Musculoskeletal Disease, University of Leeds,<br />
Leeds, United Kingdom; 3 Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds,<br />
United Kingdom<br />
267 THE PREVALENCE AND ASSOCIATIONS OF AN ABNORMAL ANKLE-BRACHIAL PRESSURE<br />
INDEX IN SYSTEMIC VASCULITIS: A PILOT STUDY.<br />
M Mora, C Noronha, B Grima, MA Baron, M Liz, MA Khamashta, GRV Hughes, DP D’Cruz. <strong>The</strong><br />
Lupus Research Unit, St Thomas’ Hospital, London, United Kingdom<br />
268 DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)<br />
IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE.<br />
JS McLaren, CJ Hall, RA Luqmani. Rheumatic Diseases Unit, University of Edinburgh, Edinburgh,<br />
United Kingdom<br />
269 WEGENER’S GRANULOMATOSIS: COMPARISON OF OUTCOME IN PATIENTS TREATED<br />
WITH LOW DOSE IV CYCLOPHOSPHAMIDE, ORAL CYCLOPHOSPHAMIDE OR OTHER<br />
CYTOTOXIC AGENTS.<br />
AN Bennett, C Noronha, JD Rees, DP D’Cruz, GRV Hughes. Lupus Research Unit, St Thomas’<br />
Hospital, London, United Kingdom<br />
270 THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES IN A COHORT OF PATIENTS WITH<br />
SYSTEMIC VASCULITIS.<br />
J Rees, S Lanca, PV Marques, JA Gómez-Puerta, MA Khamashta, DP D’Cruz, GRV Hughes.<br />
<strong>The</strong> Lupus Research Unit, <strong>The</strong> Rayne Institute, St Thomas’ Hospital, London, United Kingdom<br />
PAEDIATRIC RHEUMATOLOGY (271 – 278)<br />
271 SUBGROUP CLASSIFICATION OF CHILDREN WITH JIA USING THE ILAR SCHEME DOES<br />
NOT CHANGE OVER 12 MONTHS OF OBSERVATION.<br />
N Adib 1 , J Davidson 2 , E Baildam 3 , M Lay 1 , A Silman 1 , W Thomson 1 . 1<br />
ARC Epidemiology Unit,<br />
Manchester University Medical School, Manchester, United Kingdom; 2 <strong>Rheumatology</strong>, Royal<br />
Liverpool Children’s Hospital, Liverpool, United Kingdom; 3 <strong>Rheumatology</strong>, Royal Manchester<br />
Childrens Hospital, Manchester, United Kingdom<br />
272 CONFIRMATION OF ASSOCIATION OF HLA-DRB1*13 WITH UVEITIS IN JUVENILE<br />
IDIOPATHIC ARTHRITIS.<br />
E Zeggini 1 , W Thomson 2 , P Wordsworth 3 , MA Hall 3 , JC Packham 4 . 1<br />
Centre <strong>for</strong> Integrated Genomic<br />
Medical Research, University of Manchester, Manchester, United Kingdom; 2 ARC Epidemiology<br />
Unit, University of Manchester, Manchester, United Kingdom; 3 Nuffield Orthopaedic Centre,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 4 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Haywood<br />
Hospital, Stoke on Trent, United Kingdom<br />
63
273 A USER PERSPECTIVE OF THE RHEUMATOLOGY ADOLESCENT PLANNER - AN AID TO<br />
TRANSITIONAL CARE FORADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS.<br />
D O’Connor, KL Shaw, JE McDonagh. Medical School, University of Birmingham, Birmingham, West<br />
Midlands, United Kingdom<br />
274 TRANSITIONAL CARE IN JUVENILE IDIOPATHIC ARTHRITIS: PROFESSIONAL, PATIENT AND<br />
PARENT VIEWS OF BEST PRACTICE AND FEASIBILITY.<br />
KL Shaw, TR Southwood, JE McDonagh, on Behalf of the BPRG, CCAA, LHT & AC Funded by ARC.<br />
Institute of Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom<br />
275 WHAT’S IN A NAME? DISEASE KNOWLEDGE IN JUVENILE IDIOPATHIC ARTHRITIS.<br />
KL Shaw, TR Southwood, JE McDonagh, on Behalf of the BPRG, CCAA, LHT, AC. Funded by the ARC.<br />
1<br />
Institute of Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom<br />
276 RAYNAUD’S PHENOMENON IN CHILDHOOD: 33 PATIENTS FOLLOW UP.<br />
JJ Bethencourt, S Bustabad, JC Quevedo, S Machin, T Gonzalez. <strong>Rheumatology</strong>, Hospital Universitario<br />
de Canarias, La Laguna, Santa Cruz de Tenerife, Spain<br />
277 THE STATUS OF VITAMINS A, E, C, B 12 AND FOLATE FOR CHILDREN WITH JUVENILE<br />
IDIOPATHIC ARTHRITIS AND ITS CONNECTION WITH AN ANEMIC SYNDROME.<br />
VM Dudnyk, OO Pentiuk, LM Stanislavchuk. Children Diseases, National Medical University, Vinnycia,<br />
Ukraine<br />
278 NUTRITIONAL STATUS IN JUVENILE IDIOPATHIC ARTHRITIS.<br />
G Cleary 1 , L Gillian 2 , F Annan 3 , JA Sills 1 , JE Davidson 1 . 1<br />
Department of <strong>Rheumatology</strong>, Royal Liverpool<br />
Children’s Hospital, Liverpool, United Kingdom; 2 Centre <strong>for</strong> Medical Statistics and Health Evaluation,<br />
University of Liverpool, Liverpool, United Kingdom; 3 Department of Nutrition and Dietetics, Royal<br />
Liverpool Children’s Hospital, Liverpool, United Kingdom<br />
CASE REPORTS (279 – 295)<br />
279 REVERSING MYOCARDIAL MICROVASCULAR DISEASE IN RHEUMATOID ARTHRITIS.<br />
K Raza 1 , M Banks 2 , GD Kitas 2 . 1<br />
Division of Immunity and Infection, MRC Centre <strong>for</strong> Immune Regulation,<br />
University of Birmingham, Birmingham B15 2TT, United Kingdom; 2 Departments of <strong>Rheumatology</strong> and<br />
Cardiology, Dudley Group of Hospitals NHS Trust, Dudley, DY1 4SE, United Kingdom<br />
280 REGRESSION OF NEPHROTIC SYNDROME DUE TO REACTIVE AMYLOIDOSIS IN A PATIENT WITH<br />
ANKYLOSING SPONDYLITIS FOLLOWING COLCHICINE THERAPY.<br />
S Jain 1 , DS Mathur 1 , V Ravindran 2 . 1<br />
Division of <strong>Rheumatology</strong>, Department of Medicine, S M S Medical<br />
College and Teaching Hospitals, Jaipur, Rajasthan, India; 2 Division of <strong>Rheumatology</strong>, Department of<br />
Medicine, Epsom General Hospital, Epsom, Surrey, United Kingdom<br />
281 RHEUMATOLOGISTS AND BREASTS: FOUR CASES OF GRANULOMATOUS MASTITIS.<br />
N Raj 1 , RD MacMillan 2 , CM Deighton 3 . 1<br />
<strong>Rheumatology</strong>, Nottingham City Hospital, Nottingham,<br />
United Kingdom; 2 Surgery, Nottingham City Hospital, Nottingham, United Kingdom; 3 <strong>Rheumatology</strong>,<br />
Derbyshire Royal Infirmary, Derby, United Kingdom<br />
282 TWO CASES OF LIFE-THREATENING METHOTREXATE TOXICITY INDUCED BY ACUTE<br />
RENAL FAILURE.<br />
AH Strang, T Pullar. <strong>Rheumatology</strong>, Ninewells Hospital & Medical School, Dundee, Tayside,<br />
United Kingdom<br />
283 RITUXIMAB TREATMENT FOR RECALCITRANT RHEUMATOID PLEUROPERICARDIAL<br />
DISEASE -CASE REPORT.<br />
SN Kamath, AB Hassell, A Brownfield, J Fisher, PT Dawes. Haywood Hospital, Staf<strong>for</strong>dshire<br />
<strong>Rheumatology</strong> Centre, Stoke on Trent, Staf<strong>for</strong>dshire, United Kingdom<br />
64
284 OPEN LABEL PILOT STUDY OF INFLIXIMAB IN YOUNG ADULTS WITH JUVENILE<br />
IDIOPATHIC ARTHRITIS.<br />
E Rankin 1 , L Waterhouse 1 , D Carruthers 2 . 1<br />
<strong>Rheumatology</strong>, University Hospital Birmingham NHS<br />
Trust, Birmingham, United Kingdom; 2 <strong>Rheumatology</strong>, City Hospital NHS Trust, Birmingham,<br />
United Kingdom<br />
285 ELEVATION IN CREATINE KINASE (CK): CASES HIGHLIGHTING IMPORTANT RELATED<br />
ISSUES.<br />
LM Thomas, AL Thomas, JM Ledingham. <strong>Rheumatology</strong> Department, Queen Alexandra Hospital,<br />
Portsmouth, Hants, United Kingdom<br />
286 LIPOMA ARBORESCENS - IS IT A RARE CONDITION?<br />
AR Clewes 1 , VV Kaushik 1 , JK Dawson 1 , VE Abernethy 1 , O Harris 2 , BG Bolton-Maggs 3 . 1<br />
Department<br />
of <strong>Rheumatology</strong>, St Helens and Knowsley NHS Trust, St Helens, Merseyside, United Kingdom;<br />
2<br />
Department of Radiology, St Helens and Knowsley NHS Trust, St Helens, Merseyside, United<br />
Kingdom; 3 Department of Orthopaedics, St Helens and Knowsley NHS Trust, St Helens,<br />
Merseyside, United Kingdom<br />
287 SEVERE HERPES ZOSTER ON INFLIXIMAB TREATMENT.<br />
S Stevens, AJ Kinder, J Francis, P Sheldon. <strong>Rheumatology</strong>, Leicester Royal Infirmary, Leicester,<br />
United Kingdom<br />
288 POLYMYOSITIS WITH NORMAL CREATINE PHOSPHOKINASE.<br />
B Galarraga 1 , T Pullar 1 , M Garton 2 . 1<br />
Rheumatic Diseases Unit, Ninewells Hospital and Medical<br />
School, Dundee, United Kingdom; 2 Rheumatic Diseases Unit, Perth Royal Infirmary, Perth,<br />
United Kingdom<br />
289 EOSINOPHILIC GASTROENTERITIS AND RHEUMATOID ARTHRITIS.<br />
WF Ng 1 , P Cohen 2 , S Hamdulay 1 , A Hepburn 1 , M Carpani 3 , JC Mason 1 . 1<br />
<strong>Rheumatology</strong>,<br />
Hammersmith Hospital, London, United Kingdom; 2 Histopathology, Hammersmith Hospital,<br />
London, United Kingdom; 3 Gastroenterology, Hammersmith Hospital, Du Cane Road, London,<br />
United Kingdom<br />
290 AN UNUSUAL CAUSE OF A ‘DRY TAP’: LIPOMA ARBORESCENS.<br />
J Francis 1 , A Kinder 1 , PJ Sheldon 1 , K Jeyapalan 2 . 1<br />
<strong>Rheumatology</strong>, University Hospitals of Leicester<br />
NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom; 2 Radiology, University Hospitals of<br />
Leicester NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom<br />
291 GENERALIZED MORPHEA IN A PATIENT WITH SYSTEMIC SCLEROSIS.<br />
GA Mittal 1 , W Williams 2 , PJ Maddsion 1 . 1<br />
<strong>Rheumatology</strong>, Ysbyty Gwynedd, Bangor, Gwynedd,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, Ysbyty Glan Clwyd, Rhyl, Denbighshire, United Kingdom<br />
292 XRAY AND MRI IMAGING IN CAMURATI-ENGELMANN DISEASE.<br />
R Callaghan 1 , J Chandy 2 , J Coppock 2 . 1<br />
<strong>Rheumatology</strong> Department, Selly Oak Hospital, Birmingham,<br />
United Kingdom; 2 <strong>Rheumatology</strong> Department, Walsgrave Hospital, Coventry, United Kingdom<br />
293 SEVERE MYOPERICARDITIS ASSOCIATED WITH JUVENILE ANKYLOSING SPONDYLITIS.<br />
R Bessant, C Li, C Pilkington. Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London Hospitals,<br />
London, United Kingdom<br />
294 AMYOPATHIC DERMATOMYOSITIS WITH LUNG INVOLVEMENT.<br />
SE Woodham, J Joseph. Department of <strong>Rheumatology</strong>, <strong>The</strong> Hillingdon Hospital, Uxbridge,<br />
Middlesex, United Kingdom<br />
295 RECURRENCE OF NON HODGKINS LYMPHOMA (NHL) PRESENTING AS SCIATICA.<br />
LM Thomas, JM Ledingham. <strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth,<br />
Hants, United Kingdom<br />
65
Poster <strong>View</strong>ing Session 3<br />
Friday 23 April 2004, 08:30 – 10:00<br />
SPONDYLARTHROPATHIES: CLINICAL ASPECTS (296 – 319)<br />
296 FIVE YEAR OUTCOME FOLLOWING THE ONSET OF INFLAMMATORY POLYARTHRITIS IN THOSE<br />
WITH AND WITHOUT PSORIASIS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER.<br />
C Morgan 1 , S Mottram 1 , D Bunn 2 , DPM Symmons 1 , AJ Silman 1 . 1<br />
ARC Epidemiology Unit, Manchester<br />
University, Manchester, United Kingdom; 2 NOAR, Norfolk and Norwich University Hospital, Norwich,<br />
United Kingdom<br />
297 AN INVESTIGATION OF PIIINP AS A MARKER OF HEPATIC FIBROSIS IN PSORIASIS :<br />
DOES THE ARTHRITIS AFFECT PIIINP LEVELS?<br />
K Lindsay, A Gough, A Layton, M Goodfield, S Fraser. 1<br />
<strong>Rheumatology</strong>, Harrogate District Hospital,<br />
Harrogate, West Yorkshire, United Kingdom; 2 Dermatology, Harrogate District Hospital, Harrogate,<br />
West Yorkshire, United Kingdom; 3 Dermatology, Leeds General Infirmary, Leeds, West Yorkshire,<br />
United Kingdom<br />
298 ULTRASONOGRAPHY IN PATIENTS WITH PSORIATIC ARTHRITIS: CORRELATION WITH OTHER<br />
OBJECTIVE DISEASE ACTIVITY MEASURES.<br />
Z Karim 1 , RJ Wakefield 1 , A Fraser 1 , S Jarret 1 , M Quinn 1 , AK Brown 1 , BAC Dijkmans 2 , P Emery 1 , D Veale 1 .<br />
1<br />
Academic Unit of Musculoskeletal Medicine, Department of <strong>Rheumatology</strong>, Leeds General Infirmary,<br />
Leeds, West Yorkshire, United Kingdom; 2 <strong>Rheumatology</strong>, VU University Medical Centre, Amsterdam,<br />
<strong>The</strong> Netherlands<br />
299 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES ARE A MARKER OF DISEASE SEVERITY IN<br />
PSORIATIC ARTHRITIS.<br />
E Korendowych, PA Owen, J Lewis, CR Carmichael, J Ravindran, NJ McHugh. Department of Research<br />
and Clinical Effectiveness, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom<br />
300 MEASUREMENT OF ENTHESITIS IN PSORIASIS AND PSORIATIC ARTHRITIS: COMPARISON<br />
OF THE NEWCASTLE ENTHESITIS INDEX AND THE MAASTRICHT ANKYLOSING SPONDYLITIS<br />
ENTHESITIS SCORE.<br />
MJ Bridges 1 , NJ Reynolds 2 , LJ Kay 1 . 1<br />
Department of <strong>Rheumatology</strong>, Newcastle Hospitals NHS Trust,<br />
Newcastle upon Tyne, Tyne & Wear, United Kingdom; 2 Department of Dermatology, University of<br />
Newcastle, Newcastle upon Tyne, Tyne & Wear, United Kingdom<br />
301 THE INFLUENCE OF TOBACCO SMOKING ON DISEASE ACTIVITY AND FUNCTIONAL STATUS IN<br />
ANKYLOSING SPONDYLITIS.<br />
LP Robertson 1 , E Stanley 2 , MJ Davis 2 . 1<br />
<strong>Rheumatology</strong> Unit, Bristol Royal Infrimary, Bristol, Avon,<br />
United Kingdom; 2 Dept of <strong>Rheumatology</strong>, Royal Cornwall Hospital, Truro, Cornwall, United Kingdom<br />
302 FUNCTIONAL IMPAIRMENT IN PSORIATIC ARTHRITIS.<br />
L Williamson, N Dalbeth, JL Dockerty, R Weatherall, P Wordsworth. 1 <strong>Rheumatology</strong> Department, Nuffield<br />
Orthopaedic Centre, Ox<strong>for</strong>d, Oxon, United Kingdom; 2 ICRF/NHS Centre <strong>for</strong> Statistics in Medicine,<br />
Institute of Health Sciences, Ox<strong>for</strong>d, Oxon, United Kingdom<br />
303 SACROILIAC JOINT INVOLVEMENT IN PSORIASIS: CLINICAL, RADIOLOGICAL AND COMPUTED<br />
TOMOGRAPHY FINDINGS.<br />
AM Abdel-Nasser 1 , OA Khalil 2 . 1<br />
<strong>Rheumatology</strong> & Rehabilitation, Minia University, Minia, Egypt;<br />
2<br />
Radiolology, Minia University, Minia, Egypt<br />
66
304 CAN EARLY DIAGNOSIS AND MANAGEMENT OF COSTOCHONDRITIS REDUCE ACUTE<br />
CHEST PAIN ADMISSIONS?<br />
JE Freeston 1 , Z Karim 1 , K Lindsay 1 , AKS Gough 1,2 . 1<br />
<strong>Rheumatology</strong>, Harrogate District Hospital,<br />
Harrogate, North Yorkshire, United Kingdom; 2 Academic Department of <strong>Rheumatology</strong>, Leeds<br />
General Infirmary, Leeds, West Yorkshire, United Kingdom<br />
305 USING A MODIFIED SHARP SCORE TO ASSESS RADIOLOGICAL PROGRESSION IN<br />
PSORIATIC ARTHRITIS.<br />
J Ravindran 1 , C Carmichael 1 , C Balakrishnan 2 , S Jones 3 , E Korendowych 1 , N McHugh 1 .<br />
1<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, P.D.Hinduja National Hospital and Medical Research Centre, Mumbai, India;<br />
3<br />
<strong>Rheumatology</strong>, University of Wales, Cardiff, United Kingdom<br />
306 ASSESSING INFLAMMATION AND PREDICTING RADIOLOGICAL OUTCOME IN EARLY PSO-<br />
RIATIC ARTHRITIS: ROLE OF ESR, CRP, SERUM AMYLOID A AND CARTILAGE OLIGOMERIC<br />
MATRIX PROTEIN.<br />
DJ Kane 1 , T Saxne 2 , JP Doran 3 , B O’ Shea 3 , B Bresnihan 3 , O FitzGerald 3 . 1<br />
<strong>Rheumatology</strong>, University<br />
of Newcastle, Newcastle, United Kingdom; 2 <strong>Rheumatology</strong>, University of Lund, Lund, Sweden;<br />
3<strong>Rheumatology</strong>, St Vincent’s University Hospital, Dublin, Ireland<br />
307 THE IMPACT OF ANKYLOSING SPONDYLITIS ON QUALITY OF LIFE AND ABILTY TO WORK.<br />
N Barkham, KO Kong, A Fraser, A Tennant, P Emery. Academic Unit of Musculoskeletal Disease,<br />
University of Leeds, Leeds, United Kingdom<br />
308 THE VALUE OF SERUM TYPE III PROCOLLAGEN AMINOPEPTIDE(P3NP) IN MONITORING<br />
METHOTREXATE INDUCED LIVER FIBROSIS IN PSORIATIC ARTHRITIS.<br />
CE Buckley, PA Sanders. <strong>Rheumatology</strong> Department, South Manchester University Hospitals,<br />
Manchester, M20 2LR, United Kingdom<br />
309 BASDAI ASSESSMENT FOR ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS.<br />
S Mackenzie, S Miah, D Kane, H John, S Roger. 1<br />
Centre <strong>for</strong> Rheumatic Diseases, Division of<br />
Immunology, Infection and Inflammation, University of Glasgow, Glasgow, Scotland, United<br />
Kingdom; 2 <strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom<br />
310 PROFILE OF PATIENTS WITH ANKYLOSING SPONDYLITIS ATTENDING A DISTRICT GENERAL<br />
HOSPITAL - HOW MANY MIGHT BE SUITABLE FOR TREATMENT WITH ANTI-TNF THERAPY?<br />
J Novak, A Griffiths, JK Dawson, VE Abernethy. <strong>Rheumatology</strong> Department, St Helens and<br />
Knowsley Hospitals, St Helens, WA9 3DA, United Kingdom<br />
311 THE INCIDENCE OF LONG-TERM METHOTREXATE HEPATOTOXICITY IN<br />
PSORIATIC ARTHRITIS.<br />
K Lindsay, A Gough, M Goodfield, A Layton, S Fraser. 1<br />
<strong>Rheumatology</strong>, Harogate District Hospital,<br />
Harrogate, West Yorkshire, United Kingdom; 2 Dermatology, Harrogate District Hospital, Harrogate,<br />
West Yorkshire, United Kingdom; 3 Dermatology, Leeds General Infirmary, Leeds, West Yorkshire,<br />
United Kingdom; 4 <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom<br />
312 AS YOU LIKE IT THE POTENTIAL SIZE OF THE UK AS POPULATION MERITING<br />
ANTI-TNFα TREATMENT.<br />
PJ Cornell, J Haynes, SCM Richards. <strong>Rheumatology</strong>, Poole Hospital NHS Trust, Poole, Dorset,<br />
United Kingdom<br />
313 NAIL DISEASE IN PSORIATIC ARTHRITIS: CLINICALLY IMPORTANT, POTENTIALLY<br />
TREATABLE AND OFTEN OVERLOOKED.<br />
L Williamson, N Dalbeth, JL Dockerty, B Gee, R Weatherall, P Wordsworth. 1 <strong>Rheumatology</strong><br />
Department, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, Oxon, United Kingdom; 2 Dermatology<br />
Department, Churchill Hospital, Ox<strong>for</strong>d, Oxon, United Kingdom; 3 ICRF/NHS Centre <strong>for</strong> Staistics in<br />
Medicine, Institute of Health Sciences, Ox<strong>for</strong>d, Oxon, United Kingdom<br />
67
314 CHANGE IN PATIENT-ASSESSED HEALTH FOLLOWING PHYSICAL THERAPY FOR ANKYLOSING<br />
SPONDYLITIS (AS): A STRUCTURED REVIEW.<br />
KL Haywood, AM Garratt, PT Dawes. 1 Unit of Health-Care Epidemiology, Department of Public Health,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 2 Unit of Health-Care Epidemiology, Department of Public<br />
Health, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 3 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, University<br />
Hospital of North Staf<strong>for</strong>dshire NHS Trust, Stoke-on-Trent, Staf<strong>for</strong>dshire, United Kingdom<br />
315 THE SPONDYLOARTHROPATHY OF INFLAMMTORY BOWEL DISEASE.<br />
S Salman, AA Abdulla. 1 Rheumatoloy Dept., Faculty of Medicine University of Baghdad, Iraq, Baghdad,<br />
Iraq; 2 Rheumatoloy Dept, Faculty of Medicine, University of Baghdad, Iraq, Baghdad, Iraq<br />
316 MUSCLE MASS AND FUNCTION IN ANKYLOSING SPONDYLITIS PATIENTS.<br />
F Casanova 1 , SM Marcora 1 , ER Williams 1 , AB Lemmey 1 , J Jones 2 , P Maddison 2 . 1<br />
School of Sport, Health<br />
and Exercise Sciences, University of Wales, Bangor, Gwynedd, United Kingdom; 2 <strong>Rheumatology</strong><br />
Department, Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom<br />
317 SPINAL OSTEOTOMY FOR THE CORRECTION OF SEVERE DEFORMITY IN ANKYLOSING<br />
SPONDYLITIS.<br />
K Dani, MJ M, SD Roger. 1<br />
Centre <strong>for</strong> Rheumatic Diseases, Division of Immunology, Infection and<br />
Inflammation, Faculty of Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Spinal<br />
De<strong>for</strong>mity Centre, Edinburgh Royal Infirmary, Edinburgh, Scotland, United Kingdom<br />
318 PATTERN OF PRESENTATION OF SINGLE JOINT EFFUSION AMONG PATIENTS ATTENDING<br />
A DISTRICT GENERAL HOSPITAL.<br />
A Salih, A Cox, E Williams. <strong>Rheumatology</strong> Department, Warrington Hospital, Warrington, Cheshire,<br />
United Kingdom<br />
319 ELIGIBILITY FOR ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS: WHAT’S THE REAL<br />
SITUATION?<br />
RF Mascarenhas 1 , MJ Davis 1 , LP Robertson 2 . 1<br />
<strong>Rheumatology</strong>, Royal Cornwall Hospital, Truro, Cornwall,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, United Bristol Healthcare Trust, Bristol, United Kingdom<br />
SPONDYLARTHROPATHIES: AETIOPATHOGENESIS (320 – 327)<br />
320 MAPPING THE NON-B27 MHC ASSOCIATIONS OF ANKYLOSING SPONDYLITIS (AS).<br />
A-M Sims 1 , M Bernardo 2 , J Broxholme 3 , I Herzberg 1 , L Bradbury 1 , A Calin 4 , BP Wordsworth 1 , C Darke 5 ,<br />
MA Brown 1 . Botnar Research Centre, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom; 2 Ox<strong>for</strong>d<br />
Transplant Centre, Churchill Hospital, Ox<strong>for</strong>d, United Kingdom; 3 Wellcome Trust Centre <strong>for</strong> Human<br />
Genetics, Ox<strong>for</strong>d, United Kingdom; 4 Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United<br />
Kingdom; 5 Welsh Blood Service, Pontyclun, United Kingdom<br />
321 EVIDENCE FOR A TNF α HAPLOTYPE ASSOCIATION WITH PSORIATIC ARTHRITIS INDEPENDENT<br />
OF HLA-Cw6.<br />
J Ravindran 1 , A Lagan 2 , T Ahmed 3 , P Owen 1 , E Korendowych 1 , C Carmichael 1 , J Lewis 1 , K Welsh 2 ,<br />
N McHugh 1 . 1<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom;<br />
2<br />
Clinical Genomics, National Heart and Lung Institute, London, United Kingdom; 3 Gastroenterology Unit,<br />
Radcliffe Infirmary, Ox<strong>for</strong>d, United Kingdom<br />
322 HLA-B27 ALLELES ASSOCIATED WITH SUSCEPTIBILITY TO ANKYLOSING SPONDYLITIS (AS)<br />
EXHIBIT DIFFERENT PHENOTYPES IN A CELL LINE DEFECTIVE IN ANTIGEN PROCESSING.<br />
JC Goodall, JSH Gaston. Medicine, Cambridge University, Cambridge, Cambridgeshire, United Kingdom<br />
323 APPENDECTOMY IS A RISK FACTOR FOR SERONEGATIVE SPONDYLOARTHROPATHIES.<br />
R Scarpa 1 , F Manguso 1 , A Oriente 1 , R Peluso 1 , M Atteno 1 , F Ayala 2 , P Punzetto 1 , D Di Minno 1 , S Iervolino 1 ,<br />
A D’Arienzo 1 . 1<br />
Clinical and Experimental Medicine, Federico II University, Federico II University, NA, Italy;<br />
2<br />
Systematic Pathology, Federico II University, Federico II University, NA, Italy<br />
68
324 CHARACTERIZATION OF AUTOREACTIVE IL-4 PRODUCING T CELLS ISOLATED FROM<br />
PATIENTS WITH SPONDYLOARTHROPATHY (SpA).<br />
LB Jarvis, MK Matyszak, JSH Gaston. Department of Medicine, University of Cambridge,<br />
Cambridge, United Kingdom<br />
325 PHENOTYPIC CHARACTERIZATION OF NATURAL KILLER CELLS AND RECEPTORS IN<br />
SPONDYLOARTHRITIS.<br />
ATY Chan, S Kollnberger, A McMichael, P Bowness. Human Immunology Unit, Weatherall Institute<br />
of Molecular Medicine, Ox<strong>for</strong>d, United Kingdom<br />
326 METHOTREXATE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS INCREASES<br />
APOPTOSIS THROUGH DECREASE OF Bcl-2 PRODUCTION AND ACTIVATION OF CASPASE-3.<br />
MJ Benito, B Bresnihan, D Kane, O FitzGerald. <strong>Rheumatology</strong>, St. Vincent’s University Hospital,<br />
Dublin, Ireland<br />
327 OSTEOPROTEGERIN (OPG) AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR<br />
KAPA-BETA-LIGAND (RANKL) IN THE SERA OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS):<br />
CORRELATIONS WITH METROLOGY, FUNCTIONAL AND ACTIVITY INDEXES.<br />
A Cauli, G Dessole, R Pala, A Vacca, A Mameli, G Passiu, A Mathieu. 2nd <strong>Rheumatology</strong> Unit,<br />
University of Cagliari, Cagliari, Italy<br />
SPONDYLARTHROPATHIES: THERAPY (328 – 331)<br />
328 INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF ACTIVE<br />
ANKYLOSING SPONDYLITIS: A DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL USING<br />
MAGNETIC RESONANCE IMAGING.<br />
H Marzo-Ortega 1 , D Mc Gonagle 1,2 , S Jarrett 1 , G Haugeberg 3 , E Hensor 1 , P O’Connor 4 , AL Tanv, PG<br />
Conaghan 1 , A Greenstein 1 , P Emery 1 . 1<br />
Academic Unit of Musculoskeletal Disease, Department of<br />
<strong>Rheumatology</strong>, University of Leeds, Leeds, West Yorkshire, United Kingdom; 2 Department of<br />
<strong>Rheumatology</strong>, Calderdale General Hospital, Halifax, West Yorkshire, United Kingdom; 3 Oslo City<br />
Department of <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway; 4 Department of Radiology,<br />
Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom<br />
329 AN OPEN STUDY OF PULSE PAMIDRONATE THERAPY IN SEVERE ANKYLOSING<br />
SPONDYLITIS, AND ITS EFFECT ON BIOCHEMICAL MARKERS OF BONE TURNOVER.<br />
AP Cairns 1 , SA Wright 1 , AJ Taggart 1 , SM Coward 2 , GD Wright 1 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
Musgrave Park Hospital, Belfast, Northern Ireland, United Kingdom; 2 Department of Biochemistry,<br />
Musgrave Park Hospital, Belfast, Northern Ireland, United Kingdom<br />
330 A CLINICAL AND MAGNETIC RESONANCE IMAGING ASSESSMENT OF THE EFFICACY<br />
OF INFLIXIMAB AT A DOSE OF 3MG/KG IN COMBINATION WITH METHOTREXATE IN THE<br />
TREATMENT OF PSORIATIC ARTHRITIS.<br />
H Marzo-Ortega 1 , D Mc Gonagle 1,2 , AL Tan 1 , L Rhodes 3 , S Tanner 3 , PG Conaghan 1 , P O’Connor 4 ,<br />
A Fraser 1 , D Veale 5 , P Emery 1 . 1<br />
Academic Unit of Musculoskeletal Disease, University of Leeds,<br />
Leeds, West Yorkshire, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Calderdale General<br />
Hospital, Halifax, West Yorkshire, United Kingdom; 3 Academic Unit of Medical Physics, Leeds<br />
General Infirmary, Leeds, West Yorkshire, United Kingdom; 4 Department of Radiology, Leeds<br />
General Infirmary, Leeds, West Yorkshire, United Kingdom; 5 Department of <strong>Rheumatology</strong>,<br />
St Vincent’s University Hospital, Dublin, Ireland<br />
331 ANTI-TNFα THERAPY IN PSORIASIS AND PSORIATIC ARTHRITIS: CLINICAL AND<br />
ANGIOGENIC RESPONSES.<br />
T Markham 1 , U Fearon 1 , S Rogers 2 , L Golden-Mason 3 , B Bresnihan 1 , O FitzGerald 1 , DJ Veale 1 .<br />
1<br />
<strong>Rheumatology</strong>, St. Vincents University Hospital and <strong>The</strong> Conway Institute, Dublin, Ireland;<br />
2<br />
Dermatology, ST. Vincents University Hospital, Dublin, Ireland; 3 Liver Unit, St.Vincents University<br />
Hospital, Dublin, Ireland<br />
69
MISCELLANEOUS RHEUMATIC DISEASE (332 – 336)<br />
332 BAKER’S CYST - AN AUDIT OF MISSED OPPORTUNITY.<br />
RS Tattersall, JT Bourne. <strong>Rheumatology</strong> and General Medicine, Chesterfield and North Derbyshire Royal<br />
Hospital, Chesterfield, Derbyshire, United Kingdom<br />
333 IS IT NECESSARY TO DO CELL COUNTS ON SYNOVIAL FLUID?<br />
S Abdullah, S YoungMin, CA Kelly, C Heycock, S Hudson, J Hemmings, JD Hamilton. 1 Department of<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom; 2 Department of<br />
Microbiology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom<br />
334 INTER AND INTRAOBSERVER ERROR IN RECORDED OBSERVATIONS AND DIRECT GROSS<br />
ANALYSIS OF SYNOVIAL FLUID.<br />
S Abdullah, S Young Min, CA Kelly, CR Heycock, JD Hamilton. Department of <strong>Rheumatology</strong>, Queen<br />
Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom<br />
335 OCULAR TOXICITY AND HYDROXYCHLOROQUINE : AUDIT OF CURRENT PRACTICE.<br />
SI Yeo, AN Bennett, T Gibson. <strong>Rheumatology</strong> Department, Guy’s & St. Thomas’ Hospital, London,<br />
United Kingdom<br />
336 LONG TERM OUTCOME FROM SEPTIC ARTHRITIS ON FIVE-YEAR FOLLOW-UP.<br />
A PROSPECTIVE STUDY.<br />
MN Gupta, M Field. Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow, Strathclyde, United Kingdom<br />
RHEUMATOID ARTHRITIS: AETIOPATHOGENESIS (337 – 341)<br />
337 MATRIX METALLOPROTEINASE GENOTYPE IS ASSOCIATED WITH FUNCTIONAL STATUS IN<br />
RHEUMATOID ARTHRITIS.<br />
E Dennison 1 , K Walker Bone 1 , N Patodi 2 , I Reading 1 , L Dunleavey 2 , S Ye 2 . 1<br />
Medical Research Council<br />
Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United<br />
Kingdom; 2 Human Genetics Division, Southampton General Hospital, Southampton, Hants,<br />
United Kingdom<br />
338 CD56 BRIGHT NK CELLS: “NATURAL INFLAMMATORY CELLS”?<br />
N Dalbeth 1,2 , R Gundle 3 , R Davies 4 , M Callan 1,2 . 1<br />
Department of Immunology, Imperial College London,<br />
London, United Kingdom; 2 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine,<br />
Ox<strong>for</strong>d, United Kingdom; 3 Department of Orthopaedics, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United<br />
Kingdom; 4 Chest Unit, Churchill Hospital, Ox<strong>for</strong>d, United Kingdom<br />
339 INACTIVATION OF XANTHINE OXIDOREDUCTASE IS ASSOCIATED WITH INCREASED ACUTE<br />
ANTIGEN-INDUCED ARTHRITIS.<br />
R Klocke 1,2 , A Mani 3 , KP Moore 3 , CJ Morris 1 , DR Blake 1,2 , PI Mapp 1 . 1<br />
Department of Pharmacy &<br />
Pharmacology/School <strong>for</strong> Health, University of Bath, Bath, United Kingdom; 2 Royal National Hospital <strong>for</strong><br />
Rheumatic Diseases, NHS Trust, Bath, United Kingdom; 3 Centre <strong>for</strong> Hepatology, Department of Medicine,<br />
Royal Free & University College Medical School, UCL, London, United Kingdom<br />
340 THE ASSOCIATION OF THE “SHARED EPITOPE” WITH SYNOVIAL IMMUNOHISTOCHEMICAL<br />
CHANGES IN EARLY RHEUMATOID ARTHRITIS.<br />
CF Matthews 1 , P Maxwell 2 , GD Wright 1 , D Middleton 3 , B Bresnihan 4 , O FitzGerald 4 , PW Hamilton 2 , MME<br />
Rooney 1 . 1<br />
Department of <strong>Rheumatology</strong>, Musgrave Park Hospital, Belfast, County Antrim, United<br />
Kingdom; 2 Department of Quantitative Pathology, Queen’s University of Belfast, Belfast, County Antrim,<br />
United Kingdom; 3 Department of Tissue Typing, Belfast City Hospital, Belfast, County Antrim, United<br />
Kingdom; 4 Department of <strong>Rheumatology</strong>, St Vincent’s University Hospital, Dublin, County Dublin, Ireland<br />
70
341 THE ASSOCIATION BETWEEN HLA GENES AND RADIOLOGICAL EROSIONS IN MALAYSIAN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
SS Yeap 1 , A Mohd 1 , G Kumar 2 , KF Kong 3 , EML Goh 1 , SK Chow 1 , ME Phipps 3 . 1<br />
Department of<br />
Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2 Department of<br />
Radiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 3 Department of<br />
Allied Health Sciences, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia<br />
RHEUMATOID ARTHRITIS: CLINICAL ASPECTS (342 – 357)<br />
342 CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN ADULTS & CHILDREN WITH ARTHRITIS IN<br />
A DISTRICT GENERAL HOSPITAL SETTING.<br />
K Hurley 1 , SS Hamdulay 2 , A Steuer 2 , A Hall 2 , H Chapel 1 , BL Ferry 1 . 1<br />
Immunology, Wexham Park<br />
Hospital, Slough, United Kingdom; 2 <strong>Rheumatology</strong>, Wexham Park Hospital, Slough,<br />
United Kingdom<br />
343 THE PREDICTIVE VALUE OF ANTIBODIES TO CYCLIC CITRULLINATED PEPTIDE IN VERY<br />
EARLY INFLAMMATORY ARTHRITIS.<br />
K Raza 1 , GM Breese 2 , KY Lee 3 , T Potter 2 , CD Buckley 1 , C Gordon 1 , M Salmon 1 , GD Kitas 2 . 1<br />
MRC<br />
Centre <strong>for</strong> Immune Regulation, Division of Immunity and Infection, University of Birmingham,<br />
Birmingham B15 2TT, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals<br />
NHS Trust, Dudley, DY1 4SE, United Kingdom; 3 Department of Radiology, City Hospital, Dudley<br />
Road, Birmingham B18 7QH, United Kingdom<br />
344 STRUCTURAL DAMAGE AS MEASURED BY RADIOGRAPHS ACCELERATES BETWEEN<br />
YEARS TWO AND THREE IN EARLY RHEUMATOID ARTHRITIS - IMPORTANT IMPLICATIONS<br />
FOR TREATMENT AND TRIAL DESIGN.<br />
J Dixey 1 , C Sollymossy 1 , P Jones 2 , A Young 1 , T McCourt 1 , L Waterhouse 1 . 1<br />
On Behalf of the<br />
Early Rheumatoid Arthritis Study (ERAS), St Albans City Hospital, St Albans, Hert<strong>for</strong>dshire,<br />
United Kingdom<br />
345 CAN WE PREDICT DEVELOPMENT OF RA IN ‘PRE-RHEUMATOID’ PATIENTS?<br />
SN Kamath 1 , PT Dawes 1 , S Griffiths 1 , PW Jones 2 , A Brownfield 1 , J Fisher 1 , DL Mattey 1 . 1<br />
Haywood<br />
Hospital, Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Stoke on Trent, Staf<strong>for</strong>dshire, United Kingdom;<br />
2<br />
Department of Mathematics, Keele University, Stoke on Trent, Staf<strong>for</strong>dshire, United Kingdom<br />
346 INFLUENCES OF SEROPOSITIVITY AND GENDER ON DISEASE ACTIVITY SCORE (DAS)<br />
IN EARLY RHEUMATOID ARTHRITIS (RA).<br />
L Connell, R Ramachandran, R Madhok, H Capell. Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary<br />
on Behalf of the MASCOT Group, Glasgow, United Kingdom<br />
347 AN AUDIT OF VITAMIN D LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
A Sinclair, N McAvoy, EA Murphy. Department of <strong>Rheumatology</strong>, Wishaw General Hospital,<br />
Wishaw, ML2 0DP, United Kingdom<br />
348 INVESTIGATION OF GROWTH HORMONE SECRETION AND SENSITIVITY IN<br />
RHEUMATOID ARTHRITIS.<br />
GA Mittal 1,4 , S Marcora 4 , AB Lemmey 4 , A Wayte 2 , PJ Maddison 1,4 , A Wilton 3,4 . 1<br />
<strong>Rheumatology</strong>,<br />
Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom; 2 Clinical Chemistry, Ysbyty Gwynedd,<br />
Bangor, Gwynedd, United Kingdom; 3 Endocrinology, Ysbyty Gwynedd, Bangor, Gwynedd, United<br />
Kingdom; 4 School of Sports, Health and Exercise Sciences, University of Wales, Bangor, Gwynedd,<br />
United Kingdom<br />
349 RESPONSE RATES TO JOINT INJECTION THERAPY IN RHEUMATOID ARTHRITIS.<br />
C Rao, MAS Bukhari. <strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster, Lancashire,<br />
United Kingdom<br />
71
350 ARE FLEXION/EXTENSION VIEWS OF THE CERVICAL SPINE NECESSARY IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS?<br />
ASM Jawad 1 , A Malhorta 2 , Z Chan 2 , M Adler 1 , O Chan 2 . 1<br />
<strong>Rheumatology</strong> Department, <strong>The</strong> Royal London<br />
Hospital, London, E1 4DG, United Kingdom; 2 Radiology Department, <strong>The</strong> Royal London Hospital,<br />
London, E1 4DG, United Kingdom<br />
351 OCCURRENCE AND RISK FACTORS FOR FALLS IN RHEUMATOID ARTHRITIS.<br />
C Armstrong1, CM Swarbrick2, SR Pye2, TW O’Neill1,2. 1Department of <strong>Rheumatology</strong>, Hope Hospital,<br />
Sal<strong>for</strong>d, United Kingdom; 2ARC Epidemiology Unit, University of Manchester, Manchester, United<br />
Kingdom<br />
352 AUDIT OF INFLUENZA VACCINE UPTAKE BY RHEUMATOID ARTHRITIS (RA) PATIENTS.<br />
L Connell, M McDonald, HA Capell. Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow,<br />
United Kingdom<br />
353 DIETARY INTAKE AND NUTRITIONAL STATUS OF PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
P Judd, L Goodacre, J Goodacre. Lancashire School of Health and Postgraduate Medicine, University of<br />
Central Lancashire, Preston, Lancs, United Kingdom<br />
354 WHICH PATIENTS WITH EARLY RA DEVELOP FAST PROGRESSIVE DISEASE? PROGNOSTIC<br />
FACTORS FOR SEVERE FUNCTIONAL LOSS FROM AN INCEPTION COHORT WITH 9 YEAR FOLLOW UP.<br />
N Bansback 1 , A Brennan 1 , A Young 2 , C Sollymossy 2 , J Dixey 2 , H Dart 2 . 1<br />
Operational Research, School of<br />
Health and Related Research, Sheffield, United Kingdom; 2 Early Rheumatoid Arthritis Study (ERAS),<br />
St Albans City Hospital, St Albans, Hert<strong>for</strong>dshire, United Kingdom<br />
355 CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENT’S WHO MAINTAIN THE THE<br />
REMISSION WITHOUT DMARD’s.<br />
R Gupta, V Marwaha, R Grover, A Kumar. Clinical Immunology & <strong>Rheumatology</strong> Service, Department of<br />
Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India<br />
356 OUTCOME OF A LARGE SECONDARY CARE INCEPTION COHORT OF EARLY RA PATIENTS USING<br />
A STANDARDISED TREATMENT PROTOCOL: SETTING STANDARDS FOR OUTCOME IN EARLY RA WITH<br />
CONVENTIONAL DISEASE MODIFYING THERAPIES.<br />
MA Quinn, PG Conaghan, MJ Green, S Jarret, A-M Keenan, H King, P Emery. <strong>Rheumatology</strong>, Leeds<br />
Musculoskeletal Institute, Leeds, West Yorkshire, United Kingdom<br />
357 THE IMPACT OF THE PUBLICATION OF SIGN GUIDELINES ON MANAGEMENT OF EARLY<br />
RHEUMATOID ARTHRITIS (RA).<br />
E Suresh, NL Maiden, VB Dhillon, ER McRorie. 1 Rheumatic Diseases Unit, Western General Hospital,<br />
Edinburgh, United Kingdom; 2 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United<br />
Kingdom; 3 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom; 4 Rheumatic<br />
Diseases Unit, Western General Hospital, Edinburgh, United Kingdom<br />
RHEUMATOID ARTHRITIS: ASSESSMENT (358 – 366)<br />
358 VA L I D ATING PATIENT BASED DISEASE ACTIVITY SCORE (PDAS) IN RHEUMATOID ARTHRITIS (RA).<br />
B Khoshaba 1 , DJ Cooper 2 , AJ MacGregor 3 . 1<br />
Academic Department of <strong>Rheumatology</strong>, Guy’s King’s St<br />
Thomas Hospitals School of Medicine, London, United Kingdom; 2 In<strong>for</strong>mation Services, Guy’s King’s<br />
St Thomas Hospitals School of Medicine, London, United Kingdom; 3 Department <strong>Rheumatology</strong>,<br />
Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom<br />
359 USING PATIENT SELF-ASSESSMENT IN RHEUMATOID ARTHRITIS TO CONSTRUCT A PATIENT<br />
DISEASE ACTIVITY SCORE (PDAS).<br />
B Khoshaba 1 , DJ Cooper 2 , AJ MacGregor 3 , DL Scott 1 , EHS Choy 1 . 1<br />
Academic Department of<br />
<strong>Rheumatology</strong>, Guy’s, King’s College and St Thomas Hospitals School of Medicine, London, United<br />
Kingdom; 2 Department of In<strong>for</strong>mation Services, Guy’s, King’s College and St Thomas Hospitals School of<br />
Medicine, London, United Kingdom; 3 Norfolk and Norwich Hospital University NHS Trust, Depatment of<br />
<strong>Rheumatology</strong>, Norwich, United Kingdom<br />
72
360 SELF-MONITORING OF BLOODS AND SYMPTOMS IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS RECEIVING METHOTREXATE.<br />
KM Mitchell 1,3 , AL Mandeville 1 , J Manson 2 , A Olaleye 2 , M Shipley 2 , SP Newman 1 . 1<br />
Centre <strong>for</strong><br />
Behavioural and Social Sciences in Medicine, University College London, London, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, University College Hospitals NHS Trust, London, United Kingdom;<br />
3<br />
Department of Psychology, Thames Valley University, London, United Kingdom<br />
361 RHEUMATOID ARTHRITIS IN INDIA: ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE<br />
IN RELATION TO DISEASE ACTIVITY.<br />
GS Bedi 1 , N Gupta 1 , H Pal 2 , RM Pandey 3 , R Handa 4 . 1<br />
Undergraduate Student, All India Institute of<br />
Medical Sciences, New Delhi, Delhi, India; 2 Dept. of Psychiatry, All India Institute of Medical<br />
Sciences, New Delhi, Delhi, India; 3 Dept. of Biostatistics, All India Institute of Medical Sciences,<br />
New Delhi, Delhi, India; 4 Clinical Immunology & <strong>Rheumatology</strong> Service, All India Institute of<br />
Medical Sciences, New Delhi, Delhi, India<br />
362 MUSCLE STRENGTH INDEX IS AN OBJECTIVE INDICATOR OF THE EFFECTIVENESS OF<br />
TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
NB Ursol 1 , MA Stanislavchuk 2 . 1<br />
<strong>Rheumatology</strong>, Khmelnytsky District Hospital, Khmelnytsky,<br />
Ukraine; 2 <strong>Rheumatology</strong>, National Medical University, Vinnytcia, Ukraine<br />
363 ULTRASONOGRAPHY OF THE MCP’S: AN OBJECTIVE DISEASE ACTIVITY MEASURE IN<br />
PATIENTS WITH EARLY RHEUMATOID ARTHRITIS.<br />
Z Karim, MA Quinn, PG Conaghan, RJ Wakefield, AK Brown, A Fraser, P Emery. Academic Unit of<br />
Musculoskeletal Medicine, Department of <strong>Rheumatology</strong>, Leeds General Infirmary, Leeds, West<br />
Yorkshire, United Kingdom<br />
364 FOOT INVOLVEMENT, DISEASE ACTIVITY AND DISABILITY IN RHEUMATOID ARTHRITIS.<br />
SJ Farrow, B Khoshaba, DL Scott, EHS Choy. Academic Department of <strong>Rheumatology</strong>, Guy’s,<br />
King’s College and St Thomas Hospitals School of Medicine, London, United Kingdom<br />
365 IS DAS 28 OBJECTIVE ENOUGH FOR MEASURING DISEASE ACTIVITY IN RHEUMATOID<br />
ARTHRITIS BEFORE STARTING BIOLOGICAL THERAPIES? : AN ULTRASOUND STUDY<br />
RJ Wakefield, Y Seto, KO Kong, D Loeuille, MH Buch, D Bryer, V Bejarano, AK Brown, Z Karim, P<br />
Emery. Department of <strong>Rheumatology</strong>, Academic Unit of Musculoskeletal Diseases, Leeds General<br />
Infirmary, Leeds, United Kingdom<br />
366 A COMPARATIVE STUDY OF DISEASE SEVERITY, TREATMENT MODALITIES AND<br />
DEPRESSION IN AUSTRALIAN AND BRITISH CAUCASIAN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS.<br />
CE Neville 1 , W Hassan 2 , K Gibson 1 . 1<br />
<strong>Rheumatology</strong>, Liverpool Hopsital, South West Sydney, NSW,<br />
Australia; 2 <strong>Rheumatology</strong>, University Hospitals of Leicester, Leicester, Leicestershire, United<br />
Kingdom<br />
RHEUMATOID ARTHRITIS: CARDIOVASCULAR (367 – 382)<br />
367 THE INFLUENCE OF ELEVATED CRP AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS<br />
ON CARDIOVASCULAR MORTALITY IN PATIENTS WITH INFLAMMATORY POLYARTHRITIS.<br />
NJ Goodson 1 , M Lunt 1 , D Bunn 2 , AJ Silman 1 , DPM Symmons 1 . 1<br />
ARC Epidemiology Unit,<br />
Manchester University, Manchester, United Kingdom; 2 Norfolk Arthritis Register, Norfolk and<br />
Norwich University Hospital, Norwich, United Kingdom<br />
368 CARDIOVASCULAR MORBIDITY AND MORTALITY IN AN INCEPTION COHORT OF<br />
PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
NJ Goodson 1 , M Lunt 1 , JS Marks 2 , DPM Symmons 1 . 1<br />
ARC Epidemiology Unit, University of<br />
Manchester, Manchester, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Stepping Hill Hospital,<br />
Stockport, United Kingdom<br />
73
369 COMORBIDITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGIC<br />
THERAPY - RESULTS FROM THE BSR BIOLOGICS REGISTER.<br />
K Hyrich, K Watson, D Symmons, A Silman, the BSR Biologics Register. ARC Epidemiology Unit,<br />
University of Manchester, Manchester, United Kingdom<br />
370 SMALL AND LARGE ARTERY COMPLIANCE IN RHEUMATOID ARTHRITIS.<br />
AR Clewes 1 , SA Hulme 2 , MP Lynch 1 , JK Dawson 1 . 1<br />
Department of <strong>Rheumatology</strong>, St Helens and Knowsley<br />
NHS Trust, St Helens, Merseyside, United Kingdom; 2 Department of Diabetes, Whiston Hospital, Prescot,<br />
Merseyside, United Kingdom<br />
371 DIFFERENCES IN PREDICTED CARDIOVASCULAR RISK BETWEEN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS AND THEIR SAME SEX SIBLING.<br />
N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , DJ Walker 1 , PN Platt 1 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Department of<br />
Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of<br />
Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom<br />
372 RELATIONSHIP BETWEEN DISEASE CHARACTERISTICS OF RHEUMATOID ARTHRITIS AND CAUSE<br />
OF DEATH. RESULTS FROM AN INCEPTION COHORT OF 1388 PATIENTS.<br />
G Koduri 1 , A Young 1 , M Batley 1 , E Kulinskaya 2 , S Staf<strong>for</strong>d 1 . 1<br />
On Behalf of the Early Rheumatoid Arthritis<br />
Study (ERAS), St Albans City Hospital, St Albans, Hert<strong>for</strong>dshire, United Kingdom; 2 Health Research and<br />
Development Support Unit, University of Hert<strong>for</strong>dshire, Hatfield, Hert<strong>for</strong>dshire, United Kingdom<br />
373 ACCELERATED EARLY ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS: SMOKING EFFECT ON<br />
CAROTID INTIMAL-MEDIAL THICKNESS.<br />
Y Sherer 1 , R Gerli 2 , G Vaudo 3 , G Schiallaci 3 , B Gilburd 1 , A Giordano 2 , EB Bucci 2 , R Allegruci 2 , S Marchesi 3 ,<br />
E Mannarino 3 , Y Shoenfeld 1 . 1<br />
Department of Medicine B and Center of Autoimmune Diseases, Sheba<br />
Medical Center, Tel-Hashomer, Israel; 2 Section of Internal Medicine & Oncological Sciences, Center <strong>for</strong><br />
the Study of Rheumatic Diseases, University of Perugia, Perugia, Italy; 3 Section of Internal Medicine,<br />
Angiology & Atherosclerosis Diseases, Department of Clinical & Experimental Medicine, University of<br />
Perugia, Perugia, Italy<br />
374 DIFFERENCES IN CAROTID ARTERY INTIMA MEDIA THICKNESS BETWEEN INDEX CASES WITH<br />
RHEUMATOID ARTHRITIS AND THEIR SAME SEX SIBLINGS.<br />
N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , DJ Walker 1 , PN Platt 1 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Deaprtment of Biochemistry, Royal Victoria<br />
Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of Cardiology, Freeman Hospital,<br />
Newcastle-upon-Tyne, United Kingdom<br />
375 VASCULAR ABNORMALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
YK Otkalenko 1 , MA Stanislavchuk 1 , OS Otkalenko 2 . 1<br />
<strong>Rheumatology</strong>, National Medical University, Vinnycia,<br />
Ukraine; 2 Ultrasonography, Vinnytcia District Hospital, Vinnytcia, Ukraine<br />
376 BODY MASS INDEX (BMI) AND RELEVANCE TO ASSESSMENT OF DISEASE ACTIVITY IN<br />
RHEUMATOID ARTHRITIS (RA).<br />
RA Munro 1 , R Hampson 2 , R Madhok 2 , HA Capell 2 . 1<br />
<strong>Rheumatology</strong>, Wishaw General Hospital, Lanarkshire,<br />
United Kingdom; 2 Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom<br />
377 STROKE AND RHEUMATOID ARTHRITIS: A RETROSPECTIVE, MATCHED CASE-CONTROL STUDY.<br />
PD Mudd 1 , RW Heycock 1 , J Hamilton 2 , CA Kelly 2 , DH Barer 1 . 1<br />
Stroke Research Unit, Queen Elizabeth<br />
Hospital, Gateshead, Tyne and Wear, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Queen Elizabeth<br />
Hospital, Gateshead, Tyne and Wear, United Kingdom<br />
74
378 A PILOT STUDY IN THE USE OF THE ROSE ANGINA QUESTIONNAIRE IN THE ASSESSMENT<br />
OF ISCHAEMIC HEART DISEASE IN THE RHEUMATOID PATIENT.<br />
N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , PN Platt 1 , DJ Walker 1 . 1<br />
Department of<br />
<strong>Rheumatology</strong>, Musculoskeletal Unit, Freeman Hospital, High Heaton, Newcastle-upon-Tyne,<br />
United Kingdom; 2 Department of Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne,<br />
United Kingdom; 3 Department of Cardiology, Freeman Hospital, High Heaton,<br />
Newcastle-upon-Tyne, United Kingdom<br />
379 HEALTH SCREENING INTERVENTIONS ARE PARTIALLY SUCCESSFUL IN REDUCING<br />
CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
AM Meadows, NJ Sheehan. Department of <strong>Rheumatology</strong>, Edith Cavell Hospital, Peterborough,<br />
Cambridgeshire, United Kingdom<br />
380 PULMONARY ARTERY PRESSURES MEASURED WITH DOPPLER ECHOCARDIOGRAPHY IN<br />
RHEUMATOID ARTHRITIS PATIENTS OVER A FIVE YEAR PERIOD.<br />
AR Clewes 1 , A Burkart 2 , LM Crolla 2 , MP Lynch 1 , JK Dawson 1 . 1<br />
Department of <strong>Rheumatology</strong>,<br />
St Helens and Knowsley NHS Trust, St Helens, Merseyside, United Kingdom; 2 Cardiorespiratory<br />
Department, Whiston Hospital, Prescot, Merseyside, United Kingdom<br />
381 A HIGH PREVALENCE OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN A<br />
RHEUMATOID POPULATION.<br />
GS Bhatia 1 , MD Sosin 1 , KA Grindulis 2 , FH Khattak 2 , GY Lip 1 , RC Davis 1 . 1<br />
University Department of<br />
Medicine & Department of Cardiology, University of Birmingham and Sandwell & West<br />
Birmingham Hospitals NHS Trust, Birmingham, United Kingdom; 2 Department of <strong>Rheumatology</strong>,<br />
Sandwell Hospital, Sandwell & West Birmingham Hospitals NHS Trust, West Bromwich, West<br />
Midlands, United Kingdom<br />
382 THE EFFECTS OF PSYCHOLOGICAL AND POSTURAL STRESS ON CARDIOVASCULAR AND<br />
INFLAMMATORY ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
JJCS Veldhuijzen van Zanten 1,3 , C Ring 1 , D Carroll 1 , GD Kitas 2,3 . 1<br />
School of Sport and Exercise<br />
Sciences, University of Birmingham, Birmingham, United Kingdom; 2 School of Medicine, University<br />
of Birmingham, Birmingham, United Kingdom; 3 Department of <strong>Rheumatology</strong>, Dudley Group of<br />
Hospitals NHS Trust, Dudley, United Kingdom<br />
RHEUMATOID ARTHRITIS: MANAGEMENT (383 – 386)<br />
383 THE VALUE OF ANTI-CCP ASSAYS IN AN OUTPATIENT RHEUMATOLOGY CLINIC.<br />
R Ramachandran 1 , A Farrell 2 , M Thomas 2 , R Madhok 1 , HA Capell 1 . 1<br />
Centre <strong>for</strong> Rheumatic Diseases,<br />
Royal Infirmary, Glasgow, United Kingdom; 2 Department of Clinical Immunology, Western<br />
Infirmary, Glasgow, United Kingdom<br />
384 PATIENT-INITIATED REVIEWS AND PHYSICIAN-INITIATED REVIEWS IN RA:<br />
HOW APPROPRIATE ARE THEY?<br />
M Hehir 1 , S Hewlett 1 , J Kirwan 1 , K Mitchell 1 , J Pollock 2 , D Memel 3 , PS Blair 4 . 1<br />
Academic<br />
<strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom; 2 Dept Health and Social Care,<br />
University of the West of England, Bristol, United Kingdom; 3 Air Balloon Surgery, Bristol, United<br />
Kingdom; 4 Div Child Health, University of Bristol, Bristol, United Kingdom<br />
385 AGGRESSIVE TREATMENT OF RHEUMATOID ARTHRITIS FOR THE BUSY CLINICIAN.<br />
TC Barnes, V Gupta, EJ Tunn, RC Bucknall, KW Nelson. <strong>Rheumatology</strong>, Royal Liverpool University<br />
Hospital, Liverpool, United Kingdom<br />
386 CHANGES IN DEMOGRAPHIC AND DISEASE PATTERNS AMONG PATIENTS WITH<br />
RHEUMATOID ARTHRITIS ENTERING LARGE CLINICAL TRIALS OVER A 20 YEAR PERIOD.<br />
R Ramachandran, E Garrity, R Madhok, HA Capell. Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary,<br />
Glasgow, United Kingdom<br />
75
BHPR (387 – 437)<br />
387 A LIFESTYLE MANAGEMENT FOR ARTHRITIS PROGRAMME: SHORT-TERM OUTCOMES<br />
FOR PEOPLE WITH INFLAMMATORY ARTHRITIS.<br />
A Hammond, J Bryan, A Hardy. <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, Derbyshire,<br />
United Kingdom<br />
388 THE IMPACT OF OSTEOARTHRITIS ON PERSONAL RELATIONSHIPS AND SEXUAL ACTIVITY.<br />
J Hill, N Reay. Academic and Clinical Unit Musculoskeletal Nursing, Academic Unit of Musculoskeletal<br />
Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom<br />
389 RELATIONSHIP BETWEEN CAUSAL BELIEFS OF KNEE OSTEOARTHRITIS AND PAIN, FUNCTION,<br />
MOOD AND SELF-EFFICACY.<br />
HL Mitchell 1 , JA Weinman 2 , NE Walsh 1 , MV Hurley 1 . 1<br />
Rehabilitation Research Unit, GKT School of<br />
Medicine and Dentistry, London, United Kingdom; 2 Department of Psychological Medicine, GKT School<br />
of Medicine and Dentistry, London, United Kingdom<br />
390 RHEUMATOLOGY TELEPHONE HELPLINES: PATIENT AND HEALTH PROFESSIONAL<br />
REQUIREMENTS.<br />
SJ Brown 1 , CS McCabe 1 , S Hewlett 2 , JA McDowell 3 , J Cushnaghan 4 , AM Breslin 5 , S Staf<strong>for</strong>d 6 , CR<br />
Carmichael 7 . 1<br />
RACE, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath BA1 1RL, United Kingdom;<br />
2<br />
University of Bristol, Bristol, United Kingdom; 3 Here<strong>for</strong>d Hospitals NHS Trust, Here<strong>for</strong>d, United Kingdom;<br />
4<br />
Lymington Hospital, Lymington, United Kingdom; 5 Ysbyty Gwynedd, Bangor, United Kingdom; 6 <strong>The</strong><br />
Royal Hampshire County Hospital, Winchester, United Kingdom; 7 Research and Development Support<br />
Unit, Royal United Hospital, Bath, United Kingdom<br />
391 BELIEFS ABOUT CAUSES OF RHEUMATOID ARTHRITIS(RA) OF PATIENTS AND THEIR SPOUSES.<br />
M Carr 1 , R Hughes 1 , A Carr 2 , M Hankins 3 , C Thwaites 1 , J Weinman 3 . 1<br />
<strong>Rheumatology</strong>, St Peters Hospital,<br />
Chertsey, United Kingdom; 2 <strong>Rheumatology</strong>, Nottingham University, Nottingham, United Kingdom;<br />
3<br />
Psychology, GKT School of Medicine, London, United Kingdom<br />
392 OFF-THE-SHELF CONTOURED ORTHOSES DEMONSTRATE COMPARABLE MECHANICAL<br />
PROPERTIES TO CUSTOM-MADE FOOT ORTHOSES AT LESS COST.<br />
AC Redmond 1 , KB Landorf 2 , A-M Keenan 1 , P Emery 1 . 1<br />
Academic Unit of Musculoskeletal Disease,<br />
University of Leeds, Leeds, W. Yorks, United Kingdom; 2 School of Exercise and Health Sciences,<br />
University of Western Sydney, Sydney, NSW, Australia<br />
393 PATIENT-INITIATED REVIEW: SPECIFIC HELPLINE SUPPORT IS REQUIRED.<br />
K Mitchell 1 , S Hewlett 1 , J Kirwan 1 , M Hehir 1 , D Memel 2 , PS Blair 3 , S Tipler 1 , J Haynes 4 , J Pollock 5 .<br />
1<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom; 2 Air Balloon Surgery, Bristol,<br />
United Kingdom; 3 Division of Child Health, University of Bristol, Bristol, United Kingdom; 4 <strong>Rheumatology</strong><br />
Dept, Southmead Hospital, Bristol, United Kingdom; 5 Dept Health and Social Care, University of the<br />
West of England, Bristol, United Kingdom<br />
394 INTERIM RESULTS OF A RANDOMISED PLACEBO-CONTROLLED TRIAL OF PHYSIOTHERAPY<br />
TREATMENT FOR ROTATOR CUFF TENDINOPATHIES.<br />
JT Wies 1 , M Latham 2 , T Viljoen 2 , BL Hazleman 1 , CA Speed 1 . 1<br />
<strong>Rheumatology</strong> Research Unit, Addenbrookes<br />
NHS Trust, Cambridge, Cambridgeshire, United Kingdom; 2 Oupatients Physiotherapy Department,<br />
Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom<br />
395 A STANDARDISED PHYSIOTHERAPY REGIME VERSUS SOFT TISSUE MANIPULATION IN FROZEN<br />
SHOULDER: A RANDOMISED CONTROLLED PILOT STUDY.<br />
JT Wies 1 , M Latham 2 , T Viljoen 2 , H Humphreys 2 , BL Hazleman 1 , CA Speed 1 . 1<br />
<strong>Rheumatology</strong> Research Unit<br />
- E6, Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom; 2 Outpatient Physiotherapy<br />
Department, Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom<br />
76
396 WHAT’S IT LIKE TO HAVE RHEUMATOID ARTHRITIS? RESEARCHING AN<br />
EDUCATIONAL WEBSITE.<br />
JC Carter, DR Blake. Research and Clinical Effectiveness, Royal National Hospital <strong>for</strong> Rheumatic<br />
Diseases, Bath, Somerset, United Kingdom<br />
397 UPPER LIMB SENSORIMOTOR DYSFUNCTION AND FUNCTIONAL PERFORMANCE IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS.<br />
LM Bearne, AF Coomer, MV Hurley. Physiotherapy Division, Guys, Kings & St Thomas’s School of<br />
Biomedical Sciences, Kings College London, London, SE1 1UL, United Kingdom<br />
398 PATIENTS’ PERSPECTIVE OF QUALITY OF LIFE FOLLOWING COMMENCEMENT OF NEW<br />
BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS.<br />
NJ Marshall. Musculoskeletal Department, Newcastle upon Tyne Hospitals NHS Trust, Newcastle<br />
upon Tyne, Tyne & Wear, United Kingdom<br />
399 A STUDY TO EXPLORE THE INFLUENCES WHICH DRIVE CLINICAL DECISION MAKING<br />
AMONGST RHEUMATOLOGY NURSES.<br />
DJ Bryer. Regional <strong>Rheumatology</strong> Centre, Leeds Teaching Hospitals NHS Trust, Leeds, West<br />
Yorkshire, United Kingdom<br />
400 PROPRIOCEPTIVE ACUITY OF THE LUMBAR SPINE IN LOW BACK PAIN AND NON-LOW<br />
BACK PAIN SUBJECTS.<br />
DR Phillips 1 , MV Hurley 2 , CA Davey 1 , MA Mullee 3 . 1<br />
School of Health Professions & Rehabilitation<br />
Sciences, University of Southampton, Southampton, United Kingdom; 2 Rehabilitation Research<br />
Unit, King’s College London, London, United Kingdom; 3 Medical Statistics Group, University of<br />
Southampton, Southampton, United Kingdom<br />
401 THE USE OF QUANTITATIVE ULTRASOUND TO DIAGNOSE OSTEOPOROSIS IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS.<br />
JR Cryer 1 , SJ Otter 2 , CJ Bowen 3 . 1<br />
Podiatry, Eastbourne Downs PCT, Eastbourne, East Sussex, United<br />
Kingdom; 2 Health Professions, University of Brighton, Eastbourne, East Sussex, United Kingdom;<br />
3<br />
Heath Professions & Rehabilitation Science, University of Southampton, Southampton, Hampshire,<br />
United Kingdom<br />
402 FOOT PROBLEMS IN PAGETS DISEASE.<br />
AE Williams 1,2 , TW ONeill 2 , S Mercer 2 , CJ Nester 3 . 1<br />
Directorate of Podiatry, University of Sal<strong>for</strong>d,<br />
Sal<strong>for</strong>d, Manchester, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Sal<strong>for</strong>d Royal Hospitals NHS<br />
Trust, Sal<strong>for</strong>d, Manchester, United Kingdom; 3 Centre <strong>for</strong> Rehabilitation and Human Per<strong>for</strong>mance<br />
Research, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d, Manchester, United Kingdom<br />
403 UPPER LIMB FUNCTIONAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS.<br />
J Adams 1 , A Hammond 2 , J Burridge 1 , C Cooper 3 . 1<br />
School of Health Professions and Rehabilitation<br />
Sciences, University of Southampton, Southampton, Hants. SO17 1BJ, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Derby Royal Infirmary, Derby, Derbyshire, United Kingdom; 3 Medical Research<br />
Council, University of Southampton NHS Trust, Southampton, Hants, United Kingdom<br />
404 DOES FLATFOOT DEVELOP DURING PREGNANCY? A PROSPECTIVE STUDY.<br />
AA Ginawi, NST Gendi, AR Haloob. 1 <strong>Rheumatology</strong>, Basildon & Thurrock University Hospitals NHS<br />
Trust, Basildon, Essex, United Kingdom; 2 <strong>Rheumatology</strong>, Basildon & Thurrock University Hospitals<br />
NHS Trust, Basildon, Essex, United Kingdom; 3 Obstetrics & Gynaecology, Basildon & Thurrock<br />
University Hospitals NHS Trust, Basildon, Essex, United Kingdom<br />
405 THE IMPACT OF HAND OSTEOARTHRITIS ON THE INDIVIDUAL.<br />
S Hill, BN Ong, PY Choi, KS Dziedzic. Primary Care Sciences Research Centre, Keele University,<br />
Keele, Staf<strong>for</strong>dshire, United Kingdom<br />
77
406 PHYSIOTHERAPISTS’ PERCEIVED PREDICTORS OF OUTCOME IN NECK PAIN.<br />
J Hill 1 , M Lewis 1 , KS Dziedzic 1 , J Sim 1 , EM Hay 1,2 . 1<br />
Primary Care Sciences Research Centre, Keele University,<br />
Keele, Newcastle, Staffs, United Kingdom; 2 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Haywood Hospital,<br />
Stoke-on-Trent, Staffs, United Kingdom<br />
407 A STUDY TO INVESTIGATE FACTORS THAT MAY BE ASSOCIATED WITH PATIENTS’ DECISIONS<br />
ABOUT STARTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS.<br />
SJ Skingle. Department of <strong>Rheumatology</strong>, Addenbrookes NHS Hospital Trust, Cambridge,<br />
United Kingdom<br />
408 OSTEO-ARTHRITIS, IDENTITY AND COPING; AN INTERPRETATIVE PHENOMENOLOGICAL<br />
APPROACH.<br />
A Mandeville 1 , K Mulligan 1 , J Smith 2 , M Shipley 3 , S Newman 1 . 1<br />
Unit of Health Psychology, Centre <strong>for</strong><br />
Behavioural and Social Sciences in Medicine, University College London, London, United Kingdom;<br />
2<br />
School of Psychology, Birkbeck College, University of London, London, United Kingdom; 3 Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, University College London Hospitals, London, United Kingdom<br />
409 THE PREVALENCE OF DEPRESSION IN RA AND ITS RELATIONSHIP TO DISABILITY,<br />
PAIN AND FATIGUE.<br />
PS Heslop 1 , CS Chandler 2 , DJ Walker 1 . 1<br />
Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne,<br />
United Kingdom; 2 School of Health, Community & Education Studies, University of Northumbria,<br />
Newcastle-upon-Tyne, United Kingdom<br />
410 THE DEVELOPMENT OF A HAND ASSESSMENT FOR CLINICAL RESEARCH: A CONSENSUS STUDY<br />
USING A MODIFIED DELPHI APPROACH.<br />
HL Myers 1 , KS Dziedzic 1 , E Thomas 1 , EM Hay 1,2 , PR Croft 1 . 1<br />
Primary Care Sciences Research Centre, Keele<br />
University, Keele, Staffs, United Kingdom; 2 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Haywood Hospital,<br />
Stoke-on-Trent, Staffs, United Kingdom<br />
411 A SURVEY OF PRACTICE IN NURSE LED RHEUMATOID ARTHRITIS CLINICS.<br />
S Ryan 1 , J Hill 2 . 1<br />
Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, <strong>The</strong> Haywood Hospital, Burslem, Stoke on Trent,<br />
ST6 7AG, United Kingdom; 2 ACUMeN, Academic Unit of Musculoskeletal Disease, Chapel Allerton<br />
Hospital, Leeds, LS7 4SA, United Kingdom<br />
412 DOES MENSTRUAL CYCLE PHASE INFLUENCE DAS 28 SCORES?<br />
RP Brett. <strong>Rheumatology</strong>, Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom<br />
413 WHAT CONSTITUTES USUAL PHYSIOTHERAPY TREATMENT FOR PAINFUL SHOULDER,<br />
AND WHAT FACTORS INFLUENCE THIS?<br />
AC Ryall. MRC Environmental Epidemiology Unit, University of Southampton, Southampton, Hampshire,<br />
United Kingdom<br />
414 THE EXTENT AND NATURE OF OUTPATIENT REFERRALS TO OCCUPATIONAL THERAPY<br />
AND PHYSIOTHERAPY IN EARLY RHEUMATOID ARTHRITIS.<br />
JS Lewis 1 , F Tonepohl 1 , LC Cory 1 , C Carmichael 1 , J McCaulder-Ojeda 1 , TR Jenkinson 1,2 . 1 <strong>Rheumatology</strong>,<br />
<strong>The</strong> Royal National Hospital For Rheumatic Diseases, Bath, Somerset, United Kingdom; 2 Sports and<br />
Exercise Sciences, University of Bath, Bath, Somerset, United Kingdom<br />
415 IMPACT OF USING PATIENT PARTNERS TO TEACH JOINT EXAMINATION TO NURSE<br />
PRACTITIONER STUDENTS.<br />
JM Mooney. School of Nursing, University of East Anglia, Norwich, United Kingdom<br />
416 AUDIT OF THE EFFECT ON PAIN SCORES OF INTRA-ARTICULAR HYALGAN INJECTION IN<br />
PATIENTS WITH OSTEOARTHRITIS OF THE KNEE IN A NURSE-LED CLINIC.<br />
DM Johnson. Department of <strong>Rheumatology</strong>, St Georges Hospital, Tooting, London SW17 0QT,<br />
United Kingdom<br />
78
417 A DEVELOPING ROLE WITHIN RHEUMATOLOGY NURSING.<br />
C Thwaites 1 , S Ryan 2 , A Hassell 2 . 1<br />
Department of Nursing and Midwifery, Keele University, Keele,<br />
Staffs, United Kingdom; 2 Department of <strong>Rheumatology</strong>, University Hospital of North Staf<strong>for</strong>dshire<br />
NHS Trust, Stoke-on-Trent, Staffs, United Kingdom<br />
418 A REVIEW OF A CONSULTANT PHYSIOTHERAPIST’S FIRST YEAR IN POST.<br />
K Stevenson. 1 Physiotherapy Department, University Hospital of North Staf<strong>for</strong>dshire, Stoke on<br />
Trent, Staf<strong>for</strong>dshire, United Kingdom; 2 Department of Physiotherapy Studies, Keele University,<br />
Stoke on Trent, Staf<strong>for</strong>dshire, United Kingdom<br />
419 THE IMPORTANCE OF CERVICAL SCREENING PRIOR TO ANTI TNF THERAPY.<br />
B Rhys-Dillon, C Rhys-Dillon. Dept of <strong>Rheumatology</strong>, University Hospital of Wales, Cardiff, Wales,<br />
United Kingdom<br />
420 CAN AN ADVANCED NURSE PRACTITIONER APPROPRIATELY MANAGE PATIENTS WITH<br />
EARLY RHEUMATOID ARTHRITIS USING AN INTEGRATED CARE PATHWAY?<br />
AE Campbell 1 , C Estrach 2 , MP Lynch 1 , VE Abernethy 1 . 1<br />
<strong>Rheumatology</strong> Department, St Helens and<br />
Knowsley NHS Trust, St Helens, Merseyside, United Kingdom; 2 <strong>Rheumatology</strong> Department,<br />
Countess of Chester Hospital, Chester, United Kingdom<br />
421 ANTI-TNF-α THERAPY PRESCRIBING IN BERKSHIRE - ARE WE COMPLIANT WITH NICE<br />
GUIDELINES?<br />
M Magliano 1 , G Ramroop 1 , R Holtom 2 , A Steuer 1 , J McNally 2 . 1<br />
<strong>Rheumatology</strong>, Wexham Park<br />
Hospital, Slough, Berkshire, United Kingdom; 2 <strong>Rheumatology</strong>, Wexham Park Hospital, Slough,<br />
Berkshire, United Kingdom<br />
422 AUDIT OF A MULTI-DISCIPLINARY JOINT INJECTION RHEUMATOLOGY SERVICE.<br />
J Novak, AE Griffiths, AE Campbell, VE Abernethy, JK Dawson. <strong>Rheumatology</strong>, St Helens &<br />
Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom<br />
423 THE DEVELOPMENT OF A USER LED CLINICAL SERVICE FOR NEWLY DIAGNOSED<br />
RHEUMATOID ARTHRITIS PATIENTS - AN ACTION RESERCH STUDY.<br />
MA Cox. <strong>Rheumatology</strong> Department, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom<br />
424 METHOTREXATE MONITORING IS IMPORTANT BUT PATIENT EMPOWERMENT<br />
IS SUB-OPTIMAL.<br />
MS Lillicrap, C Ellis. Department of <strong>Rheumatology</strong>, Norfolk and Norwich University Hospital,<br />
Norwich, United Kingdom<br />
425 EXPEDITED REVIEW APPOINTMENTS IN A RHEUMATOLOGY OUTPATIENT (OP)<br />
DEPARTMENT.<br />
R Shaban, A Wood, KR Mackay, FC McCrae, AL Thomas, RG Hull, JM Ledingham. <strong>Rheumatology</strong><br />
Department, Queen Alexandra Hospital, Portsmouth, Hants, United Kingdom<br />
426 TO OPERATE OR NOT TO OPERATE. CAN AN INTERVENTION BY THE HAND<br />
OCCUPATIONAL THERAPIST (OT) PREVENT THE NEED FOR HAND SURGERY?<br />
SE Bradley 1 , P Cornell 2 . 1<br />
Occupational <strong>The</strong>rapy, Hand Unit, Poole Hospital NHS Trust,<br />
Poole, Dorset, United Kingdom; 2 <strong>Rheumatology</strong>, Poole Hospital NHS Trust, Poole, Dorset,<br />
United Kingdom<br />
427 AN INVESTIGATION OF THE PRESCRIBING TRENDS OF NON-STEROIDAL<br />
ANTI-INFLAMMATORY DRUGS IN AN ELDERLY POPULATION : IN A HOSPITAL AND<br />
PRIMARY CARE SETTING.<br />
ES Koshy 1 , G Coakley 2 . 1<br />
General Practice / Primary Care, <strong>The</strong> Fairfield Centre, London, United<br />
Kingdom; 2 <strong>Rheumatology</strong>, Queen Elizabeth Hospital, London, United Kingdom<br />
79
428 EVALUATION OF AN IN-PATIENT JOINT PROTECTION EDUCATION PROGRAMME.<br />
Y Mooney, C Carroll, S Haughey, O McAlinden, D Rowe. Occupational <strong>The</strong>rapy Dept, <strong>Rheumatology</strong><br />
Rehabilitation, Our Lady’s Hospice, Dublin 6W, Ireland<br />
429 EFFECTIVENESS OF A LOAN-AND-PURCHASE SERVICE.<br />
AE Griffiths, AM Clayton, VE Abernethy, MP Lynch, I Spencer, JK Dawson. <strong>Rheumatology</strong>,<br />
St Helens & Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom<br />
430 RHEUMATOLOGY HELPLINE.<br />
SA Gibson, EW Spark, BB Wood. <strong>Rheumatology</strong>, Wirral Hospital NHS Trust, Wirral, Merseyside,<br />
United Kingdom<br />
431 NURSE PRESCRIBING IN RHEUMATOLOGY PRACTICE.<br />
EW Spark, BB Wood, SL Hennell, E George. <strong>Rheumatology</strong>, Wirral Hospital NHS Trust, Wirral,<br />
Merseyside, United Kingdom<br />
432 USER SATISFACTION WITH HOSPITAL LED RHEUMATOLOGY MONITORING SERVICE.<br />
R Wiswell, TA O’Rourke, C Brownsell, VE Abernethy, MP Lynch, JK Dawson. <strong>Rheumatology</strong> Unit,<br />
St Helens & Knowsley NHS Trust, St Helens, Merseyside, United Kingdom<br />
433 AGE DIVIDE IN THE UPTAKE OF PNEUMOVAX AND INFLUENZA (‘FLU) VACCINATION AMONGST<br />
RHEUMATOLOGY PATIENTS TAKING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs).<br />
S Shenton, A Wood, F McCrae, K MacKay, A Thomas, R Hull, R Shaban, J Ledingham. <strong>Rheumatology</strong><br />
Department, Queen Alexandra Hospital, Portsmouth, Hants, United Kingdom<br />
434 MANAGEMENT OF CHRONIC FATIGUE SYNDROME IN MULTIDISCIPLINARY GROUP SETTING.<br />
RB Belgamwar 1 , MS Jorsh 1 , A Marpole 1 , H Snowden 1 , E Mayall 1 , J Packham 2 , P Dawes 2 . 1 Department of<br />
Liaison Psychiatry, North Staf<strong>for</strong>dshire Combined Health Care NHS Trust, Stoke-on-Trent, Staf<strong>for</strong>dshire,<br />
United Kingdom; 2 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, <strong>The</strong> Haywood Hospital, University Hospital of<br />
North Staf<strong>for</strong>dshire NHS Trust, Stoke on Trent, Staf<strong>for</strong>dshire, United Kingdom<br />
435 AN AUDIT OF THE PROVISION AND EFFICACY OF DISEASE MODIFYING ANTI-RHEUMATIC<br />
DRUG INFORMATION LEAFLETS FOR PATIENTS WITH INFLAMMATORY ARTHRITIS.<br />
CA Adams, LP Robertson. <strong>Rheumatology</strong> Unit, Bristol Royal Infirmary, Bristol, Avon, United Kingdom<br />
436 THE DEVELOPMENT AND EVALUATION OF A NURSE-LED BIOLOGICS REVIEW CLINIC.<br />
GM Grundy 1 , L Brinkley 1 , J Lamb 1 , M Lawrence 1 , E Solomon 1 , RN Thompson 1 , VE Abernethy 2 , RJ Moots 1 .<br />
1<br />
Academic <strong>Rheumatology</strong> Dept, University Hospital Aintree, Liverpool, l9 7AL, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, St Helens NHS Trust, St Helens, Merseyside, United Kingdom<br />
437 MULTI-DISCIPLINARY ANKYLOSING SPONDYLITIS SERVICE.<br />
AE Griffiths, J Novak, AE Campbell, JK Dawson, VE Abernethy. <strong>Rheumatology</strong>, St Helens & Knowsley<br />
Hospitals NHS Trust, St Helens, Merseyside, United Kingdom<br />
80
Abstract Reviewers<br />
<strong>The</strong> BSR Heberden Committee was expanded substantially <strong>for</strong> the purposes of abstract<br />
assessment to ensure that every abstract was peer reviewed, blind, by at least 4 reviewers.<br />
<strong>The</strong> Heberden Committee is extremely grateful <strong>for</strong> the assistance of everyone that gave up<br />
their time to review abstracts, and acknowledges them accordingly:<br />
Dr David Abraham<br />
Dr Rod Amos<br />
Dr Rupa Bessant, Heberden Committee<br />
Dr Fraser Birrell<br />
Dr Simon Bowman, Heberden Committee<br />
Dr Paul Bowness, Heberden Committee<br />
Dr John Brockbank<br />
Dr Marwan Bukhari, Heberden Committee<br />
Dr Hilary Capell<br />
Dr Jiri Chard<br />
Prof Yuti Chernajovsky, Heberden Committee<br />
Dr Ernest Choy<br />
Dr Ian Clark<br />
Dr Gavin Clunie<br />
Dr David Collins, Heberden Committee<br />
Dr Andrew Cope<br />
Dr Paul Creamer<br />
Dr Peter Croft<br />
Dr David D’Cruz<br />
Dr Chris Deighton<br />
Dr John Delamere<br />
Prof Michael Doherty<br />
Dr Victor Duance<br />
Dr Krysia Dziedzic, Heberden Committee<br />
Prof Brian Foxwell<br />
Prof Simon Frostick<br />
Prof Hill Gaston, Heberden Committee<br />
Dr Nicola Goodson<br />
Dr Caroline Gordon<br />
Dr Ian Griffiths<br />
Dr Alan Hakim<br />
Dr Frances Hall<br />
Dr John Halsey<br />
Dr Alison Hammond<br />
Dr Andy Hassell<br />
Prof Elaine Hay<br />
Dr Ariane Herrick<br />
Dr Rod Hughes, Heberden Committee<br />
Dr Mike Hurley<br />
Dr Charles Hutton<br />
Dr Ali Jawad<br />
Dr David Jayne<br />
Dr Adrian Jones, Heberden Committee<br />
Dr Andrew Keat<br />
Dr George Kitas, Heberden Committee<br />
Dr Maria Koutanji<br />
Dr Alison Leak, Heberden Committee<br />
Dr Mark Lillicrap<br />
Dr Raashid Luqmani<br />
Prof Peter Maddison, Heberden Committee<br />
Dr Rajan Madhok<br />
Dr Rizgar Mageed<br />
Dr Justin Mason<br />
Mrs Candy McCabe<br />
Dr Michael McDermott<br />
Dr Julie McHale<br />
Prof Iain McInnes<br />
Prof Robert Moots, Heberden Committee<br />
Dr Donncha O’Gradaigh<br />
Dr Elizabeth Price<br />
Dr John Raphael<br />
Dr Shirley Rigby<br />
Dr Graham Riley<br />
Dr Clive Ryder<br />
Dr Deva Situnayake<br />
Dr Manouche Tavakoli<br />
Dr Jon Tobias, Heberden Committee<br />
Mr Gareth Treharne<br />
Dr Richard Watts, Heberden Committee<br />
Dr Lucy Wedderburn<br />
Dr Andy Whallet<br />
Dr Amanda Williams<br />
Prof Bryan Williams<br />
Dr Adam Young<br />
Dr Steven Young<br />
81
Exhibition Floor Plan<br />
82
List of 2004 Exhibitors<br />
Stand Company<br />
1 LCA SA<br />
2 Eli Lilly<br />
3 Otsuka Pharmaceuticals (UK) Ltd<br />
4,5 Genzyme<br />
6 Janssen-Cilag<br />
7 Actelion<br />
8,9,10,11 Schering Plough<br />
12 Wyeth<br />
13,14,15,16 MSD (Vioxx & Fosamax)<br />
17 Q Med<br />
18 Dimethaid International<br />
20 BSR<br />
21 ARMA<br />
22 <strong>British</strong> Sjogrens Syndrome Association<br />
23 Arthritis Care<br />
24 Aventis/Alliance <strong>for</strong> Better Bone<br />
25 Abbott<br />
26 Surgicraft<br />
27 Lanmark<br />
28 Syner-Med<br />
Stand Company<br />
29 BHPR<br />
30 RCN<br />
31 Pfizer<br />
32 Novartis<br />
33 MSD (Arcoxia)<br />
34 4S Dawn Clinical Software<br />
35 Dynamic Imaging<br />
36 TRB Chemedica<br />
37 Rainy Day Software<br />
38 NRAS<br />
39 ERAN<br />
40 Scleroderma <strong>Society</strong><br />
41 Raynauds & Scleroderma Association<br />
42 Kyphon Europe<br />
43 Vertec Scientific<br />
44 OUP<br />
45 Wisepress<br />
46 arc<br />
47 NASS<br />
83
Exhibitor Product Listings<br />
4S Dawn Clinical Software<br />
Some key problems with monitoring DMARD therapy are:<br />
• Time consumed in monitoring of laboratory test results, which must be carried out in an exacting manner<br />
• Not <strong>for</strong>getting to follow up on actions decided <strong>for</strong> the patient<br />
• Auditing therapy management<br />
Dawn DMARD software overcomes this by:<br />
• Rigorously monitoring test results automatically<br />
• Produces electronic alerts<br />
• Providing an auditing/report writing facility<br />
Abbott<br />
HUMIRA ®▼ (adalimumab – Abbott Laboratories Ltd) is a fully human monoclonal antibody, indicated <strong>for</strong> the treatment of<br />
moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs including<br />
methotrexate has been inadequate. HUMIRA ®▼ can be given in combination with MTX or as monotherapy in case of<br />
intolerance to MTX or when continued treatment with MTX is inappropriate.<br />
Actelion<br />
Tracleer the first dual Endothelin receptor antagonist, a significant advance in the treatment of Pulmonary Arterial<br />
Hypertension (PAH) related to connective tissue disease.<br />
• Tracleer is the only licensed treatment <strong>for</strong> Scleroderma patients with PAH<br />
• Tracleer significantly improves exercise capacity<br />
• Tracleer significantly decreases the rate of clinical worsening<br />
• Tracleer has a convenient b.d. dosage.<br />
For further in<strong>for</strong>mation call 0845-0750555. Reference: Tracleer SmPC June 2003<br />
arc<br />
<strong>The</strong> Arthritis Research Campaign (a r c) is the fourth-largest medical research charity in the UK with an annual income in 2002-3<br />
of £23.5 million. a r c funds research into all <strong>for</strong>ms of arthritis and related conditions, and also provides in<strong>for</strong>mation to the public<br />
(including more than 80 patient booklets) and health professionals. a r c also funds a variety of fellowships and bursaries.<br />
ARMA<br />
<strong>The</strong> Arthritis and Musculoskeletal Alliance (ARMA) is the UK umbrella organisation bringing together 27 members including<br />
support groups, research organisations and medical/ non-medical professionals’ societies. Visit our stand to pick up<br />
in<strong>for</strong>mation on our Member organisations and find out about our consultation on Standards of Care <strong>for</strong> people with MSCs.<br />
Rheumatologists have been closely involved in this project and we want to hear your views on the standards.<br />
Arthritis Care<br />
Arthritis Care is the UK’s largest voluntary organisation <strong>for</strong> people with all types of arthritis. Our aim is to empower<br />
people to take control of their arthritis, their organisation and their lives. We offer a range of services including helplines,<br />
publications, self-management and hotels. We also campaign to ensure the voice of people with arthritis is heard at both a<br />
national and local level.<br />
Aventis/Alliance <strong>for</strong> Better Bone<br />
Actonel ® (risedronate sodium), a bisphosphonate produced by <strong>The</strong> Alliance For Better Bone Health (Procter and Gamble<br />
/ Aventis). <strong>The</strong> Alliance is committed to the timely identification and treatment of postmenopausal<br />
osteoporosis.<br />
Arava ® (leflunomide) produced by Aventis<br />
A disease-modifying antirheumatic drug (DMARD) that represents a significant advance in the treatment of adult patients with<br />
active rheumatoid arthritis.<br />
84
BHPR<br />
<strong>The</strong> BHPR was <strong>for</strong>med in 1985 to bring together health professionals whose major interests lay in the management<br />
of people with rheumatic diseases. <strong>The</strong> aim of the BHPR is to encourage a multi-disciplinary approach to the<br />
management of people with rheumatic diseases. To provide a <strong>for</strong>um through which health professionals can<br />
exchange knowledge, skills and experience. To generate greater awareness of the contribution of health professionals<br />
<strong>British</strong> Sjögren's Syndrome Association<br />
<strong>The</strong> <strong>British</strong> Sjögren's Syndrome Association is a registered charity and self help organisation dedicated to providing<br />
mutual support and in<strong>for</strong>mation to individuals affected by Sjögren's Syndrome - the second most common<br />
auto-immune disease after Rheumatoid arthritis. We aim to educate patients, GPs, dentists and other medical<br />
professionals about the condition, raise awareness surrounding its existence and symptoms and support research<br />
into its cause and treatment.<br />
BSR<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> (BSR) is a professional medical society with 1,400 members. We are committed<br />
to advancing knowledge and practice in the field of rheumatology. Visit the BSR stand to find out more about the<br />
society's work in promoting arthritis and musculoskeletal conditions as a health priority and pick up other useful<br />
n<strong>for</strong>mation including copies of BSR's new draft clinical guidelines.<br />
Dimethaid International<br />
Dimethaid produces and Acer Medical markets Pennsaid ® , a new topical solution of diclofenac <strong>for</strong>mulated with<br />
DMSO, a well recognised enhancer of dermal penetration. Pennsaid ® is approved <strong>for</strong> the treatment of osteoarthritis in<br />
superficial joints including the knee. For more in<strong>for</strong>mation on Pennsaid ® or the randomised, controlled clinical studies<br />
in osteoarthritis of the knee in which Pennsaid ® has been compared with vehicle/placebo and oral diclofenac, please<br />
visit the Pennsaid ® stand.<br />
Dynamic Imaging<br />
High frequency musculoskeletal ultrasound has become an established imaging technique <strong>for</strong> diagnosis and follow up<br />
of patients with rheumatic diseases. In addition to assessing soft tissue pathology, fluid and cartilage, bone surfaces<br />
can be visualised and guided aspiration, biopsy, and injections can be carried out. Dynamic assessments of joint and<br />
tendon movements can also aid the detection of structural abnormalities.<br />
Eli Lilly<br />
Lilly – Over 125 years of innovation<br />
Eli Lilly was founded by Colonel Eli Lilly in 1876 in Indianapolis, USA. Since then, Lilly has been at the <strong>for</strong>efront of<br />
many of the most significant breakthroughs in modern medicine from the production of the world’s first insulin treatment<br />
in 1922 to the recent launch of the first ever treatment to build bone in the treatment of severe osteoporosis.<br />
ERAN<br />
<strong>The</strong> Early Rheumatoid Arthritis Network (ERAN) has been recognised as part of the sponsored National Clinical Audit<br />
Programme (Commission <strong>for</strong> Health Improvement – CHI).<br />
Make sure you are involved in this rapidly expanding Network.<br />
Come and visit stand 39 <strong>for</strong> more in<strong>for</strong>mation or contact Wendy Garwood on<br />
+44 (0)1753 480400 or wgarwood@phlexglobal.com<br />
Genzyme Biosurgery<br />
Synvisc ® is the viscosupplement clinically proven to relieve the pain and immobility of knee OA <strong>for</strong> up to 12 months.<br />
Now also clinically proven and approved <strong>for</strong> use in patients with symptomatic hip OA, Synvisc is effective in all stages<br />
of joint pathology, and is particularly indicated <strong>for</strong> patients where symptoms are not controlled by conservative<br />
measures, where NSAID's are contraindicated, or where surgery should be delayed or avoided.<br />
85
Janssen-Cilag<br />
Janssen-Cilag Limited is a top-ten pharmaceutical company serving the United Kingdom. It has an outstanding record of<br />
innovation and is a part of Johnson & Johnson, a family of around 190 healthcare companies active worldwide. Each has<br />
its own mission and identity. Janssen-Cilag Ltd is the maker of DUROGESIC‘ (transdermal fentanyl) and TRAMACET 〉<br />
(37.5mg tramadol Hcl and 325mg paracetamol).<br />
Kyphon Europe<br />
Kyphon focuses its energy in revolutionising spine therapy.<br />
Balloon Kyphoplasty is a minimally invasive procedure to treat vertebral body compression fractures.<br />
<strong>The</strong> technique is designed to reduce and stabilise the fracture in a controlled way, to correct spinal de<strong>for</strong>mity and to provide<br />
immediate pain relief and improved quality of life.<br />
LCA SA<br />
ARTHRUM H is a viscoelastic device specially designed <strong>for</strong> viscosupplementation of synovial fluid in osteoarthritic joints.<br />
ARTHRUM H viscoelastic device is indicated <strong>for</strong> maintenance of endoarticular space, relief of pain and restoration of joint<br />
mobility by replacing and providing viscoelastic supplementation of the diseased synovial fluid present in osteoarthritic joints.<br />
MSD<br />
Arcoxia ®<br />
Merck Sharp & Dohme Limited (MSD) has a 60-year heritage in musculoskeletal research. Since 1936, when the company<br />
introduced an early therapy <strong>for</strong> rheumatoid arthritis, MSD has made significant contributions to the development of new<br />
medicines <strong>for</strong> arthritis and other musculoskeletal disorders, resulting in more than a dozen products including etoricoxib<br />
(ARCOXIA ® ). MSD is the UK subsidiary of Merck & Co., Inc. of Whitehouse Station, New Jersey, USA – a leading researchbased<br />
pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical<br />
products to improve human health.<br />
MSD<br />
Vioxx/Fosamax<br />
Merck Sharp & Dohme Limited (MSD) have a 60-year heritage in musculoskeletal research. Since 1936, when the company<br />
introduced an early therapy <strong>for</strong> rheumatoid arthritis, MSD has made significant contributions to the development of new<br />
medicines <strong>for</strong> arthritis and other musculoskeletal disorders, resulting in more than a dozen products including rofecoxib<br />
(VIOXX) and alendronate sodium (FOSAMAX). Both rofecoxib and alendronate sodium were discovered and developed by<br />
MSD. MSD is the UK subsidiary of Merck and Co Inc of Whitehouse Station, New Jersey, USA a leading research based<br />
pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical products<br />
to improve human health.<br />
NASS<br />
<strong>The</strong> National Ankylosing Spondylitis <strong>Society</strong> (NASS) was founded in 1976. It produces patient education material and has a<br />
national network of over 100 branches providing supervised remedial physiotherapy one evening per week <strong>for</strong> approximately<br />
2000 sufferers in one week.<br />
It has provided the rheumatology profession and individual patients with over 110, 000 guide books.<br />
NRAS<br />
NRAS is a patient-led national Charity focussing specifically on Rheumatoid Arthritis.<br />
Aims:<br />
• Provision of a dedicated help-line and website advisory and in<strong>for</strong>mation service<br />
• Raising public, government and professional awareness of RA<br />
• Campaigning <strong>for</strong> increased funding <strong>for</strong> the treatment and delivery of care in RA<br />
• Promoting self-help in the management of the disease, in<strong>for</strong>med choice and facilitating the<br />
networking of patients<br />
86
Otsuka Pharmaceuticals (UK) Ltd<br />
Commonwealth House, Hammersmith, London W6 8DW. Phone: 020-8600-6770<br />
www.otsuka-europe.com and www.Adacolumn.com<br />
Otsuka is a diversified health care company dedicated to the research and development of innovative medical,<br />
pharmaceutical, and nutritional consumer products. <strong>The</strong> Adacolumn apheresis system is an innovative therapeutic<br />
option available and in use in the UK since early 2003. <strong>The</strong> Adacolumn is an extracorpeal leucocyte apheresis device<br />
and is CE marked and approved in the EU <strong>for</strong> use in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, Behcet’s<br />
disease and systemic lupus erythematosus (SLE).<br />
OUP<br />
Ox<strong>for</strong>d University Press is an international publishing house dedicated to the advancement and spread of learning<br />
in all academic fields including science, technology, and medicine. Publications cover the range of the academic<br />
spectrum from scholarly journals that successfully combine traditional values of quality and service together with<br />
innovative use of latest technologies; through to elementary college textbooks and books <strong>for</strong> the general reader;<br />
practical handbooks and reference works <strong>for</strong> professionals<br />
Pfizer<br />
Visit the Pfizer stand to order your copy of the BSR SPEAKER PRESENTATION SLIDES, and <strong>for</strong> more in<strong>for</strong>mation<br />
about the exciting program of speakers at “HOT TOPICS 3” the Pfizer symposium.<br />
Also visit to find out more in<strong>for</strong>mation on CELEBREX‚ (celecoxib) and BEXTRA (valdecoxib),<br />
the Pfizer Coxib portfolio.<br />
It is estimated that on any given day, 40 million people around the world are treated with a Pfizer medicine.<br />
CEL 109113/02/04<br />
Q Med<br />
Durolane ® : <strong>The</strong> Single Injection Treatment For Osteoarthritis<br />
Durolane is based upon a patented manufacturing process which uses NASHA (Non Animal Stablised Hyaluronic<br />
Acid) technology. This dramatically increases the intra-articular residence time dispensing with the need <strong>for</strong> repeated<br />
injections. Durolane is derived from a non-animal source, and there<strong>for</strong>e contains no residual animal impurities.<br />
Rainy Day Software<br />
RDS develops and distributes medical software. RheMOS is a drug monitoring solution that has correspondence,<br />
reporting, graphing, Patient Administration System and PDA modules. RheDAS enables the collection of anti-TNF data<br />
and can be used as a standalone module or integrated with RheMOS. It enables email submission to the BSRBR of<br />
relevant <strong>for</strong>ms, as well as local audit of data. RheDAS is free to UK rheumatologists.<br />
Raynauds & Scleroderma Association<br />
<strong>The</strong> Raynaud’s & Scleroderma Association are launching a new range of health professional booklets.<br />
<strong>The</strong> association aims to promote a greater awareness and understanding of these conditions and to raise funds <strong>for</strong><br />
research and welfare projects. Quarterly newsletters give up to date in<strong>for</strong>mation on research, treatments available,<br />
tips and aids <strong>for</strong> daily living.<br />
To be added to our mailing list please visit stand no. 41.<br />
87
RCN<br />
<strong>The</strong> Royal College of Nursing (RCN) <strong>Rheumatology</strong> Forum Committee stand will have a number of useful guidance<br />
documents <strong>for</strong> practitioners as well as news on <strong>conference</strong>s and other educational initiatives <strong>for</strong> nurses. <strong>The</strong> RCN RF have<br />
recently published guidance <strong>for</strong> practitioners in the administration of subcutaneous methotrexate which will be available on<br />
the stand. Come and collect a copy or access it through the RCN website www.rcn.or.uk and go to guidelines.<br />
If you would like: • In<strong>for</strong>mation on joining the RCN<br />
• Wish to have advice on rheumatology nursing or how to develop rheumatology nursing posts<br />
• Would like to hear about bursaries and awards <strong>for</strong> nurses<br />
• Obtain guidelines prepared by the <strong>for</strong>um.<br />
• Or would like advice on nursing issues related to rheumatology<br />
Please come and visit our stand which will be manned by members of the committee who would be pleased to meet you<br />
<strong>The</strong> Scleroderma <strong>Society</strong><br />
<strong>The</strong> Scleroderma <strong>Society</strong> is a voluntary charity founded in 1982. Our aim is to help sufferers and their families to obtain<br />
appropriate support/in<strong>for</strong>mation and fund medical research. Scleroderma is a rare connective tissue disease and the <strong>Society</strong><br />
helps patients/members to feel less isolated through group meetings, quarterly newsletters, telephone and email helpline<br />
and message board on www.sclerodermasociety.co.uk. Patient in<strong>for</strong>mation leaflets available at our stand<br />
Surgicraft<br />
Surgicraft are delighted to be exhibiting Orthovisc, a pure hyaluronic acid injection indicated <strong>for</strong> the treatment of<br />
osteoarthritis in all synovial joints.<br />
Orthovisc is reported to have a significantly lower rate of adverse events, due to its proprietary manufacturing process and<br />
<strong>for</strong>mulation. As an efficient and safe 3-injection treatment, Orthovisc is fast becoming the HA of choice.<br />
Syner-Med<br />
Syner-Med (PP) Ltd supply Venofer ® (i.v. iron sucrose) to the UK and Ireland health care providers.<br />
Anaemia is a debilitating condition which can compound the symptoms of diseases such as rheumatoid arthritis. Venofer ® is<br />
suitable <strong>for</strong> the treatment of iron deficiency anaemia sometimes characterised in rheumatoid patients. Venofer ® does not<br />
contain Dextran, there<strong>for</strong>e worsening of the joint condition and anaphylaxis are not encountered. Venofer ® is also suitable<br />
<strong>for</strong> patients undergoing hip and knee surgery to support blood loss where blood transfusion avoidance is considered.<br />
TRB Chemedica<br />
TRB Chemedica specialises in the manufacture of a variety of highly purified, non-animal sourced, Hyaluronic Acid based<br />
products. Ostenil ® is <strong>for</strong> the relief of OA pain in large joints, <strong>for</strong> example the knee and hip & Ostenil mini ® is <strong>for</strong> the relief of<br />
OA pain in the small joints, <strong>for</strong> example, the upper and lower limbs and the facet joints of the lumbar spine.<br />
Vertec Scientific<br />
Vertec Scientific Ltd, the UK’s leading supplier of Dexa scanners introduces the Hologic DiscoveryTM including Hologic’s<br />
innovative Instant Vertebral Assessment (IVA), the new Standard of Vertebral Osteoporosis Assessment. Vertec are also<br />
launching the New Hologic ExplorerTM just released in the UK.<br />
Wisepress<br />
Wisepress Online Bookshop is pleased to present a display of titles selected especially <strong>for</strong> the <strong>British</strong> <strong>Society</strong> of<br />
<strong>Rheumatology</strong> Annual Conference 2004 from the world’s leading publishing houses. All titles can be bought / ordered at<br />
the congress or via our website: www.wisepress.co.uk . Whatever your book requirements, Wisepress will be happy to help<br />
Wyeth<br />
Enbrel is a twice – weekly injection licensed <strong>for</strong> the treatment of active rheumatoid arthritis (RA) including early RA,<br />
ankylosing spondylitis (AS), active and progressive psoratic arthritis (PsA) and active juvenile chronic arthritis (JCA). Enbrel<br />
has a unique mode of action as the only approved tumor necrosis factor (TNF) receptor, and has been used in over<br />
215,000 people worldwide, including over 4,000 <strong>British</strong> adults and children since its UK launch in 2000.<br />
88
Acknowledgements<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> would like to thank the following companies <strong>for</strong><br />
their support in the areas listed below:<br />
MSD <strong>for</strong> their support of the BSR Young Investigator Awards.<br />
Novartis <strong>for</strong> sponsoring the provision of the <strong>programme</strong> on screens around the EICC.<br />
Pfizer <strong>for</strong> sponsoring the delegate bags, printed <strong>programme</strong>s and speakers CD-ROMs.<br />
Wyeth <strong>for</strong> sponsoring the registration staff and badges, and <strong>for</strong> organising the fun run.<br />
Abbott, Genzyme Biosurgergy, MSD, Novartis, Pfizer and Schering Plough<br />
<strong>for</strong> supporting the provision of satellite symposia <strong>for</strong> delegates.<br />
BSR, 41 Eagle Street, London WC1R 4TL<br />
Telephone: +44 (0) 207 242 3313 Fax: +44 (0) 207 242 3277<br />
Email: <strong>conference</strong>s@rheumatology.org.uk<br />
Website: www.rheumatology.org.uk<br />
A Company limited by guarantee with charitable status<br />
VAT No. 404 5637 66 Company Reg. No. 3470316 Charity Reg. No. 1067124<br />
89